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ABSTRACT
The work presented in this thesis employed magnetic resonance imaging 
(MRI) techniques to determine the volume and metabolite profile of brain grey 
matter (GM) and white matter (WM) in people with clinically early relapsing- 
remitting m ultiple sclerosis (MS). C ross-sectional MRI and clinical data was 
obtained from 27 subjects with relapsing-remitting MS within 3 years of first 
symptom onset, and com pared with MRI data from 29 normal control subjects. 
Subsets o f  these groups also provided longitudinal data over 18 months for 
volumetric analysis.
The principal observations were that: GM and WM atrophy may be observed 
early in the clinical course o f  the disease; WM atrophy was more apparent at 
baseline, but over the period of follow-up GM atrophy occurred more rapidly than 
that o f  WM; changes in metabolite concentrations were found in GM and WM 
suggesting neuronal and axonal dam age, and WM glial activation and or 
proliferation; WM lesion loads explained a fraction of GM and WM atrophy and 
metabolite variability; clinical outcome related more closely to tissue metabolite 
changes (GM glutamate and glutamine, and normal-appearing WM inositol) than 
atrophy at this stage of the disease.
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A BBREVIATIONS
BBB = blood brain barrier
BP = brain parenchyma
BPF = brain parenchymal fraction
CDMS = clinically definite multiple sclerosis
CGM = cortical grey matter
CHESS = chemical shift selective saturation
Cho = choline containing compounds
CIS = clinically isolated syndrome
CNS = central nervous system
CPMS = clinically probable multiple sclerosis
Cr = creatine plus phosphocreatine
CSE = conventional spin echo
CV = coefficient of variation
EAE = experimental allergic encephalomyelitis
EDSS = expanded disability status scale
FID = free induction decay
FLAIR = fast fluid-attenuated inversion-recovery
FS = functional system
FSE = fast spin echo
FSPGR = fast spoiled gradient recalled
Gd = gadolinium
Glu = glutamate
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Gin = glutamine
Glx = glutamate plus glutamine
GM = grey matter
G M F = grey matter fraction
GNDS = G uy’s neurologic disability scale
'H-MRS = proton magnetic resonance spectroscopy
'H-MRSI = proton magnetic resonance spectroscopic imaging
HPT = nine hole peg test
ICC = intra-class correlation coefficient
IL = interleukin
InHC = inhomogeneity corrected 
Ins = myo-inositol 
IV = intravenous
LCModel = linear combination model (a software package) 
LF = lesion fraction
LSDMS = laboratory supported definite multiple sclerosis
LSPMS = laboratory supported probable multiple sclerosis
M BP = myelin basic protein
MHC = major histocompatibility complex
MOG = myelin oligodendrocyte glycoprotein
MR = magnetic resonance
MRI = magnetic resonance imaging
MS = multiple sclerosis
MSFC = MS functional composite
MSIS-29 = MS impact scale (29 questions)
MSSS = multiple sclerosis severity score
MT = magnetisation transfer
NAA = jY-acety 1-aspartate
NAAG = /V-acetyl-aspartyl-glutamate
NAWM = normal-appearing white matter
NC = normal control
ND = not determined
NEX = number of excitations
NO = nitric oxide
OPC = oligodendrocyte precursor cell
PASAT = paced auditory serial addition test
PP = primary progressive
PPMS = primary progressive multiple sclerosis
ppm = parts per million
PRESS = point resolved spectroscopy
RC = reliability coefficient
RF = radio-frequency
RR = relapsing-remitting
RRMS = relapsing-remitting multiple sclerosis
SD = standard deviation
SE = standard error or spin echo
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SP = secondary progressive
SPMS = secondary progressive multiple sclerosis
SPM99 = statistical parametric mapping version 99 (a software package)
STEAM = stimulated echo acquisition mode
TE = echo time
TI = total intra-cranial
TR = repetition time
tNAA = /V-acetyl-aspartate plus N-acetyl-aspartyl-glutamate
TN F = tumour necrosis factor
TW T = Twenty-five foot timed walk test
VC = validity coefficient
VEP = visual evoked potential
WM = white matter
W M F = white matter fraction
2D = two-dimensional
3D = three-dimensional
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1 INTRO DUCTIO N AND AIMS
Since its first recognition (Charcot, 1877), multiple sclerosis (MS) has 
predom inantly  been characterised as a multifocal inflam m atory demyelinating 
disorder of central nervous system (CNS) white matter (WM). However, more recent 
histopathological work has begun to question this concept of MS, demonstrating that 
disease effects are not necessarily focal, nor restricted to the WM. Further, with the 
advent of magnetic resonance (MR) imaging (MRI), it has been possible to explore 
the in vivo  relationship between evolving pathology and clinical outcomes; early 
work concentrated on the WM lesions, characterising the dynamics of their genesis 
and subsequent growth or resolution, and rather contrary to intuition, it has been 
shown that focal lesions do not readily account for a significant proportion of the 
clinical disease burden (McFarland et al.,2002). Building upon these observations, 
and concurrent with the development and refinement of MR techniques, attention has 
turned to consider both non-lesional tissues and pathological processes other than 
inflammation or dem yelination. One aspect o f  this has been an exploration of 
neuronal and axonal dam age that, while long recognised (Kornek and Lassmann, 
1999), has only recently been the focus of concerted study.
The work contained in this thesis concentrates on two MR methodologies, 
tissue specific volume measures that enable an assessment of differential disease 
effects upon both W M  and grey matter (GM), and proton magnetic resonance 
spectroscopy ( 'H -M RS) that offers information on tissue metabolite concentrations, 
and to a degree insight in to cell specific disease effects.
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There has been relatively limited work studying the earliest clinical stages of 
MS, although such studies have indicated that early changes in lesion loads may 
partially determine longer-term clinical outcomes (Brex et al.,2002) and that axonal 
damage in lesions may be more marked early in the course of the disease (Kuhlmann 
et al.,2002). Further, it has also been shown that clinical outcomes at two years after 
clinical onset can be used to define the longer term disease severity (Roxburgh et 
a l. ,2005). Given the potential impact early disease activity may have on the 
trajectory of subsequent disease progression, there is a clear need to obtain more 
information on the evolution of, and interplay between, pathological processes soon 
after disease onset. With this in mind, the work contained in this thesis focuses on 
observations made in subjects with MS within three years o f  first symptom onset, 
who were not or had not been treated with disease modifying agents.
This thesis begins by considering aspects of MS pathology and its clinical 
features, along with methods for assessing clinical outcomes; this is followed by an 
overview of MRI, and more specifically the role volumetric and spectroscopic 
measures have investigating aspects o f  in vivo pathology. It then moves on to the 
reliability o f  the MRI techniques used in work included in this thesis, before 
proceeding to explore clinically early MS disease effects.
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2 BACK G R O U ND
2.1 M ULTIPLE SCLEROSIS
2.1.1 CLINICAL PRESENTATIO N AND RECOGNISED PH ENO TYPES
Charcot (Charcot, 1877) first clearly defined a clinical syndrome associated
with sclerose en plaques  and, it was apparent that just as the lesions could manifest 
themselves throughout the central nervous system (CNS), symptoms could similarly 
affect a wide range of neurological functions. While some symptom s are more 
common with MS than other disorders, for example optic neuritis, spinal cord and 
brainstem syndromes, none can be considered diagnostic on its own. Indeed this may 
simply reflect the clinical eloquence of lesions within the optic nerve, spinal cord, 
brainstem and cerebellum rather than a genuine predilection for these sites. While the 
most readily recognized features of the disease are those associated with sensory or 
motor neurological deficits, cognitive (Rao et a l . ,1991a; Rao *7 «/., 1 99  1 b) 
impairment and psychiatric morbidity (Ron and Logsdail, 1989; Zorzon et al.,2001) 
contributes significantly to disability.
The clinical course of MS is equally variable ranging between forms that are 
progressive from clinical onset, occasionally leading to death within a few years, to a 
relatively benign form with little or no fixed disability several decades after the first 
clinical events. This clinical heterogeneity leads to difficulties with diagnosis and 
assigning prognoses. Defining the clinical course of MS has tended to be quite 
subjective, with a wide range of over-lapping terms applied. This heterogeneity was 
addressed by Lublin & Reingold (1996) (Table 2.1.1) when they undertook a survey 
of clinicians to reach consensus definitions of disease patterns. This was reached for
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relapsing-remitting (RR), primary-progressive (PP), secondary-progressive (SP), 
progressive-relapsing (PR) patterns but not for relapsing-progressive (RP) MS. The 
latter was considered to overlap with the definitions o f  RRMS and SPMS, and could 
not be distinctly separated from them. They did not define what constitutes an attack, 
stating that this needs to be considered for individual studies, although both Poser et 
al. (1983) and McDonald et al. (2001) did.
17
Table 2.1.1a: Lublin & Reingold (1996) definitions of clinical course.
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2.7.2 D IAG NOSTIC CRITERIA
Diagnostic criteria have been, and still are, based upon demonstrating lesion 
genesis disseminated in both time and place, although for those who present with 
sym ptom  progress ion  from onset w ithout ev idence o f  p reced ing  ep isodic 
neurological deficits it has proven difficult to establish a diagnosis on clinical 
grounds alone. W ith the inclusion o f  information derived from MRI studies, 
cerebrospinal fluid (CSF) examination for oligoclonal bands, and visual evoked 
potentials (VEP), this has become more reliable. The diagnostic criteria have 
remained under review and have recently been updated (M cD onald  et a l.,2001 ; 
Pol man et al., 2005) to take greater account of MRI data.
In this work, the Poser et al. (1983) diagnostic criteria were employed (Table 
2.1.1b). They define a relapse (also described as an attack, bout, episode, or 
exacerbation) based on symptoms lasting more than 24 hours with or without 
objective confirmation typical of the diagnosis, separated by a period of one month 
or more from a previous clinical event. Reliable historical information consistent 
with the diagnosis, for which no better explanation can be identified, is acceptable as 
evidence of a relapse. Remission is defined as a definite improvement in signs or 
symptoms for more than 24 hours. Clinical evidence of a lesion requires examination 
by a com petent clin ician; how ever, signs need not be persistent. Signs of 
simultaneously occurring separate lesions are acceptable, although optic neuritis 
spreading to involve the other eye within 15 days is not. The presence o f  oligoclonal 
bands on examination o f  the cerebrospinal fluid (CSF) adds laboratory support to the 
diagnosis. Visual evoked potentials and MRI findings are considered paraclinical
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evidence. The Poser et al. criteria do not address those subjects with PPMS, although 
Thompson et al. (2000) have subsequently defined diagnostic criteria for this form of 
the disease and these have been incorporated in to the more recent McDonald et al. 
(2001) diagnostic criteria.
20
Table 2.1.1b: Poser et al. (1983) diagnostic criteria.
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2.1.3 EPID EM IO LOG  Y 
Incidence and prevalence
A relatively recent survey o f  neurological disease centred on London 
estimated an incidence of 7 (95% confidence interval 4-11) cases per 100,000 of the 
population per year, with a lifetime prevalence of 2 (95% confidence interval of 2-3) 
cases per 1000 of  the population (MacDonald et a l.,2000). However, there is wide 
geographical variability  in the prevalence o f  MS, both between and within 
continental regions, and latitudinal gradients have been identified (Compston, 1999), 
suggesting both environmental and genetic factors contribute towards susceptibility 
to MS. Gender differences, with a female to male ratio of about 2:1 (Confavreux et 
al.,2000; Prat and Antel, 2005), have also been observed.
Epidemics and infections
Whilst regional incidence and prevalence studies support the presence of 
environmental factors, some have argued that apparent epidemics of MS indicate an 
infective environmental agent (Kurtzke, 1993) and others have suggested that the 
change in prevalence represents an epidemic of recognition (Benedikz et al., 1994). 
To date a single potential infective trigger agent has not been clearly implicated, 
although it is recognized that viral infections (particularly H erpesviridae  such as 
Epstein-Barr and more recently Human herpes virus 6) may predispose to the 
subsequent development of MS (Cermelli and Jacobson, 2000). It may transpire that 
an exogenous trigger actually consists of a suite of infective, or other, agents acting 
in concert.
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Genetics
Pedigree studies have indicated that there is a genetic com ponent to the 
disease although its influence is far from absolute. The age-adjusted risk for siblings 
of an affected individual is circa 3%, and circa 2% for both parents and children. In 
the United Kingdom and Canada, both countries where the prevalence of MS is high, 
monozygotic twins showed a much higher concordance rate when compared with 
dizygotic twins (circa 25% and 3% respectively) (Com pston, 1999). Having 
established this, it has proven more difficult to identify particular genes, and this in 
part may reflect both disease heterogeneity and multifactorial genetic contributions. 
Association between a number of class II major histocompatibility complex alleles 
(DR 15, DQ6 and to a lesser degree DR4) and MS have been identified but none are 
considered particularly strong.
Clinical phenotype distribution
The commonest initial presentation of MS is the RR form, recently estimated 
at 85% of cases (Confavreux et al.,2000). After a mean o f  11 years of the 85% 
classified as having RRMS, 68% remain so classified, with 32% developing SPMS. 
During the relapsing remitting phase, relapses occur approximately once per year in 
untreated cases (Compston and Coles, 2002).
As noted above, some people with MS do not appear to have relapses at any 
stage but have syndromes that upon investigation are compatible with the diagnosis. 
It remains unclear whether PPMS is fundamentally different from SPMS, and there is 
some debate in the area (Thompson et al., 1997).
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The relationship between relapses and progression is not as clear as may be 
expected. Confavreux et al. (2003; 2000) have found limited evidence to support a 
direct relationship, suggesting that relapses and long-term disease progression may 
be to a degree dissociated. In contrast, Brex et al. (2002) found a modest association 
between early lesion accumulation and clinical outcome 14 years after disease onset 
was observed.
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2.1.4 PATH O LO G Y AND  IM M UNOLO GY
The presence of discoloured and atrophied lesions in the brain and spinal cord 
WM was noted in advance of the clinical phenotype being established (Carswell, 
1838; Cruvellhier, 1842). It was Charcot who later described them as sclerose en 
p la q u e s  and clearly connected them with the clinical manifestations we now 
recognize (Charcot, 1877).
Microscopic examinations of these lesions revealed marked inflammation and 
demyelination, with relative sparing of axons associated with inflammation (Chareot, 
1877). Demyelination was considered to be the pre-eminent cause of disability with 
subsequently limited consideration given to axonal and neuronal structures. With the 
recent development and application o f  further histopathological tools, a greater 
understanding of the extent and degree o f  neuronal and, in particular, axonal 
involvement has em erged along with insight into the pathological mechanisms 
leading to dam age. Histopathological changes within norm al-appearing WM 
(NAWM) (Allen and McKeown, 1979; Guseo and Jellinger, 1975) and in cortical 
GM (CGM)(Bo et al.,2000; Brownell and Hughes, 1962; Kidd et al., 1999; Peterson 
et al.,2001) matter have been observed, indicating that MS is neither as focal as 
initially thought nor is it restricted to the WM.
Focal white matter lesions
It remains unclear why changes in MS are quite so spatially heterogeneous. 
While there are widespread changes (discussed below), focal WM lesions are much 
more readily apparent, and it has yet to be shown what triggers their formation.
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Is has been proposed that MS lesions can be divided in to four types 
dependent upon the pattern o f  inflammation, demyelination and remyelination, and 
oligodendrocyte characteristics, and that at a given time this is homogeneous within a 
given subject (Lucchinetti et a l.,2000). O f these, patterns I and II are thought to 
relate to a T-cell or T-cell plus antibody response whilst patterns III and IV, have 
been described as reminiscent of virus or toxin induced damage with oligodendrocyte 
dystrophy. Interestingly, pattern III lesions have been predominantly found in 
subjects with a clinical course of less than 8 weeks, and pattern IV lesions have so far 
have been seen exclusively in PPMS. From this study, it was unclear if these patterns 
III and IV were maintained long-term, however the apparent change in frequency of 
lesion types in those with clinical manifestations o f  greater than 1 year to one 
dominated by pattern II lesions suggests that pattern III represents the initial response 
to either a viral or toxic trigger. Previous work has also noted marked heterogeneity 
in MS lesion characteristics related to the duration of clinical disease and lesion 
maturation (Gay et al., 1997). Lesions early in the clinical evolution of MS appear to 
show demyelination effected by resident microglia in association with a marked 
plasma cell and less marked T-cell response. Such early lesions do not exhibit clear 
evidence for a breakdown in the blood brain barrier (BBB), perhaps suggesting that 
microglial activation precedes this. It has also been suggested that demyelination 
may be preceded by apoptosis o f  oligodendrocytes, again in association with 
microglial activation (Barnett and Prineas, 2004). As lesions mature and the clinical 
course extends, a T-cell response becomes more evident (Gay et al., 1997). Taken 
together, these studies would appear to suggest that pathology at the earliest stages of
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MS is not necessarily primarily inflammatory, but that it may evolve into a self- 
perpetuating T-cell mediated process. In this context it is interesting to note that 
axonal damage in WM lesions may be more marked early rather than later in the 
course of the disease (Kuhlmann et cil.,2002).
Normal-appearing white matter
Macroscopically NAW M  is not necessarily microscopically so. Studies have 
shown that dem yelination (Guseo and Jellinger, 1975), astrogliosis (Allen and 
McKeown, 1979) and axonal loss (Evangelou et a l.,2000) occurs in such tissues. 
Further, macroscopically normal-appearing tissues may not be so on MRI, and as 
such may still contain focal lesions (De Groot et c//.,20() 1). The detection of lesions 
on MRI also depends upon the imaging methodology employed and thus normal- 
appearing on one MR sequence may not be so on another (see section 3.1.3). Given 
that even on MRI, despite a long disease duration, most brain tissue would be 
classified as normal-appearing (Kalkers et al.,2001), it is clear that to ignore subtle 
disease effects in such tissues may significantly underestimate the overall magnitude 
of disease effects.
MRI observations in the NAW M of subjects with established MS have noted 
abnormalities in magnetisation transfer (MT) (for example (Cercignani et a l.,2001; 
Dehmeshki et al.,2003; Ge et al.,2002; Griffin et al.,2002a; Griffin et al.,2000; Leary 
et al., 1999b; Siger-Zajdel and Selmaj, 2001), diffusion (for example (B am m er ^  
al.,2000; Cercignani et al.,2000; Ciccarelli et al.,2001; Filippi et a l.,2000; Guo et 
a l . ,2002; R ovaris  et a l.,2002; W erring  et a l.,2 0 0 1 ) ,  T, and T 2 relaxation 
characteristics (Goodkin et al., 1998; Griffin et al.,2002b; Parry et al.,2002; Whittall
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et a l.,2002), and metabolite alterations (discussed in greater detail below), which 
appear consistent histopathological findings. Perhaps more importantly these 
changes might begin early in the clinical course of the disease; MT, volumetric and 
spectroscopic abnormalities have all been observed in subjects with CIS and 
clinically early MS (Brex et al.,2000a; Brex et al.,2001; Dalton et al.,2002; Dalton et 
al.,2004; Fernando et al.,2004; Fernando et al.,2005).
Grey matter
GM is not free from focal lesions (Bo et a l.,2000; Brownell and Hughes, 
1962; Kidd et al., 1999; Peterson et al.,2001), but they are more difficult to recognize, 
particularly with conventional MRI (Geurts et a/.,2005). Indeed they may be found in 
the majority of MS subjects; Lumsden reports that 93% of 60 subjects studied had 
evidence of cortical involvement (Lumsden, 1970). Such lesions appear to be less 
inflam m atory than those found in WM (Peterson et a l.,2001), with limited 
lym phocytic infiltration (Bo et a l.,2003) and com plem ent activation (Brink et 
al.,2005).
Oligodendrocytes
Demyelination has long been established as significant component of MS 
pathology, and appears to involve a spatially heterogeneous inflammatory process 
mediated by T cells and perhaps autoantibodies. S ignificant oligodendrocyte 
populations have been observed in both acute and chronic lesions, particularly in 
perip laque  reg ions  (C hang et a l.,2002; S o la n k y  et a l.,2 0 0 1 ) ,  suggesting  a 
considerable potential for remyelination (Brusa et a l.,2001; Prineas and Connell, 
1979), how ever despite this remyelination may not be com plete . It has been
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suggested that remyelination failure represents a time-dependent decrease in the 
ability of demyelinated regions to support remyelination, combined with the limited 
rate at which oligodendrocyte precursor cells (OPC) migrate into them (Chari and 
Blakemore, 2002). Thus, while OPCs may present throughout chronic lesions, they 
may have m issed a critical early phase in plaque evolu tion  conducive  to 
remyelination. The factors limiting remyelination remain uncertain (Hohlfeld, 2002).
The absolute functional significance of this is unclear, given that chronically 
demyelinated nerve fibres are still able to conduct signals, albeit at a reduced 
velocity (Felts et al., 1997). This is clearly seen when looking at recovery from optic 
neu ri t is ,  w here  fu n c tio n a l  reco v e ry  may be full d e sp i te  p e rs is te n t  
electrophysiological evidence of demyelination (Halliday et al., 1972).
In addition to their role in remyelination, oligodendrocytes may also play a 
part in the regeneration of axons following transection. It would appear that mature 
oligodendrocytes inhibit growth o f  axons in the adult CNS. However, there is 
evidence to suggest that oligodendrocytes are able to support axonal growth when 
there is relatively little tissue damage associated with axonal loss (Fawcett and 
Asher, 1999).
While axons may partly depend upon myelin for support (Yin et al., 1998), 
the reverse may also be true. Tsunada et al. (2003) employing a murine model of 
encephalomyelitis observe axonal injury preceding demyelination. From this, it may 
be speculated that dysfunction of either axons or myelin may establish a vicious 
cycle, with loss mutual support leading to the progressive degeneration of both.
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Neurons and axons
Relatively recently, it has become clear that axonal and neuronal pathology 
has a significant part to play in the evolution of disability, with evidence coming 
from a number of histopathogical studies (Ferguson et al., 1997; Peterson et al.,2001; 
Trapp et al., 1998) revisiting an issue that had been overshadowed by the more overt 
presence o f  dem yelina tion  (Kornek and Lassm ann, 1999). It has also been 
established in laboratory models of MS that axonal degeneration is present from the 
onset of the disease (Mancardi et al.,2000; Onuki et al.,2001).
It has been suggested that such axonal involvem ent is a bystander 
phenomenon associated primarily with inflammation and demyelination, and indeed 
this would be supported by the observations that axonal loss appears to be arrested in 
remyelinated lesions, but on-going in those that are chronically demyelinated 
(Kornek et al.,2000). However, in contrast, recent work has indicated that it may be 
the result of a more focussed immunological attack (Bitsch et al.,2000). In this work, 
it was suggested that axonal injury might be mediated directly by macrophages, 
microglia and, in particular CD8+ T-cells, the latter being supported by work by 
Medana et al. (2001). Further, whilst axonal loss was only found to correlate with the 
number of CD8+ T-cells, it was observed that there was considerable lesion 
heterogeneity indicating that other mechanisms may have a part to play. It has also 
been suggested that axonal degeneration in MS may, in part, be the result of immune 
targeting of neuronal proteolipid protein 1 (Garbem et al.,2002). Axonal damage has 
also been observed in the spinal cord remote from sites of focal demyelination and it
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has been postulated that degeneration of myelin may be a secondary process leading 
to an inflammatory response (Bjartmar et al.,2001).
It has been shown that demyelination per  se can lead to a reduced axonal 
diam eter (Yin et al., 1998) and such denuded and atrophied axons may be more 
vulnerable to on-going inflammatory activity. Mediators o f  axonal damage may 
include nitric oxide and glutamate, both o f  which are also associated with 
inflammation. Nitric oxide (NO) has been found to cause conduction block (Redford 
et a/., 1997) and also degeneration of electrically active axons (Smith <?/«/.,2001). 
D isturbances o f  g lu tam ate  hom eostasis  and associated  g lu tam ate  m ediated 
excitotoxicity has also been proposed as another factor contributing towards axonal 
and oligodendrocyte damage, and it has been suggested that correction of this may 
prevent on-going axonal damage (Werner et c//.,2()()l).
T-cells
Early observations noted infiltration of inflammatory cells in demyelinated 
lesions and thus a causative relationship was postulated. Subsequent studies indicated 
that this might be a T-cell mediated process with secondary microglial and 
macrophage activation. However, this may be com m on to a number o f  neuro- 
inflammatory processes, and as such may mark a general response to neural tissue 
damage rather than a disease specific finding (Neumann, 2001). Further, microglial 
and astrocytic activation may result directly from neuronal damage; through both 
cytokines and microglial antigen presentation in association with MHC class II, these 
are able to promote T-cell participation (Neumann, 2001), and the T-cell response 
may be a secondary event (Gay et al., 1997).
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It remains unclear if demyelination is driven directly by inflammation or if 
this represents a response to another as yet undefined process. Both CD4+ and, to a 
greater degree, CD8+ T-cells have been detected in MS lesions (Babbe et al.,2000; 
G ay et a l . , \9 9 1 )  suggesting a role in the pathological process. CD4+ T-cells 
(activated by antigen presentation in association with MHC class II complexes on 
resident microglia) may have a role to play in directing an inflammatory response. 
CD8+ cytotoxic T-cells (activated by antigen presentation in association with MHC 
class I complexes), derived from a limited number of cell lines suggesting antigenie 
specificity (Babbe et al.,2000), appear to predominate over CD4+ T-cells in active 
lesions (Gay et al., 1997), however no consistent role in pathogenesis has been 
defined.
Further, the direct relationship between demyelination and inflammation in 
MS has been called into question by the observation that demyelination can occur in 
the apparent absence any inflammatory process and outside focal lesions (Guseo and 
Jellinger, 1975); and that inflammation can occur in unmyelinated regions such as 
the retina (Shaw et a/., 1987). It would also appear that inflammation might also in 
part aid tissue repair rather than simply cause damage (Kappos and Duda, 2002).
Evidence from MRI would appear to support the concept that most lesions, as 
seen on T 2-weighted images, exhibit breakdown in the BBB at an early stage in their 
development (Ciccarelli et al., 1999; McFarland et al.,2002). However this does not 
establish causality; other work has suggested that MR changes may occur before 
overt Gd-enhancement (an MR marker of breakdown in the BBB (Bruck et al., 1997;
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Goodkin et al., 1998; Katz et al., 1993), and that the spatial probability distributions of 
Gd-enhancing and T2 lesions need not entirely coincide (Lee et al., 1999).
B-cells and auto-antibodies
The presence of oligoclonal intrathecal immunoglobulin synthesis in MS has 
been known about for some time, and the bands appear to be directed against a range 
of antigens (Cross et al.,2001). Some are directed against myelin antigens such as 
myelin basic protein (M BP) and myelin oligodendrocyte glycoprotein (MOG), 
although these are not specific to MS (Kami et al., 1999). Further, studies using the 
main animal model of MS, experimental allergic encephalomyelitis (EAE), indicate 
that the passive transfer of B-cells or antibodies is not able to induce demyelination 
(Cross et <r//.,2001). This contrasts with the passive transfer of sensitized T-cells or 
active im munization with myelin derived proteins that are able to do so. This 
suggests that auto-antibodies may not have a direct role in initiating pathology 
although they may play a significant part in the regulation and localization of 
inflammation, for example it has been suggested that those directed against MBP 
may actually prom ote remyelination (Rodriguez et al., 1996) while anti-M OG 
antibodies may promote demyelination (Linington and Lassmann, 1987).
Astrocytes
The role o f  astrocytes in the pathology of MS remains unclear. Astrocytes 
react to a variety o f  CNS insults and resultant glial scars consist predominately of 
meshworks o f  astrocyte processes (Fawcett and Asher, 1999). In MS, astroglial 
proliferation appears widespread, having been observed in both focal WM lesions 
and NAW M (Allen and McKeown, 1979); it has yet to be clearly established if it has
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a beneficial or detrimental effect upon clinical outcomes. It has been suggested that 
over-expression of cytokines by astrocytes, in particular glial maturation factor, may 
promote immune activation in the nervous system (Zaheer et al.,2002). This in turn 
may be mediated by microglia, which when stimulated express M HC class II 
antigens.
From present ev idence , axonal regenera tion  seem s to occur in a 
predominantly astrocytic environment, particularly at sites of focal damage. This 
environment may promote and inhibit axonal growth dependent on a variety of 
interacting factors, although the exact nature of these is far from clear (Fawcett and 
Asher, 1999). A strocytes may also promote oligodendrocyte survival, possibly 
through cell surface  in teractions  (lam inin  on as trocy tes  and integrin  on 
oligodendrocytes) or humoral factors (Corley et al.,2001), and this in turn may have 
a role promoting timely remyelination.
Microglia
Microglia act as the C N S ’s resident macrophages and antigen presenting 
cells, and are rapidly and stereotypically activated in many CNS disease processes 
(Kreutzberg, 1996). After activation they proliferate and migrate to the site of injury 
while becoming morphologically more macrophage-like and expressing increasing 
levels of MHC class I and II antigens. They may both promote damage and repair, 
and their role in MS remains unclear.
Complement
Complement would appear to have a role mediating cellular damage in MS. It 
is activated by both antibodies and via the classical pathway by myelin itself
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(possibly through MOG) (Vanguri et al.) and has been localized to WM lesions 
(Compston et al., 1989; Lucchinetti et al.,2000) but less consistently to those in the 
GM (Brink et tf/M2005; Schwab and McGeer, 2002). The relative importance o f  its 
contribution to tissue damage has yet to be fully established.
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2 .1.5 PA TH OPH YSIOLOG Y
Symptoms experienced by people with MS can be broadly divided into 
positive and negative, and these may wax and wane or be irreversible (Smith and 
McDonald, 1999). Negative symptoms include anaesthesia and paralysis and are the 
result of conduction delay and block. Positive symptoms include paraesthesia and 
neuralgia, which may be associated  with m echanical action on regions of 
demyelination (as in Lherm itte’s sign (Al-Araji and Oger, 2005)), and are due to 
axonal hyper-excitability and spontaneous discharges.
Many axons in the nervous system are not myelinated but still readily able to 
convey signals. However, myelination speeds up conduction velocities and thus 
offers advantages when information needs to be transmitted rapidly. Conduction in 
myelinated axons differs from that of unmyelinated fibres, which rely upon a 
continuous wave of depolarisation, in that only discrete sections of the axon 
membrane (the nodes of Ranvier) between regions of myelination need to depolarise 
for an action potential to be conducted, a process known as saltatory conduction. The 
changes in membrane potential associated with the passage of an action potential rely 
upon the controlled influx of Na+ ions into the axon. The Na channels through which 
they pass are concentrated at the nodes of Ranvier in myelinated fibres and are more 
evenly distributed in unmyelinated fibres.
Negative symptoms
Negative symptoms are the result of conduction block and signal attenuation, 
and this in turn may be due to a variety of transient and longer-term factors. Acutely, 
the loss of myelin stops saltatory conduction, leaving remote islands o f  Na+ channels
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that arc unable to support action potential propagation. With time, N a+ channels may 
redistribute themselves more evenly over the axonal membrane so restoring signal 
conduction, albeit at a reduced velocity (Smith and M cD onald , 1999). Such 
demyelinated axons also appear sensitive to the effects of NO, which may lead to 
further transient conduction block (K a p o o r  et <7 /.,1999), and well-recognised 
temperature sensitivity (U h th o ffs  symptom (Selhorst and Saul, 1995)). In addition 
humoral factors such as cytokines or antibodies may also act as neuro-electrie 
blocking factors (Smith and McDonald, 1999), although exactly which components 
are involved remains unclear.
Positive symptoms
Positive symptoms are the result of axonal hyper-excitability, with persistent 
and excessive activity. This may be spontaneous, or associated with mechanical 
(Lhermitte’s phenomenon and phosphenes on eye-movemcnt (Davis et al., 1976)) and 
possibly molecular factors such as glutamate-mediated excitation.
Relapses, remissions and persistent disability
An acute symptomatic event need not be associated with demyelination alone 
(Barnett and Prineas, 2004), and similarly recovery from such episodes need not 
imply that remyelination has occurred (Brusa et al.,2001). Thus, a relapse and 
subsequent remission may represent a variety of pathological events. Irreversible 
disability may follow a relapse or may be a slowly progressive feature of the disease. 
While it seems reasonable to assume that such unrecoverable functional deficits 
reflect the unrecoverable loss of signal transmission, and thus by implication the final 
loss o f  an axon or entire neuron, the pathways leading to this may differ dependent
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upon their association with relapses. Axonal damage (Ferguson et al., 1997) and 
transection (Trapp et al., 1998) have been observed in acute white matter lesions, the 
latter offering a clear link between incomplete recovery from an acute relapse and 
inflammatory activity. Progressive changes may be mediated by: (i) less marked but 
either more persistent or more widespread inflammation; (ii) other processes either 
initiated by acute inflammation but not dependent upon its persistence; or (iii) 
processes which are e ither independent or at least sem i-independent o f  focal 
inflammation. The possibility of such semi-independence is suggested by some of 
the work previously considered (section 2.1.3) and from clinical work by Confavrcux 
et al. (2000) who, in a study exploring the relationships between acute relapses and 
longer-term disability, found no clear link between these clinical parameters.
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2.1.6 MEASURES OE CLINICAL OUTCOME
Assessing disability in MS is difficult. The effects of MS are widespread, and 
to fully assess its effects would require an extensive battery of specific tests. Further, 
it is difficult to effectively design and implement tests that assess either a single 
function or the integrity of any single com ponent of the nervous system. Thus, 
measures currently em ployed in MS are a com prom ise between specificity to a 
particular function and global sensitivity to disease effects.
At present the main measures of disability used in clinical studies are the 
expanded disability status scale (EDSS) (Kurtzke, 1983), and more recently, the MS 
functional composite score (MSFC) (Cutter et al., 1999; Fischer et al., 1999).
The expanded disability status scale
The EDSS is a twenty-point scale from 0.0 to 10.0. It is based upon a 
combination o f  functional systems (FS) scores and in its mid-levels estimates 
ambulation (see Appendix). It is a non-linear scale with clinical impairment without 
disability represented by the first five points, subsequent increasing stages of 
disability, and ultimately death due to MS. It has been suggested that after a reaching 
a score of 4, progressive changes rather than those associated with relapses, account 
for further deterioration (Confavrcux et al.,2003; Confavreux et al.,2000). The non­
linear progression through the EDSS scale makes it different to compare the relative 
disease severity in subjects with differing disease durations, and to address this the 
multiple sclerosis severity scale (MSSS) was developed (Roxburgh et al.,2005).
39
The M S functional composite (MSFC) score
The MSFC is derived from the results of two 25 foot timed walk tests (TWT)
(C utter  et al., 1999), four nine hole peg tests (HPT) (two trials for each hand)
(Goodkin et al., 1988), and a paced serial addition test (PASAT) with 3 second
stimulus intervals (Gronwell, 1977). The average of the two TW T and reciprocal
average of the four HPT are calculated. The preferred method for calculating the
MSFC uses the study cohort to create Z-scores for all three measures (Fischer et
al., 1999). To calculate a Z-score, the mean and standard deviation (SD) of a given
parameter are first calculated using data from all subjects in the cohort. The average
cohort parameter value is then deducted from a given subjects results, and this
difference is then divided by the whole cohorts parameter SD. Thus for the PASAT:
CohortMeanVASAl -  SubjectrAS ll 
"1 IVI1 f 'ohortSD,,ASAI
Similarly, Z-scores are calculated for the TW T (Z/VVT) and reciprocal average o f  the 
HPT (ZIIHPT). The MSFC is then calculated as:
M S F C  =  ^ l/9///,/ ~  ^ 2 5 TWT +  ^ I ’ASAT
3
Relative merits  o f  the expanded disability status scale and  multiple sclerosis  
functional composite scores
The EDSS has a number of limitations related to its intrinsically non-linear 
nature and limited sensitivity to change (Hobart et al.,2000) and the M SFC was 
designed to address some of these issues. While the EDSS is weighted towards lower 
limb function, the M SFC was specifically designed to include upper limb and
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cognitive function in the score. In addition the components of the MSFC measure 
rather than classify function. There is evidence to suggest the inclusion of arm and 
cognitive function measures in the MSFC adds relevant information to such global 
scores of disability in MS (Kalkers et al.,2001), although the MSFC is not perfect 
and there is an argument in favour of using the components o f  the measure rather 
than the composite. Further, for a given EDSS score, clinicians will immediately 
have some conception of a given subject’s level of disability, i.e. if they require a 
walking aid or not, while the MSFC does not offer such readily accessible clinical 
information.
Neither the EDSS nor MSFC directly assesses the subject’s perceptions of 
disability, which will be central to their perceived well being and so the success or 
failure of a given treatment. The G uy’s neurologic disability scale (GNDS) is patient 
centred, and it would appear that on this scale, subject’s perceptions of disability 
correlate strongly with both the EDSS and MSFC (Hoogervorst et «/.,2001). The 
GNDS still potentially retains some bias toward a clin ician’s belief about the 
importance of symptoms, and more recently the MS impact scale (MSIS-29) has 
been developed using a more rigorous psychometric m ethodology (Hobart et 
tf/.,2001). Its clinical utility has yet to be established.
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2.2 M A G N E T IC  R E S O N A N C E  IM A G IN G
2.2.1 PHYSICS
MRI exploits the properties of subatomic particles in magnetic fields and 
their interactions with electromagnetic radiation. In the present work, the particle of 
interest is the hydrogen nucleus ('H), although other nuclei may be studied with 
MRI. Fortunately, 'H is ubiquitous in the human body, predominantly in the form of 
water, but also in observable amounts in a number of other molecules.
There are four main properties o f  materials (tissues) that are used by MRI to 
determine structural and constituent information: T, and T 2 relaxation times, proton 
densities (PD) and chemical shifts. These will be discussed in the following section. 
Electromagnetic properties o f 'H  nuclei
'H nuclei consist of single protons that exhibit a property known as nuclear 
spin. Nuclear spin can be thought of as a rotation about the centre of the particle 
which, if the particle is charged, creates a current loop which in turn produces a 
magnetic moment parallel to the axis of rotation. This is known as a magnetic dipole 
moment. Particles exhibiting this property are often referred to simply as spins.
In the presence of an external magnetic field (B0), spins will align themselves 
either parallel or anti-parallel to B(). These two orientations are linked to nuclear 
energy states: parallel orientation is a lower energy state than anti-parallel. Thus for a 
given spin, there will be a magnetic component parallel to B0, which by convention is 
designated the z-axis; if the spins are disturbed from equilibrium, there will also be a 
component in the xy-plane. If a 90° pulse (a radio frequency [RFJ pulse generated by
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the MR scanner) is applied, the spins magnetic moments can be fully tipped from the 
z-axis into the xy-planc.
Another property of spins is that they precess around B(), and if they are in the 
xy-plane this gives rise to an oscillating magnetic field in the xy-plane. The rate at 
which this field oscillates is described by the Larmor equation: 
co = yB0
where co is the angular precessional frequency expressed in radians per second or Hz, 
and y is the gyromagnetic ratio, which a constant for a given nucleus [y('H)=42.6 
MHz/Tesla), and B0 is the external magnetic field strength in Tesla.
MRI relies upon the absorption and emission of energy by spins in the form 
of electromagnetic radiation. The frequency at which spins both absorb and radiate 
energy is defined by the Larmor equation, and is given by co (in units o f  radian per 
second) or 2jtco (in units of Hz). For an MRI scanner operating at 1.5 Tesla, the 
frequency for 'H will be about 64 MHz, i.e. in the RF range of the electromagnetic 
spectrum.
Bulk magnetisation and Bloch equations
MRI does not look at single spins in isolation; observations are made on 
many spins simultaneously. Under such circumstances the bulk magnetic field (M) 
induced in a test material is actually observed and its behaviour under the influence 
of external magnetic fields and electromagnetic radiation is described by the Bloch 
equations. Assuming that B0 is parallel to the z-axis and RF pulses are applied in the 
xy-plane, the evolution of the components of the bulk magnetic field at a time t can 
be described by:
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where Mx, M y and M z are orthogonal components of M, and Bx, By and B, are 
orthogonal components of B, the magnetic field (comprising both the main magnetic 
field, along z, and the fields in x and y associated with RF pulses). M () (the steady 
state bulk magnetic field) is proportional to B0 and this relationship is described by:
where x  the magnetic susceptibility of a material. There are two other components 
to these equations, the T, (longitudinal or spin-lattice) and T2 (spin-spin) relaxation 
times. MRI makes use of differences in these properties between materials to provide 
contrast in structural images.
Tt relaxation
T, differs between materials, dependent of the rate at which excited spins can 
radiate energy into their surrounding molecular lattice (hence another name for T, 
relaxation being spin-lattice relaxation). The strength of M z at a time t after the 
application of a 90° RF pulse along (by convention) the x-axis is given by the 
equation:
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T2 relaxation
In a material exposed to an external field B() spins will all precess at 
approximately the same frequency, but any component of the net magnetisation in 
the xy-plane will be zero if the spins are not in phase with each other. If they are 
brought into phase an oscillating magnetic field in the xy-plane will be seen. In a 
perfectly homogeneous magnetic field, spins would always remain in phase, however 
the magnetic field experienced by individual spins will depend not only on B() but 
also surrounding spins distorting local field homogeneity. This will slightly alter the 
precessional frequency of individual spins, and will lead to dephasing with time. This 
in turn will result in the decay of M xy; following the application of a 90° RF pulse this 
is described by the equation:
M„XO = Mxy(0)e-,n'
T 2 is the transverse relaxation time, also known as the spin-spin relaxation time. This 
value will be correct in a perfectly homogeneous B() field but current technology 
cannot generate such fields. External B() field inhomogeneity will result in dephasing, 
leading to a reduction (shortening) of the apparent T2, and this value is denoted by 
T2*. A s  with T,, T 2 also varies between materials.
Proton density
Another factor influencing the potential MR signal is the number of mobile 
protons or proton density (PD) in a given volume o f  tissue. For example, CSF 
contains more mobile protons than either GM or WM, and so the maximum potential 
signal is greater for CSF than brain tissue. This has the effect of scaling the signal
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intensities predicted by the Block equations, and as illustrated below, this will alter 
apparent tissue contrasts.
Chemical shift
Spins in a given molecule will experience a slightly different external field to 
the main B() field, due to shielding of the nucleus by its electron cloud. This alteration 
in the apparent external field experienced by a given spin will alter its precessional 
frequency slightly, producing a frequency offset known as chemical shift. Many 
biological molecules contain a number of MR visible spins which are part o f  
chemically distinct groups (such as methyl or hydroxyl groups), all of which will 
experience slightly different external fields due to the molecular electron cloud 
patterns. This (in addition to J-coupling [described below]) will lead to a spectrum 
of frequencies being generated by such molecules. This spectrum provides a 
fingerprint for the molecule, and in 'H-M RS this is the basis of identifying 
metabolites and quantifying metabolite concentrations. Nuclear shielding can be 
summarised by the equation:
B, = /?„(!- a , )
where B, is the external field experienced by spin i, where the nucleus has a nuclear 
shielding term of a,. The shift in resonance frequency from a reference frequency (by 
convention rela tive to a very heavily  shielded com pound  know n a TM S 
(tetramethylsilane) is given in parts per million (ppm), a measure that is independent 
of B0. In these units, protons in water resonate at 4.7ppm, lipid protons at about 0.9- 
I.2ppm, and most metabolites somewhere in between.
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Spins in molecules may also experience J-coupling, which occurs when spins 
interact via chemical bonds. This further alters their precessional frequency, splitting 
spectral lines into multiplets. Small frequency differences between multiplets lead to 
phase shifts that may cause their signals may cancel out, leading to changes in 
apparent T2 relaxation times. Such effects may be observed for many molecules 
currently studied using 'H-M RS, although the relative importance o f  these differ 
(Govindaraju et al.,2000).
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2.2.2 STRUCTURAL IMAGING  
Inducing repeated T, and T2 relaxation
In order to determine T, and T 2 characteristics, the spins in the material must 
be repeatedly excited (i.e. magnetisation tipped into the transverse plane), and as 
noted briefly above, this is achieved using RF pulses. Recording the signal (voltage) 
in the coil immediately after an appropriate RF pulse has been applied reveals an 
oscillating decay curve, diminishing at a rate determined by the T 2* relaxation time. 
This is known as the free induction decay (FID) curve (see Figure 2.2.2a) and 
although it is not of great use in itself, using further RF pulses to induce echoes 
(effectively replicates of the FID) is.
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Figure 2.2.2a: Simulated free induction decay curve using average white matter 
relaxation values in a perfectly homogeneous 0.001 Tesla external field. Signal 
intensity is estimated relative to fully relaxed water maximum values.
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Radiofrequency pulses
Using RF pulses of a particular amplitude and duration, it is possible to 
effectively tip M z through any given angle: a 90° pulse will tip M() into the xy-plane; 
a 180° pulse will invert Mz. We are only able to detect a signal when there is net 
magnetisation in the xy-plane, and we rely upon tipping Mzinto M xy to determine the 
T, and T 2 characteristics of a material. A 180° pulse will not only invert Mz, but also 
effectively reverses the direction of precession experienced by individual spins. This 
is useful as it allows the generation of spin echoes by rephasing spins after they have 
experienced T 2* decay. By reversing the direction of precession but not the rate, 
dephasing related to B() inhomogeneities is unwound, resulting in a crescendo- 
decrescendo RF signal, known as a spin echo, that resembles mirror images of an 
FID baek-to-baek.
Echo and repetition times
Echo and repetition times (TE and TR) refer to scan acquisition parameters 
and by varying these values we are able to weight images based on the T, or T2 
characteristics of a material. The TR is the time interval between 90° RF in a series 
of excitations. As noted above there will be an FID immediately after this, although 
it is difficult to observe for technical reasons and instead imaging relies upon 
inducing spin echoes by applying further 180° pulses at given times after the initial 
90° pulse. This combination of RF pulses, along with the pattern of magnetic field 
gradients applied to encode spatial information in an image (see below), is known as 
a pulse sequence. Different pulse sequences can be used to probe different aspects of 
the MR signal, and provide different tradeoffs between image contrast, signal to
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noise, scan time and other considerations. Some examples are given in Figure 
2.2.2b). The time at which a spin echo is induced after the 90° pulse is known as the 
TE. Given that T, and T 2 decay occurs at different rates, by selecting appropriate 
combinations of TR and TE the resultant images can be weighted towards the T, or 
T 2 characteristics of a given tissue. Sequences with short TR and TE are T,-weighted 
while those with long TR and TE are T2-weighted, although it must be remembered 
that all sequences also have some degree of proton density weighting.
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Figure 2.2.2b: Images from a subject with MS acquired using a variety o f  sequences. 
From the top left clockwise: an inversion-prepared 3D fast spoiled gradient recall 
(FSPGR); 2D T,-weighted spin echo (SE); 2D T 2-weighted fast spin echo (FSE); and 
2D PD-weighted FSE. The slice thickness is 1.5 mm for the 3D FSPGR and 5 mm 
for the other images.
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Inversion preparation
While T,, T 2 and PD characteristics offer a reasonable degree of tissue 
differentiation there are situations where that nulling of signal from a particular 
tissue or fluid may be useful. In such a situation inversion prepared (also known as 
inversion recovery) sequences may be used. Rather than tipping M z through 90°, an 
initial 180° RF pulse is used to invert M z. M, will recover its equilibrium state at a 
rate determined by T, and will pass though a point where there is no net longitudinal 
magnetisation, the null point. If a 90° pulse followed by a further 180° pulse is 
applied at this time (known as the inversion time |TIJ) to generate a spin echo, Mz 
will be zero and there will be no resultant signal. As tissue T, values differ, signal 
from a particular tissue may be suppressed (selecting TI equal to In(2x7j)) ,  while 
retaining at least some signal from other tissues. In neuroimaging, this technique is 
most frequently used to null CSF (when it is known as FLAIR (fluid attenuation by 
inversion recovery) or fat (when it is known as STIR (short TI inversion recovery), 
although it could equally be used to null GM or WM. Inversion recovery prepared 
sequences can also be used simply to enhance TI contrast between tissues, choosing 
a TI that affects all the tissues but nulls none.
Spatial localisation
In order to generate either a structural image or localised measurement within 
a material, location in three dimensions has to be established: varying the frequency 
at which spins resonate, by applying magnetic field gradients, allows this.
By convention test materials are divided in to slices orthogonal to the z-axis, 
and slice selection is achieved by adding a gradient to the B0 field. This gradient
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makes the precessional frequency of spins proportional to their position along the z- 
axis, and by applying RF pulses within a defined frequency range, only those spins 
lying within a slab corresponding to these frequencies will be excited. The thickness 
of this slab depends upon the range o f  frequencies included in the RF pulse: the 
wider the range (bandwidth) the thicker the slice. It should be noted that this will also 
be dependent upon the magnitude of the B() gradient, thusfor a given RF bandwidth 
large B0 gradients will allow thinner slices than small gradients.
Having defined the slice to be acquired, position along the y-axis (usually the 
vertical axis) may be established using a phase-encoding gradient. This takes the 
form of a transient magnetic gradient applied along the y-axis that briefly alters that 
precessional frequency of spins such that they are systematically dephased by an 
amount denoting their relative position along the axis.
Position along the x-axis is determined by applying a frequency-encoding 
magnetic gradient during collection of a spin echo. This alters the frequency o f  the 
collected signal dependent upon location along the x-axis o f  the precessing spins, 
thus relative frequencies indicate position along the x-axis.
Image reconstruction
To extract the spatially encoded information from a spin echo Fourier 
transforms are em ployed to translate the time-domain signal into the frequency- 
domain. This yields the signal intensities at particular frequencies. In two- 
dimensional (2D) imaging, these define the x and y positions with a given slice, and 
the image is reconstructed as grid o f  intensities.
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Three-dimensional (3D) imaging is a modification of this, with the slice- 
selection gradient and RF pulse exciting the whole structure to be imaged, and then 
two phase-encoding gradients applied in the z and y directions, leaving frequency 
encoding to account for the x position as before. High-resolution 3D imaging has 
advantages over 2D imaging when reconstructing complex structures, although the 
former is generally limited to T,-weighted acquisitions due to lengthy scan times 
required for PD and T 2-weighting.
Fast imaging techniques
So far we have considered conventional MRI techniques to derive images. 
There are a number ways in which the process may be hastened, although there is a 
trade-off between speed and signal-to-noise ratio. M ethods include acquiring 
multiple echoes during one TR, reducing the RF pulse flip angles to allow reduced 
TR without incurring heavy TI weighting, and acquiring data more selectively. 
While such techniques yield images faster, they seek to do so with similar contrast to 
their conventional equivalents, and thus the previous discussion covers those issues 
needed to understand their practical application.
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2.2.3 PROTON MAGNETIC RESONANCE SPECTROSCOPIC IMAGING  
Spectra
W hile structural imaging relies upon a strong signal from water, MR 
techniques may also look for signals from other molecules, and 'H-MRS does 
exactly this. As noted above individual protons within a given molecule may have 
differing chemical shifts and thus a range resonant frequencies may be observed 
from a single molecule. In a given tissue, many different types o f  molecule 
contribute towards the seen signal, and Fourier transformation (now detecting 
inherent, rather than magnetic field gradient induced, frequency differences) reveals 
a range of overlapping peaks known as a spectrum (Figure 2.2.2c). The pattern of 
these signals act as a molecular fingerprint and, as with structural imaging, the 
intensity of the derived signal is proportional to molecular concentration. Metabolite 
peak locations may be reported both in Hz or parts per million (ppm). The former 
value depends on the B0 field strength, while the latter is the ratio between the peak 
location frequency and that of a reference frequency, and is independent of the B(); 
the latter is generally reported.
Water suppression
The signal from water dominates spectra (Figure 2.2.3a even after water 
suppression) and it is difficult to digitise the small amplitude signals from other 
molecules without some suppression of the water signal. In order to achieve this as 
series o f  chemical shift selective saturation (CHESS) pulses are em ployed to 
systematically stimulate and dephase water resonance signals. A single CHESS pulse
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can reduce the magnitude o f  the water signal by a factor of 100, and with multiple 
pulses able to achieve suppression by a factor of 1000.
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Figure 2.2.3a: A frequency-domain representation of a spectrum after CHESS water 
suppression; from left to right the main peaks are water (c 4.7 ppm), Ins (c 3.5 ppm), 
Cho (c 3.2 ppm), Cr (c 3.0 ppm), Glx (c 2.5 to 2.1 ppm) and NAA (c 2.0 ppm). See 
Figure 2.3.2a for an enlargem ent of the spectral region containing the main 
metabolite peaks.
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Spatial localisation
There are two commonly used methods used to localise the volume of interest 
for in vivo 'H spectroscopy examinations on clinical MR scanners, stimulated echo 
acquisition mode (STEAM) and point resolved spectroscopic (PRESS) localisation. 
Both rely upon using three slice-selective gradients, one along each axis, and three 
RF pulses. Only those spins at the intersection of all three planes defined by the 
slice-selection gradients are excited by all the pulses to yield a usable echo. PRESS 
sequences use one 90° and two 180° pulses while STEAM makes use of three 90° 
pulses. This allows the STEAM pulse sequence to be shorter than PRESS, enabling 
shorter TE at the expense of around 50% of the potentially available signal. For this 
reason, many studies now employ PRESS rather than STEAM.
'H-MRS imaging ( 'H-M RSI) extends this methodology by allowing spatial 
localisation within the volume of interest. This is achieved with phase-encoding in 
either one, two or three dimensions. Given that the frequency distribution of the 
detected signal contains chemical shift information, frequency-encoding cannot be 
used. The phase-encoded spatial information is extracted using Fourier transforms 
(FT), as for conventional structural imaging, while a further FT detects the spectral 
(frequency) information.
Outer volume suppression
While volume selection using PRESS or STEAM limits signal contamination 
from surrounding volumes it does not totally eliminate it. Signal from surrounding 
tissues can still contribute to the derived spectra and this can be a particular problem 
when the adjacent tissues contain significant amounts of 'H-MRS visible lipids. Such
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peaks can dominate spectra making quantification of metabolites less reliable. Outer 
volume suppression (OVS) complements volume selection by actively suppressing 
the signal from the outside the excitation volume. This is achieved in a similar way 
to CHESS water suppression with volume selective stimulation followed by 
dephasing.
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2.3 REVIEW OE SPECIFIC MAGNETIC RESONANCE M ETHODOLOGIES  
EMPLOYED
2.3.1 STRU C TU R AL IM A G IN G , TISSU E SE G M E N T A T IO N  A N D  VO LUM E  
MEASUREMENTS
There are four main issues to consider when selecting an acquisition for 
tissue volume estimation, these are: image acquisition times, contrast and resolution, 
and the segmentation technique to be used (discussed in the next section). Sequences 
must provide enough information to accurately and precisely define boundaries. The 
overall limiting factor is the SNR, and to maintain this while increasing image 
resolution at a given magnetic field strength requires a corresponding increase in 
scan times. This may be compensated for by the use of fast acquisition techniques, 
which typically have a greater efficiency (a greater SNR per unit time) than more 
conventional ones. It is desirable to keep acquisition times short, not simply for the 
comfort of the subject, but also to reduce the chances of the subject moving during 
the scan. Further, in those people with neurological disease, involuntary movement 
may lead to greater image degradation than would be observed in healthy control 
subjects, and so minimising scan times will help to limit any associated differentials 
in image quality.
Direct comparisons of the reliability of tissue segmentations derived from 
images of differing resolutions has not been extensively investigated, but for lesions 
in MS it appears that the higher the resolution the higher the precision o f  volume 
estimates (Filippi et al., 1997a; Molyneux et al.,1998b).
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Tissue segmentation also requires adequate image contrast to distinguish each 
type reliably. It would appear that for whole brain segmentation T,-weighting 
(perhaps further improved with inversion recovery preparation) offers better contrast 
between brain and CSF than T 2/PD-weighting, and this is reflected in higher 
precisions (Leigh et al.,2002). Differentiation of GM and WM is more difficult, 
although segmentation may be driven by both single (for example Ashburner et al. 
(2000)) and multi-contrast acquisitions (for example Alfano et al. (1997)). T 2 and 
PD-weighted images in general require longer scan times than T,-weighted images. 
This is due to the longer TR of such sequences which cannot be fully compensated 
for by the use of fast imaging techniques without loss of image quality (Mittal et 
<7 /., 1999). Given this, on balance it appears that T,-weighted 3D sequences are to be 
preferred for tissue volume estimation (Miller et al.,2002), offering a reasonable 
balance between resolution, contrast and scan acquisition times (voxels o f  1 mird 
with whole brain coverage can be acquired in under 10 minutes).
The reliability of volume determination is fundamentally limited by the 
quality o f  the images acquired and scan processing needs to be optimised to 
maximally realise this potential. A variety of approaches have been employed and all 
rely upon being able to partition volumes, either by directly identifying boundaries or 
by classifying individual voxels. While there is a wide range of techniques available 
to segment images (Miller et al.,2002), there have been few direct comparisons of 
techniques allowing an objective assessment of their relative merits (Leigh et 
al.,2002). Automated methodologies are generally more time-efficient than manual
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or semi-automated procedures, particularly when applied to high-resolution images, 
and are less open to operator bias.
Image non-uniformity associated with B, field inhomogeneity tends to lead to 
reductions in apparent tissue signal intensities, in particular in the brainstem and 
cerebellum when imaged using standard head-coils. This has lead to the development 
of a variety of correction strategies, some based upon phantom studies and others 
estimating bias fields directly from the images to be segmented. Which approach is 
optimal has yet to be clearly established and, as with segmentation techniques, there 
has been little work directly comparing inhomogeneity correction strategies (Arnold 
e t a i ,  2001).
Tissue volumes may be estimated either as absolute values or as fractions of 
an invariant volume. Absolute measures may be significantly influenced by random 
inter-subject variability and scanner scaling effects that may ablate sensitivity to age, 
gender and disease effects. The intracranial volume is an invariant measure that 
allows for random scanner scaling effects, yielding fractional volume estimates 
which are more temporally stable than their absolute equivalents (for example 
(Whitwell et al.,2001)). Such fractional measures have firmly established themselves 
in the study of atrophy in MS (Miller et al.,2002).
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2.3.2 P R O T O N  M A G N E T IC  R E S O N A N C E  I M A G IN G  A N D  M E T A B O L IT E
CONCENTRATION QUANTIFICATION
As noted in section 2.2.3 spectra may be acquired as single voxels or as part 
of spectroscopic volumes, as in 'H-MRSI. However, in terms o f  time to acquire a 
voxel, the latter is much more time efficient i.e. for a given voxel size and SNR, 
acquiring multiple voxels as a 'H-MRSI grid is faster than acquiring the same voxels 
separately. However, homogenously shimming the spectroscopic volume becomes 
more difficult the larger it is, leading to poorer line widths in the resulting spectra. In 
'H-MRSI. voxels at the edge of the volume may also not be fully excited, leading to 
lower signal intensity and problems with quantification, although this problem can be 
alleviated by exciting a region larger than that from which useable information is 
desired, and by using smaller voxels i.e. more phase-encode steps.
Disease associated effects upon metabolite T, and T 2 characteristics also need 
to be considered, particularly with relatively long TE and short TR sequences. For a 
hypothetical metabolite with a T, of 1.5 s (at the upper limit that estimated for Cr, 
Cho, Ins, Glx and NAA at 3T or less) and T 2 of 150 ms (at the lower limit o f  that 
estimated for Cr, Cho and NAA at 3T or less (Mlynarik et al.,2001)) quantified using 
a sequence with a TE of 30 ms and TR of 3 s (as employed in this work), a 10% 
change in signal would require a circa 35% change in either T, or T2; a 5% change in 
signal would require a circa 15% change in T, or a greater than 20% change in T2. 
For metabolites with shorter T, and longer T2, the percentage changes required will 
be correspondingly larger, thus these estimates represent lower limits for the
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percentage T, or T2 change required. For sequences with longer TE and shorter TR, 
the percentage changes required will be smaller.
Having obtained spectra, it remains to quantify metabolite concentrations 
from them. Most techniques make use of frequency-domain spectra, and the present 
discussion will be limited to this, although it is possible to use the time-domain data 
directly ( V an h am m e et « / . ,2 0 0 1). The two approaches should ultimately be 
equivalent although the former is intuitively more readily appreciated.
Given that the area of a frequency-domain peak is related to the number of 
spins contributing towards it, it is possible to use peak area or height as an estimate 
of a metabolites concentration. While NAA, creatine (Cr) and choline (Cho) may be 
quantified in this way, metabolites which show multiplet rather than singlet peaks, or 
short TE acquisitions with more complex spectral patterns benefit from more 
sophisticated analyses techniques. Early studies tended to report peak areas or 
heights as ratios to apparently stable metabolites such as Cr. However, Cr 
concentrations may be altered in disease states (Rooney et a/., 1997; Suhy  et 
al.,2000), and changes with age (discussed below), and as such, the reporting of 
ratios makes pathological interpretation even more difficult. In order to avoid this, 
calibrated absolute quantification techniques have been developed. An example of 
such a method is the Linear Combination Model (LCM odel) developed by 
Provencher (Provencher, 1993). It is a phantom calibrated absolute quantification 
technique that makes use of previously acquired model spectra from a range of 
m etabolites  that it com bines using linear scaling to es tim ate  m etabo lite  
concentrations. Processing also estimates a spline fitted baseline, to account for
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residual water signals and broad peaks not included in the metabolite basis sets, such 
as lipids.
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LCModel (Version 5.2-1) Copyright: S  W. Provencher Ret Magn Reson. Med. 30:672-679(1993).
3.8 3.64.0 3.4 3.2 3.0 2.8 2.6 2.4 2.2 2.0 1.8 1.6 1.2 1.01.4
Chemical Shift (ppm)
Figure 2.3.2a: Typical output from LCModel. The fitted spectrum (in red) overlays 
the observed spectrum, below which is the spline fitted baseline. The residual 
difference between the observed and fitted spectrum is shown above.
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2.4 PATHO LO GICAL INTERPRETATION OE M A G N E T IC  R ESO N AN CE  
IMAGING OBSERVATIONS
2.4.I TISSUE VOLUMES IN NORMAL CONTROL SUBJECTS
In order to assess abnormal brain volumes or atrophy, we first need to 
establish what is normal. Understanding of this is limited by a absence of either a 
clear gold standard in vivo or post mortem measurements with which to calibrate 
MRI observations. While there appears to be reasonable agreement between MRI 
and pathology studies on whole brain volumes, assessment of grey and white matter 
volumes is more problematic. Pathology studies suggest a grey to white matter ratio 
of between 1.1 and 1.5 (Miller et c//.,1980), while a variety of MRI measures have 
estimated ratios of between 1.2 and 2.0 in adult populations (Blatter et al., 1995; 
Brunetti et al.,2000; Gur et al., 1999; Guttmann et al., 1998; Harris et al., 1994b; 
Resnick et al.,2000). Pathology studies are likely to be affected by pre and post 
m ortem tissue degenera tion , and tissue fixation  arte facts  that need not 
homogeneously affect tissues (Messert et al., 1972; M iller et al., 1980; Yates et 
al., 1975); MRI studies are significantly influenced by differences in scan acquisition 
and segmentation methodologies. Therefore neither can be considered as offering 
completely accurate tissue-specific reference values. Given these difficulties 
establishing validated tissue volumes in quite large regions, it may be expected that 
smaller structures will be even more problematic.
When looking at the effects of age, gender and disease effects, there are some 
further issues that need to be addressed: cross-sectional versus longitudinal data;
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biological variability ; ad justm ents  for intra-cranial volum es; m easurem ent 
reproducibility; and statistical modelling. Considering these further:
i. Many MRI studies, and by definition all post mortem studies, are cross- 
sectional and so may be influenced by secular trends i.e. differences between 
generations of people (Miller and Corsellis, 1977). Longitudinal studies 
should be less vulnerable to confounding by such trends;
ii. The variability inherent in tissues may differ - one region or tissue may show 
quite marked inter-subject variability while another may not;
iii. Correction for intra-cranial volumes has been found to reduce the inter­
subject variability in brain tissue volumes, yielding measurements apparently 
more sensitive to age, gender and disease effects. However, the amount of 
inter-subject variability controlled for by this correction may differ between 
the tissues or brain regions, so leaving proportionally different amounts of 
residual variability;
iv. The reproducibility of tissue specific and regional measurements may differ, 
leading to methodologically related differences in data variability;
v. These factors may in turn influence the apparent magnitude and statistical 
s ignificance of age, gender and disease effects upon tissue specific or 
regional volumes. Results derived from modelling of such data should be 
considered in this context.
It appears that, on average, women have smaller brain volumes than men (the 
average brain volum e being approxim ately  1400 ml in adult m ales and 
approximately 1235 ml in females (estimated using a tissue density figure from
69
(Miller et al., 1980) and brain weights from (Pakkenberg and Gundersen, 1997)), and 
that this difference is predominantly due to smaller white matter volumes in women 
with, to a lesser degree, larger grey matter volumes in men (Good et <a/.,2001; Gur et 
al., 1999; Pakkenberg and Gundersen, 1997; Passe et al., 1997; Reiss et al., 1996; 
Resnick et al.,2000).
In adults, present evidence suggests that ageing effects both grey and white 
matter at an overall rate o f  tissue loss of about 0.2 to 0.3% per year (Blatter et 
al., 1995; Brunetti et a l. ,2000; Good et al.,2001; Gur et al., 1999; Guttm ann et 
a l . , \998; Harris et al., 1994b; Jernigan et al.,2001; Lim et al., 1992; Meier-Ruge et 
al., 1992; Miller et al., 1980; Pakkenberg and Gundersen, 1997; Passe et al.,1997; 
Pfefferbaum et al., 1994; Raz et al., 1997; Resnick et al.,2000). Whether this occurs 
simultaneously, or whether one tissue predominates over the other for certain periods 
remains open to debate. A significant number of studies attribute age-related brain 
atrophy predominantly to grey matter volume loss (Blatter et al., 1995; Brunetti et 
al.,2000; Good et al.,2001; G ur et al., 1999; Lim et al., 1992; Passe et a/., 1997; 
P fefferbaum  et al., 1994; Raz et a l . , \991 ) .  However, a number o f  studies have 
suggested that white matter atrophy may be more prominent than grey matter 
atrophy, most noticeably in those aged 70 and over (Guttmann et al., 1998; Jernigan 
et al.,2001; Meier-Ruge et al., 1992; Miller et al., 1980). A general decline in brain 
tissue volumes in adults appears to be reflected by increasing ventricular volumes 
(Blatter et al., 1995; Coffey et al., 1998; Good et al.,2001; Guttm ann et al., 1998; 
Jernigan et al.,2001; Pfefferbaum et al., 1994; Resnick et al.,2000) although this may 
not be prominent in younger adults (Gur et al., 1999). These findings suggest that
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assumptions of linear changes in brain volume with ageing may not be ideal, 
particularly in subjects below the age of 20, when brain maturation may still be 
occurring (Pfefferbaum et al., 1994; Reiss et al., 1996), and those over the age of 70.
Ageing also appears to show regional variability over and above tissue 
specific differences (Coffey et al., 1992; Good et al.,2001; Jernigan et al.,2001; Raz 
et al., 1997; Resnick et al.,2000), although studies differ in their localisation of this. 
Significant age-gender interactions have also been observed (Blatter et al., 1995; 
Coffey et al., 1998; Good et al.,2001; G ur et al., 1991; O guro et al., 1998; Xu et 
al.,2000), although the magnitude of this effect may vary between brain regions 
(Coffey et al., 1998; G ur et al., 1991; Raz et al., 1997; Xu et c//.,2000). It is also 
important to note that tissue signal intensity characteristics may also alter with age 
(C o f fe y  et al., 1992; Jern igan  et al.,2 0 0 1 ) ,  and this may influence tissue 
segmentation, leading to erroneous results.
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2.4.2 PATHOLOGICAL SUBSTRATES OF BRAIN TISSUE ATROPHY
Volumetric brain measurements on their own cannot define the intrinsic 
characteristics of the tissue being quantified (i.e. its cellular composition); this is the 
realm of other MRI measurements and histopathology studies. However, for a given 
tissue, they can help to quantify the extent and, in combination with measurements of 
composition, the magnitude of disease effects.
Studies in normal controls highlight the difficulties associated with 
interpretation of brain tissue volume measurements. In a post mortem study of 
previously healthy controls, an age related 9.5% reduction in neuron numbers was 
mirrored by a 12.4% reduction in neocortical volume and 28.0% reduction in white 
matter volume (Pakkenberg and Gundersen, 1997). Similarly, a gender related 
difference in neuron numbers o f  15.5% was mirrored by a 14.9% difference in 
neocortical volume and an 18.1% difference in WM volume. The disparity between 
neocortical and white matter atrophy suggests that, particularly in white matter, 
additional factors contribute towards volume loss, and it would appear that glial cell 
loss may also be a significant factor, particularly in those over 70 years of age 
(Meier-Ruge et al., 1992). However, as noted above, these observations may be 
influenced by pre and post mortem effects; in particular tissue oedema which may 
mask underlying tissue atrophy (Messert et al., 1972; Yates et al., 1975).
In MS studies, it seems reasonable to assume that, with certain caveats, brain 
tissue atrophy marks neuronal and axonal loss (Miller et al.,2002). However, other 
factors may also influence apparent tissue volume loss and this need not be 
consistent between tissues. Inflammation associated with oedema and demyelination
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is more marked in white matter than grey matter (discussed above) and so may be 
expected to have more obvious effects upon white matter rather than grey matter 
volume measures. Oedema may transiently mask atrophy, while demyelination may 
both directly lead to volume loss and also result in secondary axonal atrophy (Yin et 
a/.. 1998).
73
2.4.3 PATHOLOGICAL SUBSTRATES OF FOCAL BRAIN LESIONS
The effects of MS appear to be heterogeneous with relatively focal changes 
observed both on histopathology and MR examinations. Focal changes are more 
readily apparent on T 2-weighted MRI than direct inspection of pathology specimens 
(De Groot et al.,2001), while lesion changes are variably visible on MRI.
Image contrast and resolution both appear to alter the discernable lesion load. 
Considering image contrast first, fast fluid-attenuated inversion-recovery (FLAIR) 
sequences appear to detect slightly more lesions that T 2-weighted FSE sequences 
(Tubridy et al., 1999). FLAIR acquisitions appear to be significantly more sensitive 
than T 2-FSE to cortical and subcortical lesions (Bakshi et al.,2001; Tubridy et 
al., 1999), although they may be less sensitive to posterior fossa lesions (Tubridy et 
al., 1999) which may negate increased sensitivity elsewhere. Lesions are usually seen 
as hyper-intensities on such sequences, although as an interesting aside, regional 
hypo-intensity particularly in the basal ganglia and thalamus has been observed and 
attributed to iron deposition (Bakshi et al.,2000). Focal changes are generally less 
conspicuous on T,-weighed images, and are seen as hypo-intensities. T, lesions 
appear to represent a subset of T2 lesions, and as such ratios between the two may 
offer an indication of the degree of tissue damage within lesions (M cFarland et 
al., 2002).
Focal enhancem en t on T ,-w eighted im aging post in travenous (IV) 
administration of gadolinium (Gd) is generally accepted as a marker of breakdown in 
the BBB associated with acute inflammation (Bruck et al., 1997; Katz et al., 1993). 
Sensitivity to such changes appears greater when using triple dose Gd (0.3 mmol/kg)
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rather than single dose, with about a 70% increase in enhancing lesion counts (Filippi 
et al.,\ 995; Silver et <7 / . ,  1997). Further, such lesions tend to enhance for less than a 
month (Silver et al., 1999; Tortorella et al., 1999), and so the frequency of scanning 
may affect the adequacy of estimates (Lai et al., 1996). Such lesions are more 
frequently seen on T 2 rather than un-enhanced T,-weighted images, and they tend to 
persist on the former while resolving on the latter (Paolillo et al., 1999; van 
W alderveen et al., 1999b). Further, enhancing lesion loads tend to correlate more 
strongly with changing T, rather than T, lesion loads (van Walderveen et al., 1999b). 
Considered together, this would suggest that T2, and to a lesser degree, T, lesion 
loads represent accumulated focal inflammation. However, this view is challenged 
by the observation that Gd-enhancing lesions and T 2 lesions do not show the same 
spatial probability distributions (Lee et al., 1999). While this discrepancy may indeed 
indicate that T2 lesions need not show Gd-enhancement at any stage, the possibility 
of regional variability in the duration of enhancement needs to be explored.
Returning to the issue of image resolution, it has been noted that decreasing 
slice thickness may improve lesion identification by reducing partial volume effects 
(Filippi et al., 1998c; Molyneux et al., 1998b), although this may have little effect on 
the relationship between lesion loads and clinical outcomes (Rovaris et al., 1998b).
T 2 and T, lesions may have differing pathological weighting and thus 
specificity. While both may be influenced by extracellular oedema, demyelination 
and axonal loss, T, hypo-intense lesions tend to be weighted towards axonal loss in 
chronically affected MS lesions rather than acute inflammatory activity (De Groot et 
al.,2001; van Waesberghe et al., 1999; van Walderveen et al., 1998a; van Walderveen
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et al., 1998b) while new Tr weighted lesions would appear to be, in part, related to 
acute inflammatory changes (Lee et al., 1998), although an appreciable proportion of 
acute lesions display T, hypointensity that resolves over several months (Minneboo 
et al.,2005). Correlations between disability, as assessed by EDSS, and lesion loads 
appear to be greater for T, rather than T 2 lesion loads (McFarland et al.,2002).
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2.4.4 TISSU E M ET A B O LITE  C O N C E N TR A TIO N S IN N O R M A L CO NTRO L  
SUBJECTS
It is difficult to directly compare studies estimating tissue specific metabolite 
concentrations due to significant differences in the methodologies used to identify 
tissues and quantify metabolites. Further, there are considerable differences in data 
presentation, with results given as ratios to Cr or Cho, in institutional units, or 
mmol/1. Given this, only broad qualitative comparisons can be made. There are a 
reasonable number of studies looking at the relative concentrations of Cr, Cho and 
NAA in GM and WM, with somewhat fewer measuring Ins and Glx (see Table 
2.4.4a). Overlying tissue specific differences there may also be regional differences 
within given tissue types. While a number of studies have looked for regional effects 
without allowing for potential tissue specific differences, one study did (Wiedermann 
et al.,2001), producing results that suggest higher concentrations of Cr, NAA and 
Ins, and lower concentrations of Cho when comparing frontal and parietal lobe GM. 
Histopathology studies exploring tissue specific metabolite concentrations have been 
limited: Petroff and colleagues (1989) found that the anterolateral temporal lobe GM 
contained more Cr, NAA and Glu than the underlying WM, although such 
differences were not observed in other GM regions.
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Study GM to WM metabolite ratio
Cho Cr Glx Ins NAA
Soher et al. 1996 0.9 1.2 ND ND 0.9
Chang et al. 1996 1.0 1.2 ND 1.0 1.2
Wang et al. 1998 1.2 1.9 ND ND 1.5
Pan et al. 1998 0.9 1.4 ND ND 0.8
Pfefferbaum et al. 1999 0.8 2.0 ND ND 1.3
Noworolski et al. 1999 0.8 1.4 ND ND 1.3
Chang et al. 1999 1.4 1.3 1.6 1.2 1.2
Saunders et al. 1999 0.7 1.2 ND 1.1 1.1
Lundbom et al. 1999 0.8 1.3 ND ND 0.7
McLean et al. 2000 0.9 1.7 2.4 1.6 1.2
Wiedermann et al. 2001 0.5 1.1 ND 0.9 0.9
Schuff et al. 2001 1.7 1.8 ND ND 1.6
Table 2.4.4a: Grey to white matter metabolite ratios.
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Age and gender effects may also be present. However, it should be recalled 
that the resolution of 'H-MRS techniques are limited and so the volumes sampled are 
generally composites of WM, GM and other tissues, along with variable amounts of 
CSF. Factors affecting the regional distribution of these tissues, such as age and 
gender (see section 2.1.4), may confound results by altering the contents of 
apparently tissue specific voxels.
Acknowledging these limitations, there seems to be a relatively consistent 
trend towards increasing Cr and Cho with age in WM, while age effects on Ins, NAA 
and Glx are more mixed (Leary et al.,2000; Pfefferbaum et al., 1999; Schuff et 
al.,2001; Soher et al., 1996).
It has been suggested that increasing Cho and Cr may mirror decreasing brain 
water contents with age (Chang et al., 1996), and such hydration effects may offset 
age-related changes in other metabolites associated with cell loss. Gender differences 
have not been extensively explored but may also be present (Grachev and Apkarian, 
2000).
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2.4.5 P A T H O L O G I C A L  S U B S T R A T E S  O F A L T E R A T I O N S  IN TISSUE
M ETABOLITE CONCENTRATIONS
While measurement o f  metabolite concentrations does provide some useful 
insight in cell densities and cellular metabolic activity, disentangling these two 
components have proven difficult. By combining information from a variety of 
concurrently estimated metabolite concentrations, we can begin to consider the 
interplay between metabolic turnover and cellular density, although it is presently not 
possible to derive pure estimates of either.
Creatine
The Cr peaks (main peak 3.0 ppm) in 'H-MRSI include contributions from 
both creatine and phosphocreatine (Miller, 1991). Phosphocreatine serves as a high- 
energy phosphate donor, and through creatine kinase (CK) activity maintains 
adenosine-triphosphate (ATP) concentrations (Wyss and Kaddurah-Daouk, 2000). Cr 
concentration in the brain appears to be linked to CK activity and thus energy 
metabolism. Concentrations seem to be higher in GM than WM, mirroring ATP 
turnover (Wyss and Kaddurah-Daouk, 2000). Given this, Cr appears to mark energy 
flux in the brain, and this will be a function of both cellular density and metabolic 
activity.
Choline
The Cho peak (main peak 3.2 ppm) consists predominantly of phosphoryl- 
choline (PC) and g lycero-phosphory l-cho line  (GPC), a lthough phosphoryl-  
ethanolamine (PE) and glycero-phosphoryl-ethanolamine (GPE), and in certain 
disease conditions, free choline may also contribute towards the measured signal
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(Bluml et al., 1999). These choline containing compounds are mostly precursors or 
degradation products of cell membrane phosphatidyl-choline, which does not directly 
contribute significantly to the Cho peak due to its immobility. 'H-MRSI observable 
Cho appears to mark membrane turnover, of which there will be elements related to 
normal cellu lar function and cellu lar degradation (B oulanger et al.,2 0 0 0 ) .  
Concentrations vary dependent on the degree and activity o f  myelination and 
demyelination (Bluml et al., 1999). In MS, increases have been directly linked to glial 
proliferation (Bitsch et al., 1999).
Inositol
The Ins peak (main peak 3.6 ppm) marks myo-inositol, which is synthesised 
from recycling of inositol-phospholipids and de novo  from glucose-6-phosphate. 
Free inositol appears to have a role in intra-cellular osmoregulation, and in the 
synthesis of second messengers (Lubrich et al.,2000). It is particularly concentrated 
in glial cells when compared with neurons (Brand et al., 1993; Glanville et al., 1989) 
and appear to be higher in astrocytes when compared with oligodendrocytes (Urenjak 
et al., 1993) or oligodendrocyte type 2 astrocyte ( 0 2 A) progenitors (Griffin et 
al.,2002c). In MS a combined ‘H-MRS and histopathological study has shown it to 
be a marker of glial proliferation (Bitsch et al., 1999).
N-acetyl-aspartate
The tNAA peaks (main peak 2.0 ppm) comprise both N-acetyl-aspartate 
(NAA) and N-acetyl-aspartyl-glutamate (NAAG). NAA is predominantly localized 
to neurons in the adult CNS (Simmons et al., 1991), although it may also be found in 
mature oligodendrocytes (Bhakoo and Pearce, 2000) and 0 2 A  progenitors (Urenjak
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et al., 1992). Its function remains unclear. It is synthesised primarily in neurons 
(Baslovv, 2000), although its almost complete absence is compatible with neuronal 
survival (Martin et al.,2001). There is evidence to suggest that it may be related to 
myelin formation or maintenance or both (Chakraborty et al.,2001), but this remains 
to be clarified. NAAG is synthesised from NAA, and appears to have a role as 
neurotransmitter (Neale et al.,2000). Changes in NAA levels may be transient and 
related to mitochondrial metabolic dysfunction (Demougeot et al.,2001; Mader et 
al.,2000; Narayana et al., 1998) although it has been confirmed as a marker of axonal 
density in MS lesions (Bitsch et al., 1999), mature WM tracts (Bjartmar et al.,2002), 
and the spinal cord (Bjartmar et al.,2000).
Glutamate and glutamine
Glutamine is synthesised in astrocytes predominantly from cycling of 
glutamate, a major excitatory neurotransmitter, and this process appears to be tightly 
linked to glucose metabolism (Rothman et al., 1999). Thus, like Cr, alterations in 
apparent Glx concentrations may be related to neuronal and glial cellular density and 
metabolic activity.
82
2.5 F A C T O R S  I N F L U E N C I N G  D A T A  P R O C E S S I N G  A N D  
INTERPRET A TION
In order to effectively and realistically interpret the results of measurements, 
it is necessary to know something of the characteristics of the measurement 
techniques employed. We need to know that a measure is a valid representation of 
the property we wish to assess, that the measurement technique is reliable (precise, 
reproducible) and, preferably, that it is accurate. These concerns apply equally to the 
MRI and clinical measures, and this should be recalled when interpreting results.
Measurement error may be decomposed into a bias or systematic error, the 
difference between the true value and that estimated by the measurement technique, 
and subject error, the random variability due to errors in data acquisition and entry. 
This may be summarised as:
A ', =  •/; +  h +  /■;,
where X, is the observed measure in subject /, T, is the true value in subject /, b is the 
bias in the measurement, and E, is the subject error (an estimate of precision) 
(Armstrong et al., 1992). Some authors use the term accuracy to include both b and 
Eh while others restrict its use to b alone.
Precision
The precision of a measure refers to observation variability about a true value 
as assessed using that measure. In clinical studies, this usually involves repeated 
measures in a group of subjects. Variability in the resultant measures will then relate 
both to inter-subject factors such as age and gender effects, and intra-subject factors
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such as random biological variability in the param eter being estimated and 
measurement errors.
Reliability (reproducibility) may be presented in a variety of ways. It may be 
given as within-subject (intra-subject) standard deviations (SD) (Bland and Altman, 
1996c); as repeatability, which is the 95% limit for the difference between two
replicate measures, calculated as V2 x 1.96 x within-subject SD (Bland and Altman, 
1996c); as a coefficient of variation (CV), a dimensionless estimate of variability 
calculated as the within-subject SD divided mean parameter values (Bland and 
Altman, 1996b); and as a reliability coefficient (RC), defined as the ratio of between- 
subject variances to total variance (also known as the intra-class correlation 
coefficient [ICC]) (Bland and Altman, 1996a).
The concept of partitioning variability to within and betw een-subject 
components may be extended to further refine estimates o f  the sources of this 
variability. Data from appropriately designed experiments, interrogated using 
variance components analysis (Tedesch i et al., 1996), allows this. For example 
within-subject measurement variability of an MR measure may involve both random 
repositioning and intrinsic measurement errors. By repeating measures with and 
without repositioning in the same subjects, the relative magnitude o f  these effects 
may be ascertained.
Sensitivity and power
Related to the precision of a measure is its sensitivity to change with time and 
differences between groups. Using estimates of measurement error, an estimate of 
the cohort sizes required to be able to detect a defined difference with a defined
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probability may be made. In order to be able to detect a difference d  at a P<0.()5 level 
90% of the time, the size of the cohort required, n, may be approximated by:
where SDW represents within-subject SD (Bland, 1987). Such an estimate may be 
useful when interpreting results from various measurement techniques.
Bias and calibration
The bias of a measurement refers to its systematic relationship to a true value. 
This may be observable when a gold standard technique is available, or unobservable 
when one is not. Given the absence of such standards, many MRI measures may be 
considered at best methodologically accurate, i.e. yield consistent results when 
applied to the same sample when independently implemented. This means that 
absolute values derived from various techniques may not be considered equivalent, 
and while conclusions from previous studies may be used to inform interpretation of 
data, raw results should not be directly compared.
In order to improve methodological accuracy, measures may be calibrated 
using samples with known characteristics. Such calibration experiments serve two 
purposes: they enable some degree of objective in vitro accuracy to be established; 
and as part of quality assurance, they allow the temporal stability of measurements to 
be assessed and fluctuations adjusted for. Such experim ents  are critical in 
longitudinal studies, particularly when there is an alteration in the scanner hardware 
and or software due to component failure, preventative maintenance, or an upgrade.
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Differential measurement error
Measurement errors may not be the same in two groups, and if not treated 
appropriately this may lead to both ablation of genuine differences and the 
introduction of artefactual differences. Differential subject errors will tend to obscure 
relationships, while differential biases may have mixed effects. Biases may also be 
related to a confounding factor, for example estimates of brain tissue volumes may 
be altered systematically by the presence of focal lesions. Careful consideration 
should be given to the potential for such effects and their impact upon any 
conclusions drawn from a study.
Validation
Validation of a measure ideally employs a gold standard against which the 
technique under investigation is compared. However, in many instances MRI 
measures are the only way to assess a parameter in vivo, offering no absolute 
measure of the property they purport to quantify. In such circumstances, validity may 
still be explored; under certain circumstances it has been shown that the square root 
of the RC estimates the correlation between the observed measure and the true value 
of the parameter, and so in the absence of a gold standard, an estimate of the validity 
of the measure may still be obtained (Armstrong et al., 1992). This parameter is 
referred to as the validity coefficient (VC).
However, establishing how closely observations relate to a true measure 
when there is no gold standard, does not tell what is represented by the true measure. 
In this situation, construct validity needs to be considered. This takes evidence from 
other sources, and constructs hypotheses that can be tested to confirm that the
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measure assesses what it is supposed to. Taking as an example the validation of the 
EDSS by Hobart et al. (2000), they postulated that if this was a measure of disability 
then correlations with other measures of disability would be high while those with 
measures of handicap would be low, that such correlations will be predictably 
ranked, and that there should be no correlations with age.
Measurement purity
MR parameters may be influenced by a variety of factors, and thus when 
considering their validity we need to be very clear what we expect them to measure, 
and where the measurement ends and interpretation of the results begin. For 
example, a valid measure of brain tissue volume measures may not be directly 
assumed to be an equally valid measure of brain neuronal populations, although it 
may be interpreted in such terms.
Attenuation
Random errors will tend to attenuate the strength of relationships between 
parameters and thus limit the maximum strength of observable associations. An 
estimate of this attenuation may be obtained by from the reliabilities (Armstrong et 
a/., 1992). Thus:
where /3() is the observed correlation between two measurements X,  and X 2, , is
the true correlation, and p lx and p rx are the reliability coefficients of the
measurements. For example an inter-rater ICC for EDSS has been estimated at 0.78 
(Hobart et al.,2000), while for T 2 lesion loads, an intra-rater ICC of 1.00 has been
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estimated (Molyneux et al., 1998a). Assuming a perfect relationship between EDSS 
and T, lesion load, it may be expected that the maximum observable correlation 
would be attenuated to around 0.78.
Confounding factors
Factors that may spuriously influence our results are termed confounders. For 
example, we may wish to look for gender effects (strictly speaking we should say sex 
effects, although it is rare for sex to be objectively confirmed in studies not directly 
addressing sex-specific features) in a given parameter. However, if we do not 
consider age, and there is a significant age imbalance between males and females, 
apparent gender effects may be confounded by age and so be incorrectly quantified. 
Data models
Given this, the complexity of the data should dictate the complexity of the 
models used to extract information from them. A frequently employed technique is 
multiple linear regression, a subset of general linear modelling. This allows the 
simultaneous assessment of a variety of factors, both continuous covariates such as 
age, and categorical variables such as gender or disease type. Such models may be 
constructed in a variety of ways, and there are no clearly established methods for 
defining what is and is not optimal (Freund and Wilson, 1998). Prior information, be 
this from logical deduction or evidence from other studies, combined with clear 
definitions of the questions to be answered, should be used to inform initial model 
design. Models may subsequently be refined, as dictated by initial findings, to yield 
results robust to confounding factors.
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It could be argued that such data modelling lacks objectivity and that simple 
statistics such as a t-test should be consistently employed. However, such an 
approach is still effectively modelling the data, albeit using a very simple model, and 
as such is just as open to accusations of subjectivity, and perhaps more open to 
questions of confounding. Given this, a pragmatic approach to data modelling would 
counsel the use of the simplest model that adequately explains non-random 
variability.
Data interpretation
It is sobering to recall that P stands for probability in statistical tests and 
values of 1 or 0 (absolute certainty) are generally not seen. Results may be wrong, 
indeed the conventionally accepted significance level of P<0.05 accepts that 1 in 20 
times the conclusions drawn from a single test will be incorrect. Further, in a given 
study, as the number of statistical comparisons undertaken increases, so does the 
likelihood that there will be a result spuriously reaching significance; if 10 
independent comparisons are undertaken, the probability of one or more falsely 
significant results is 0.40, with 20 comparisons it is 0.64 (Bland, 1987). This 
counsels a cautious approach to interpretation of derived results, with multiple 
sources being drawn upon to increase confidence.
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3 M EASUREM ENT CHARACTERISTICS
3.1 M A G N E T IC  R E S O N A N C E  DATA A C Q U IR E D  A N D  P R O C E SSIN G  
TECHNIQUES EM PLO YED
All scans included in this work were acquired using General Electric Signa
1.5 T systems (General Electric Medical Systems, Milwaukee, WI, USA) and a 
standard quadrature head coil.
3.1.1 STRU C TU R AL IM AG IN G , TISSU E SE G M E N TA TIO N  AN D  VO LUM E  
M EASUREM ENTS
Scan acquisition
V olum etric im aging utilised an inversion recovery  prepared three- 
dimensional fast spoiled gradient recalled (3D FSPGR) scan (TR 13.3 ms, TE 4.2 
ms, inversion time 450 ms, matrix 160 * 256 interpolated to a matrix of 192 * 256, 
field of view 225 * 300 mm, final in plane resolution 1.2 mm by 1.2 mm, with 124
1.5 mm slices covering the whole brain). All data-sets were orientated with the axes 
of the imaging volume coincidental to the axes of the scanner gradients. Axial 
reconstructions were used for all processing and analyses.
During a separate scanning sessions, dual echo fast spin echo (FSE) 
sequences (TR 2000 ms, effective TE 19/95 ms, NEX 2, in plane resolution 0.9 mm 
by 0.9 mm with 28 x 5 mm slices covering the whole brain) and T,-weighted spin 
echo sequences (TR 540 ms, TE  20 ms, NEX 1, in plane resolution 0.9 mm by 0.9 
mm with 28 x 5 mm slices covering the whole brain) were acquired in all subjects. In 
MS subjects only, the latter was also acquired 20 minutes post IV Gd administration 
(0.3 mmol per kg body weight of Magnevist [Schering AG, Berlin, Germany]). The
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FSE was used to confirm the presence of lesions identified on the 3D FSPGR and 
derived T 2 lesion loads, while the T,-weighted images were used to determine T,- 
hypointense and Gd-enhancing lesion loads.
Tissue segmentation
The 3D FSPGR were automatically segmented into images representing the 
probability of any given voxel containing GM, WM, cerebrospinal fluid (CSF) and 
other tissues using SPM99 (Wellcome Department of Cognitive Neurology, Institute 
of Neurology, Queen Square, London) (Ashburner and Friston, 2000) with, unless 
otherwise specified, maximum image inhomogeneity correction applied. The SPM99 
segmentation methodology employed a mixed model cluster analysis incorporating 
tissue intensity information and tissue spatial distribution prior probabilities in the 
form of the Montreal N eurological Institute ICBM 152 tem plate (M ontreal 
Neurological Institute, Montreal, Quebec, Canada) and iteratively optimising tissue 
definition while correcting for image non-uniformity (Sled et al., 1998).
Lesion segmentation
In MS subjects, lesions were segmented from the 3D FSPGR using a semi­
automatic local thresholding technique, part of the Displmage image display package 
(Plummer, Department of Medical Physics & Bioengineering, University College 
London Hospitals NHS Trust, London, UK) (Plummer, 1992). Lesions were seen as 
hypo-intensities on this sequence; their presence was confirmed by reference to the 
proton-density PD weighted FSE images, where they appeared as hyper-intensities. 
Lesions were also segmented using the same technique applied to the proton-density 
weighted FSE images and T,-weighted pre- and post-gadolinium enhanced images,
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which provided T2, T, hypo-intense and Gd-enhancing total lesion volumes (loads) 
respeetively.
Volume determination
The spinal cord cut-off location, used to exclude cord from the brain tissue 
volume estimations, was determined visually on the 3D FSPGR image as the most 
rostral slice not containing cerebellum. The outputs from SPM99 and 3D FSPGR 
lesion segmentations were processed using in-house software, which took account of 
the user specified cord cut-off level, to quantify tissue volumes. The lesion mask 
over-rode all SPM99 tissue classifications; otherwise a voxel was classified as GM, 
WM, CSF or other tissue dependent on which mask had the greatest probability 
(maximum likelihood) at that location. This generated mutually exclusive masks for 
each tissue i.e. a given voxel was partitioned to one mask only. Results were assessed 
as fractions of total intra-cranial (TI) volume as determined by adding the GM, WM, 
lesion and CSF volumes. Brain parenchymal fraction (BPF) was calculated as GM, 
WM plus lesion volume divided by TI volume. White matter fraction (WMF) was 
calculated as WM plus lesion volumes (virtually all lesions were located in the WM) 
divided by TI volume. The grey matter fraction (GMF) was calculated as the GM 
volume divided by the TI volume. The lesion fraction (LF) was calculated as the 
lesion volume over the TI volume.
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3.1.2 PROTON MAGNETIC RESONANCE SPE CTR OSC OPIC IMAGING AND
M ETABOLITE QUANTIFICATION  
Scan acquisition
For all spectroscopic examinations, a 3D FSPGR (see section 3.1.1) was 
acquired first and used to localise the spectroscopic volume. The plane of the 
excitation volume for 'H-MRSI scan acquisition was pure axial (orthogonal to the 
scanner axes), and was immediately superior to the roof of the lateral ventricles. The 
‘H-MRSI scans were acquired using a point resolved spectroscopic (PRESS) 
localization scheme (TE 30 ms, TR 3000 ms, NEX 1, 24 * 24 phase encodes over a 
300 * 300 mm field of view, slice thickness 15 mm, spectral width 2500 Hz, 2048 
complex points), with outer-volume suppression bands contiguous with the edges of 
the PRESS selected volume in all three dimensions. The anterior to posterior and left 
to right dimensions of the outer-volume suppression bands matched those of the 
PRESS selected volume, which varied from subject to subject. Automated pre­
scanning optimised the shim, water suppression, and set both transmitter and receiver 
gains (Webb et al., 1994).
Metabolite quantification
Spectroscopy pre-processing was performed using SAGE 7.0 (General 
Electric Medical Systems, Milwaukee, Wisconsin, USA). Grids o f  voxels with 
individual voxel dimensions 12.5 mm * 12.5 mm * 15.0 mm (2.3 mL) were 
automatically extracted and passed to LCModel (version 5.2) (Provencher, 1993) for 
metabolite quantification in mmol/L. Metabolite concentrations estimated were: 
choline containing compounds (Cho); creatine and phosphocreatine (Cr), myo­
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inositol (Ins), N-acetyl-aspartate (NAA) plus N-acetyl-aspartyl-glutamate (together 
designated tNAA), and glutamate plus glutamine (Glx). GM, NAWM, cerebrospinal 
fluid (CSF) and lesion masks were derived from the 3D FSPGR images as described 
in section 3.1.1. These masks were used to quantify the tissue contents for each 'H- 
MRSI voxel. 'H-MRSI voxels were excluded from further analysis if they were not 
entirely within the PRESS excitation volume.
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3.2 WHOLE BRAIN, GREY AND WHITE MA TTER VOLUME ESTIMA TES
Introduction
Understanding the components of measurement variability, and factors 
contributing to this, enable more realistic interpretation of results. With this in mind, 
the study described here was designed to: estimate the reliability of the brain tissue 
volume measures employed in this thesis; decompose the elements of inter- subject 
variability in terms of previously observed age and gender effects; consider the 
potential for differential measurement error associated with focal white matter 
lesions; and consider the validity of these measures as estimates of brain tissue 
volumes. Previous work has suggested that image non-uniformity corrections are of 
benefit when assessing tissue volumes (Arnold et al.,2001) and that adjustments for 
intra-cranial volumes reduce inter-subject variability (Blatter et al., 1995; Mathalon et 
al., 1993; Whitwell et al.,2001). This study also explored the effects an image non­
uniformity correction has upon the resultant tissue segmentations and their reliability, 
and whether adjustment for intra-cranial volume does or does not improve sensitivity 
to known age and gender effects.
In the absence of gold standards for in vivo brain tissue volumes, validity was 
assessed in terms of  consistency with observations from previous MRI and 
histopathology work.
Materials and methods 
Subjects
The data came from a cohort of 29 normal control subjects (16 females and 
13 males, mean age 36.6 years at first scan, median 33.5, range 23.2 to 55.2) with no
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history of neurological disease or other medical conditions. A subset of the subjects 
underwent multiple scans to assess the method’s reproducibility and this is described 
in detail below. This project had approval from the ethics committee of the National 
Hospital for Neurology and Neurosurgery, Queen Square, London, UK. All subjects 
gave informed consent.
Scan Acquisition
3D FSPGR scans, as described in section 3.1.1, were acquired in all subjects. 
Segmentation and volume determination
The 3D FSPGR images were processed as outlined in section 3.1.1, except 
when assessing the effects of image inhomogeneity correction (see below), when 
images were processed with and without this adjustment.
Inhomogeneity correction
SPM99 includes an option to include a step that attempts to correct for the 
effect of B,-field non-uniformity, which may otherwise lead to artefactual image 
intensity gradients. The method employed aims to correct for low spatial frequency 
image non-uniformity by estimating tissue specific intensity profiles (peaks) and 
iteratively estimating a non-uniformity field correction that effectively minimizes 
peak width (Ashburner and Friston, 2000). The effect of this correction was tested on 
8 normal control subjects (5 males and 3 females) who had three scans, each pair 
separated by an average of 191 days (median 193, range 141 to 215 days). RC and 
CV were calculated for all parameters derived from these images with and without 
the correction.
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Effect o f  delayed re-scanning
The delay in scanning meant that there was a chance that genuine volume 
changes could have occurred over this time, for example due to ageing (see section
2.4.1) or hydration effects (Walters et al.,2001). In order to estimate an upper limit 
for the reproducibility of the measurements, three subjects underwent three scans on 
the same day, with repositioning between scans; images from this subgroup were 
processed with inhomogeneity correction.
Susceptibility to foca l white matter abnormalities
In a single subject, the effects of artificially added white matter lesions upon 
segmentation were assessed. Using tools within the D isplm age image display 
package (Plummer, Department of Medical Physics & Bioengineering, University 
College London Hospitals NHS Trust, London, UK) (Plummer, 1992), a series of 
ovoid regions within white matter, each circa 0.25 ml in volume, extending over 
multiple slices, were set to a fixed intensity to simulate the presence of lesions. Two 
main characteristics of white matter lesions may influence segmentation: total lesion 
volume and lesion intensity. Variable lesion volumes were simulated by adding 
greater numbers of artificial lesions to the test image. The total lesion volume ranged 
from 3 to 24 ml and the intensity was set to that estimated to be halfway between 
white matter and CSF. Lesion intensity effects were assessed using a fixed total 
lesion volume of 12 ml. Five intensity levels were tested: that of CSF; that of white 
matter; and three evenly spaced intervals in between.
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The artificial lesion mask generated using Displmage was employed to define 
which voxels lay within lesion regions. Lesion intensity and volume effects were 
assessed with and without this reclassification of such lesion regions as white matter. 
Statistical analyses
RC and CV were estimated as outlined in section 2.5, using variance 
estimates from restricted estimate of maximum likelihood (REM L) variance 
components models (Scheffe, 1959; Tedeschi et al., 1996). The model included 
subject as a random factor with all other variability partitioned to the error term.
The effects of age and gender on TI, BP, GM, WM, BPF, G M F and W M F 
volumes in normal control subjects were investigated using multiple linear regression 
models with gender as a categorical (fixed) factor, age (in days) as a continuous 
covariate, and an age-gender interaction term.
Results
The RC were generally in excess of 90% and this is reflected in 
correspondingly low CV (Table 3.2a and Figure 3.2a), suggesting that measurement 
errors contribute little to observed tissue variability. The image non-uniformity 
correction had little discernable effect upon RC and CV, although inspection of the 
resultant segmentations revealed clearly sharper tissue differentiation in the 
cerebellum, basal ganglia and thalamus (Figure 3.2b, 3.2c and 3.2d) when the 
correction was applied. Image non-uniformity correction also tended to increase the 
average TI volumes, and increase the volume of GM at the expense of WM (Table 
3.2b).
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At a P<0.05 level, WM and BP volumes differed significantly between 
genders but the other absolute volume measures did not. BPF did not significantly 
differ with gender, whilst both GMF and W M F did (Tables 3.2c, 3.2d and 3.2e).
Statistical modelling of this cross-sectional data revealed that overall BPF 
and G M F decreased significantly with age, whereas BP and GM volumes only 
reached borderline significance (Tables 3.2d and 3.2e, and Figure 3.2e). Excluding 
interactions between age and gender, the parameter estimate for yearly change in 
BPF was -0.002, -0.3% proportional to the mean value in the cohort (95% confidence 
interval [CIJ -0.003 to -0.001, P<0.001, model R2 0.599); for GM F was -0.002, -0.3% 
(Cl -0.003 to -0.001, PcO.OOl, model R2 0.512); for W M F was -0.001, -0.1% (Cl - 
0.001 to 0.000, P=0.172, model R2 0.183); for TI volume was 0.4, 0.0% (Cl -3.9 to 
4.8, P=0.840, model R 2 0.430); for BP volume was-2.7, -0.2% (Cl -5.8 to 0.3, 
P=0.079, model R2 0.545); for GM volume -2.2, -0.3% (Cl -4.2 to -0.2, P=0.031, 
model R2 0.499); and for WM volume was -0.5, -0.1% (Cl -1.9 to 0.8, P=0.477, 
model R2 0.498). Interactions between gender and age were significant for WM, and 
WMF, and of borderline significance for GMF (Tables 3.2d and 3.2e).
The effects of artificial WM lesions appear limited when set in the context of 
age related changes in fractional tissue volumes (Figures 3.2f, and 3.2g compared 
with 3.2e). Further, volumes corrected for lesion misclassification show only modest 
deviations from lesion free values, despite lesion intensities set to that of CSF and 
lesion volumes greater than 20 ml.
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Re­
scan
delay
(days)
InHC Reliability coefficients, coefficients of variation (%) and within- 
subject SD
Absolute volume Fractional volumes
TI BP GM WM BPF GMF W MF
190" Yes 0.993,
1.2,
16.7
0.991,
1.1,
12.6
0.986,
1.3,
9.9
0.991,
1.1,
4.4
0.936,
1.0,
0.007
0.934,
1.1,
0.006
0.925,
1.2,
0.003
1901 No 0.993,
1.3,
16.8
0.994,
0.9,
10.0
0.990,
1.1,
7.9
0.993,
1.0,
4.2
0.939,
0.9,
0.007
0.958,
0.8,
0.005
0.868,
1.3,
0.004
0h Yes 0.998,
0.2,
3.5
0.997,
0.2,
3.1
0.966,
0.6,
5.2
0.990,
0.9,
3.7
0.963,
0.2,
0.002
0.896,
0.6,
0.003
0.975,
0.8,
0.002
Table 3.2a: Reliability coefficients, coefficients of variation and within-subject SD 
for absolute and fractional tissue volumes quantified using tissue segmentations from 
SPM99 with and without image inhomogeneity correction (InHC) applied to data 
from 8 subjects imaged on 3 occasions a mean of 191 days apart, and with image 
inhomogeneity correction applied to data from 3 subjects imaged 3 times on the same 
day .a 8 subjects;b 3 subjects .
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Image Absolute volume (ml) Fraction
InHC
TI BP GM WM BPF GMF WMF
Yes 1360.5, 1135.7, 748.4, 387.2, 0.84, 0.55, 0.29,
1319.1, 1098.9, 716.0, 382.9, 0.84, 0.55, 0.29,
1170.9 1017.4 682.6 to 334.3 to 0.78 to 0.52 to 0.27 to
to
1759.7
to
1379.8
906.8 473.0 0.87 0.58 0.30
No 1341.3, 1137.8, 730.7, 407.1, 0.85, 0.55, 0.30,
1296.6, 1099.5, 698.8, 400.7, 0.85, 0.55, 0.30,
1 156.4 1020.7 668.2 to 352.1 to 0.80 to 0.51 to 0.29 to
to
1733.0
to
1390.5
889.9 500.6 0.88 0.58 0.32
Table 3.2b: Mean, median, and range of absolute and fractional tissue volumes from 
baseline scans in 8 subjects with and without image inhomogeneity correction 
(InHC).
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Gender Tissue volume (ml) Tissue fraction
TI BP GM WM BPF GMF WMF
Male 1441.0, 1208.1, 794.2, 413.9, 0.84, 0.55, 0.29,
1404.3, 1186.9, 804.6, 407.5, 0.85, 0.55, 0.28,
1284.3 1065.7 714.3 to 337.6 to 0.78 to 0.52 to 0.26 to
to
1759.8
to
1379.8
906.8 478.5 0.87 0.57 0.32
Female 1264.2, 1060.6, 710.4, 350.1, 0.84, 0.56, 0.28,
1262.8, 1056.7, 710.8, 349.6, 0.85, 0.57, 0.28,
1 109.8 916.7 to 614.6 to 301.7 to 0.78 to 0.51 to 0.25 to
to
1389.5
1169.4 795.8 404.7 0.87 0.60 0.30
Table 3.2c: Mean, median and range of absolute and fractional tissue volumes by 
gender in normal control subjects estimated from inhomogeneity corrected images. 
Results are from 13 males (mean age at scanning 36.3 years, median 32.3, range 27.2 
to 52.7) and 16 females (mean age at scanning 36.9 years, median 33.5, range 23.2 to 
55.2).
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Measure Factor
Gender Age - males Age - females Age*gender
BPF 0.009(1.1%), 
-0.050 to 0.068, 
0.754
-0.002 (-0.3%), 
-0.003 to -0.001, 
0.002
-0.002 (-0.3%), 
-0.003 to -0.001, 
<0.001
0.789
GMF 0.072(12.9%), 
0.017 to 0.126, 
0.013
-0.001 (-0.1%), 
-0.002 to 0.000, 
0.173
-0.002 (-0.4%), 
-0.003 to -0.002, 
<0.001
0.030
WMF -0.063 (22.2%), 
-0.105 to -0.020, 
0.005
-0.001 (-0.5%), 
-0.002 to -0.000, 
0.006
0.000 (0.0%), 
-0.001 to 0.001, 
0.735
0.015
Table 3.2d: Parameter estimates (% compared to the mean value for all subjects), 
95% confidence limits and P values for the effects of gender, age (estimated to the 
nearest day but presented as change per year) on absolute tissue volumes. Gender 
param eters com pare females with males. A ge*gender gives the estim ates 
significance of the difference in age effects between genders. Model R2: BPF 0.600; 
GMF 0.597; W M F 0.359.
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Measure Factor
Gender Age - males Age - females Age*gender
TI -325.5 (24.1%),
-667.2 to 16.2, 
0.061
-2.2 (-0.2%),
-9.4 to 5.1, 0.546
1.9 (0.2%),
-3.6 to 7.4, 0.479
0.365
GM -96.4 (-12.8%), 
-256.6 to 63.7, 
0.226
-2.5 (-0.3), 
-5.9 to 0.9, 
0.147
-2.1 (-0.3), 
-4.7 to 0.5, 
0.106
0.034
WM -178.3(46.7%), 
-277.3 to -79.2, 
0.001
-2.5 (-0.7%), 
-4.6 to -0.4, 
0.022
0.7 (0.2%), 
-0.9 to 2.2, 
0.400
0.021
Table 3.2e: Parameter estimates (% compared to the mean value for all subjects), 
95% confidence limits and P values for the effects of gender, age (estimated to the 
nearest day but presented as change per year) on fractional tissue volumes. Gender 
param eters com pare females with males. A ge*gender gives the estim ates 
significance o f  the difference in age effects between genders. Model R2: TI 0.449; 
BP 0.568; GM 0.500; WM 0.596.
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D iscussion
Reliability
The reliability figures suggest that over 90% of variability in tissue volumes 
obtained from non-uniformity corrected images is attributable to inter-subject 
factors. This is reflected in the correspondingly low CV values.
The use of a non-uniformity correction appears to have a limited effect upon 
the reliability of tissue segmentations, although inspection of the resultant images 
suggests greater clarity in the definition of cerebellum, basal ganglia and thalami, 
with a consequent increase in GM tissue volumes. However, anecdotal evidence 
would suggest that its most marked effect is a reduction in gross segmentation errors, 
particularly in the presence of significant tissue abnormality (Figure 3.2h). This is a 
rather extreme example of segmentation failure, and even when processed with the 
inhomogeneity correction would be deemed unsuitable due to the significant residual 
non-brain material included in the grey matter segments. The use of such a correction 
is supported by previous work looking at the effects upon tissue segmentation, 
although direct comparisons between techniques have been limited and do not 
necessarily address the effects they may have upon derived measures (Arnold et 
a/.,2001).
RC and CV figures do not appear to be greatly influenced by the delay 
between scans, although the CV are consistently lower in the group scanned on a 
single day when compared with those scanned over a year. The difference in CV may 
be explained by biological factors such as age related changes and hydration effects 
(Walters et al.,2001), and scanner scaling effects.
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Age and gender effects upon tissue volumes
The cross-sectional age trends revealed in this study indicate that while, in 
absolute terms, volume variation with age only reached borderline significance for 
BP and GM, as fractions of total intra-cranial volumes all measures were clearly 
significant. More specifically, BPF fell with age and, in the age range studied; this 
was predominantly due to GM rather than WM tissue loss. These are consistent with 
previous work (see section 2.4.1).
Looking at the gender effects seen, WM but not GM volumes differed 
significantly between males and females, in agreement with previous findings, but 
after correction for intra-cranial volume the proportions of GM and WM were both 
found to be significantly different (Tables 3.2d and 3.2e). These are consistent with 
previous work (see section 2.4.1).
Interactions between age and gender (differences in the degree of tissue loss 
with age between genders) appeared to be significant for WM (both as an absolute 
and fractional measure) and GMF. The numbers in each group are small and counsel 
caution when interpreting these results, but they do suggest that age and gender 
interact, and this is also consistent with previous work (see section 2.4.1).
Fractional tissue volumes
Significant additional trends were detected in the fractional volume data over 
and above those found in the absolute volume results. Several studies have made use 
of an adjustment for intra-cranial volume when assessing trends in the normal 
healthy population (Blatter et al., 1995; Mathalon et al., 1993; Whitwell et al.,2001) 
and the effects of disease states such as Alzheimer’s dementia and multiple sclerosis
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(Brunetti et a l.,2000; Jenkins et c//.,2000; Liu et al., 1999; Rudick et al., 1999), 
supporting the utility of such a strategy.
Bias associated with foca l white matter abnormalities
While acknowledging the imperfections of the model used to simulate white 
matter lesions, which fail to fully simulate lesion intensity, morphology and location 
heterogeneity , the results do suggest that volum es derived from SPM 99 
segmentations are relatively insensitive to the presence of white matter lesions. This 
can be seen by comparing Figures 3.2f and 3.2g with Figure 3.2e, which are all 
plotted on the same scale. Formal correction for lesion tissue misclassification 
marginally reduces their effect, although the utility of this correction would appear 
limited in subjects with small lesion volumes. Focal white matter lesions in MS 
subjects on this 3D FSPGR sequence tend to have intensities similar to GM, circa 
75% of the way between the intensity of CSF and WM. For the estimates of volumes 
effects, a lesion intensity of 50% was used, and so the effects of increasing lesion 
volume in MS subjects may be less marked than indicated by these simulations.
Tissue volume estimates compared with literature values
Literature values on BP volumes suggest the average volume in males is circa 
1400 ml and females 1240 ml (see section 2.4.1). Estimates from this study suggest 
tissue volumes of 1208 and 1060 ml respectively, which equates to 0.86 and 0.85 
times less tissue. As noted previously, we cannot rely upon post-mortem data to 
provide accurate measures of in vivo tissue volumes, and so the best that we may 
expect is a constant ratio between observations. In this regard the tissue volumes 
show good consistency between genders.
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The absolute GM volumes were estimated to be 1.9 and 2.0 times that of the 
WM volumes in males and females respectively (Table 3.2c). Post mortem studies 
have estimated this ratio to be between 1.1 and 1.5 dependent on age and previous 
MRI studies have found it to range from 1.2 to 2.0, also varying with age (see section
2.4.1). Previous work has suggested that imaging parameters may significantly effect 
tissue volumes (Blatter et al., 1995; Harris et al., 1994a), it is therefore difficult to say 
which values are correct in absolute terms.
Validity
Considering the present results in the context of previous work, it would 
appear that the use of image non-uniformity correction and adjustment for intra­
cranial volumes are reasonable when assessing tissue volumes both in cross-sectional 
and longitudinal work, and should be employed. The derived fractional volume 
measures show high reliability, which implies high validity (estimated VC > 0.95 for 
all fractional measures). Validity is also supported by consistency between estimates 
of tissue volumes, age and gender effects derived from this work and literature 
values. Qualitative assessment of the effects focal WM lesions have upon these 
fractional estimates suggests a modest influence, with a tendency to underestimate 
the degree of disease associated GM atrophy and to overestimate the degree of WM 
atrophy. This limited differential measurement error should be recalled when 
considering results comparing groups with differing volum es o f  focal W M  
abnormalities.
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Conclusions
This work suggests that fractional tissue volumes estimated from non­
uniformity corrected tissue segmentations generated by SPM99 are both reliable and 
at least as valid as other MRI measures of brain tissue volumes in normal control and 
MS subjects.
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Figure 3.2a: Fractional tissue volumes from paired scans in 10 normal
subjects.
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Figure 3.2b: Slices from a 3D FSPGR along with corresponding grey matter 
segm entation images from SPM 99, with and without image non-uniformity 
correction. From left to right: the original images; grey matter segmentation without 
non-uniformity correction; grey matter segmentation with non-uniformity correction.
I l l
Figure 3.2c: Slices from a 3D FSPGR along with corresponding white matter 
segmentation images from SPM99, with and without image non-uniformity 
correction. From left to right: the original images; white matter segmentation without 
non-uniform ity  correction; white matter segmentation with non-uniform ity  
correction.
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Figure 3.2d: Slices from a 3D FSPGR along with corresponding CSF segmentation 
images from SPM99, with and without image non-uniformity correction. From left to 
right: the original images; CSF segmentation w ithout non-uniformity correction; 
CSF segmentation with non-uniformity correction.
Fr
ac
tio
na
l 
tis
su
e 
vo
lu
m
e
0.9 
0.8 
0.7 
0.6 
0.5 
0.4 
0.3 
0.2
20 30 40 50 60
Age (years)
Figure 3.2e: Fractional tissue volumes by age and gender in 29 normal control 
subjects.
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Figure 3.2f: Effects of WM lesions on fractional tissue volume estimates, with values 
corrected and uncorrected for lesion misclassification. Lesion intensity set to that 
halfway between WM and CSF. Dashed horizontal lines represent values from the 
original lesion free images.
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Figure 3.2g: Effects of WM lesion intensity on fractional tissue volume estimates, 
with values corrected and uncorrected for lesion misclassification. Lesion volume set 
to a constant total volume of 12.1 ml. Intensity of WM is 100% and CSF is 0%. That 
of GM and focal WM lesions in MS tends to be circa 75% on this scale. Dashed
horizontal lines represent values from the original lesion free images.
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Figure 3.2h: Failed GM segmentation images from a subject with MS (3D FSPGR 
lesion volume circa 66 ml). The image on the left was processed without and on the 
right with inhomogeneity correction. Original data courtesy of Gordon Ingle.
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3.3 FOCAL WHITE MATTER LESION VOLUME ESTIMATES  
Introduction
In this work in addition the usual T,, T2 and Gd-enhancing lesion loads, 
lesions were also contoured on the 3D FSPGR. The former have previously been 
assessed and their reliability and validity considered (discussed below), while the 
characteristics of the latter have not been extensively explored.
Lesion contouring measurement error may be attributable to a number of 
factors such as the contouring method used, inter and intra-observer variability, 
subject repositioning in serial studies and scan acquisition parameters such as 
resolution and contrast weighting. Processing may be further broken down to lesion 
identification and contouring.
It would appear that semi-automated techniques offer greater reproducibility 
when compared with manual ones (Molyneux et al., 1998a). Inter-observer factors are 
potentially as important as intra-observer factors (for example on T2-weighted SE 
[5mm slice thickness] processed at two centres, intra-observer CV 5.1 and 3.1% 
compared with inter-observer 8.3 and 7.1% (Filippi et al., 1998b)). Formal operator 
training may reduce the intra-observer component of measurement variability 
(Rovaris et al., 1999). Using thinner imaging slices (3 mm instead of 5 mm) improves 
reproducibility (Filippi et al., 1997a; Filippi et al., 1998d; Molyneux et al., 1998b), 
although this need not translate into significantly increased sensitivity to change 
(Rovaris et al., 1998b). This may relate to a large effect on a small error translating 
into little change in relative sources of variability i.e. measurement errors are already 
a small component of measurement variability even on images with slice thicknesses
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of 5mm (Molyneux et al., 1998a). Subject repositioning also appears to be a 
significant component of measurement variability (Filippi et al., 1997a; Rovaris et 
al., 1998a); as is magnetic field strength, with higher main field strengths being 
associated with lower CVs (Filippi et al., 1997b).
Reproducibility appears to be affected by image contrast mechanisms. Fast 
fluid-attenuated inversion-recovery (FLAIR) images seem to yield more reproducible 
lesion measures than T 2-weighted conventional spin echo images (intra-observer CV
2.6 and 3.1% respectively; inter-observer CV 2.9 and 7.1% respectively) (Filippi et 
a l.,1998b). Differences may be less marked between conventional T, and T2- 
weighted images (Rovaris et al., 1999).
Many reproducibility studies have made use of marked scans (i.e. scans on 
which the position and approximate extent are marked on a printed copy by a single 
observer) to reduce the effect of inter-observer lesion identification variability on 
subsequent volume measurement. This may be expected to improve the apparent 
reliability of such measures by eliminating identification errors (Filippi et al., 1998a). 
Methods 
Subjects
Data came from 27 RR MS subjects (mean age 34.9 years, median 33.7, 
range 24.1 to 48.4).
Scan acquisition and processing
All subjects had 3D FSPGR, PD/T2-weighted dual echo FSE and T,-weighted 
SE sequences acquired (see section 3.1.1). These were processed using a semi­
automated contouring technique based upon tools with Displmage (see section
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3.1.1). In all subjects the T,, T 2 and Gd-enhancing lesion loads were determined by 
the same observer (WR). In eight of the subjects, the 3D FSPGR lesion loads were 
determined on two occasions separated by seven days by a different observer (DC) 
using unmarked scans.
Statistical analyses
Treating estimates of lesion loads as random samples o f  all possible 
estimates, regardless of the observer, CV and RC were estimated from all 
parameters, yielding intra-observer values for the 3D FSPGR and inter-observer 
values for the T, and T 2 lesion loads. Spearman correlations between lesion loads 
from differing images were also estimated.
Results
Total lesion loads derived from the 3D FSPGR images were closer to those 
derived from a T2-weighted rather than T,-weighted sequence (Table 3.3a). 
Spearman correlation coefficients between lesion loads were as follows: 3D FSPGR 
and T2 lesion load 0.98 (Cl 0.96 to 0.99, PcO.OOl); 3D FSPGR and T, lesion load 
0.90 (Cl 0.78 to 0.95, PcO.OOl); 3D FSPGR and Gd-enhancing lesion loads 0.19 (Cl 
-0.21 to 0.54, P=0.337); T2 and T, lesion loads 0.90 (Cl 0.79 to 0.96, PcO.OOl); T2 
and Gd-enhancing 0.26 (Cl -0 .15 to 0.59, P=0.337); T, and Gd-enhancing 0.46 (Cl 
0.08 to 0.72, P=0.017). For the 3D FSPGR the RC was 0.994, CV 7.2% and within- 
subject SD 0.6 ml.
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Lesion parameter (ml)
3D FSPGR t 2 T, Gd-enhancing
Mean 7.7 9.0 2.0 0.6
Median 4.1 4.8 0.8 0.2
Range 0.5 to 1.1 to 0.0 to 0.0 to
39.9 40.8 9.9 4.3
Table 3.3a: Lesion loads derived from differing scan sequences in 27 MS subjects.
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Discussion
These results suggest that lesion contouring on the 3D FSPGR images is 
reliable, and yields lesion loads similar to those derived from T2-weighted images, 
the current standard for lesion identification. The reliability figures compare well 
with those of T2-weighted lesions (intra-observer CV 4.2% and RC 0.998 for T 2 
lesion loads determined on m arked  scans (Molyneux et al., 1998a), compared with 
intra-observer CV of 7.2% and RC 0.994 for 3D FSPGR lesion loads determined on 
unmarked  scans).
The high correlation between lesion loads derived from the 3D FSPGR and 
T 2-weighted images suggests that they are effectively measuring the same underlying 
parameter, although with slightly differing biases. Previous work reached similar 
conclusions  when com paring  conven tional 2D T 2-w eigh ted  im ages with 
magnetisation-prepared rapid-acquisition gradient-echo (M P-RAGE) images, but 
also concluded that the former may better identify GM lesions while the latter may 
better detect WM changes (Shah et al., 1992).
Correlations between the T, and both 3D FSPGR and T2-weighted lesion 
loads are also high, although slightly lower than those observed between 3D FSPGR 
and T2 lesion loads. This discrepancy may be partly accounted for by differential 
sensitivities to underlying pathology and measurement errors (see section 2.4.3).
The lower correlations observed between the Gd-enhancing lesion loads and 
other lesion parameters would suggest that Gd-enhancing lesion loads are marking a 
different underlying parameter, which from present evidence would appear to be 
breakdown of the BBB (see section 2.4.3).
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Conclusions
This work suggests that MS lesion identification on 3D FSPGR images using 
a semi-automated contouring technique is reliable as lesion identification on T 2- 
weighted images.
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3.4 T I S S U E  S P E C I F I C  M E T A B O L I T E  C O N C E N T R A T I O N
QUANTIFICATION
Introduction
As noted in section 3.2, a robust awareness o f  methodological limitations 
along with normal factors that may influence observations is required to realistically 
interpret results derived from 'H-MRSI observations. In the case of metabolite 
quantification, as with brain tissue volume estimates, a variety of factors both 
methodological and biological need to be considered. This work aimed to assess the 
reliability of metabolite quantification on a voxel by voxel basis, both within and 
between scanners; assess the reliability and validity of tissue specific metabolite 
concentration estimates; and explore potential tissue specific age and gender effects 
in normal control subjects. As with tissue volume estimates the effects of focal 
lesions in MS needs to be considered, however unlike tissue volume estimates an 
artificial simulation of the effects lesions may have upon quantifications has not been 
possible; this will be considered in the discussion.
M ethods
Subjects
The data came from a cohort of 29 normal control subjects (16 females and 
13 males, mean age 36.6 years at first scan, median 33.5, range 23.2 to 55.2) with no 
history of neurological disease or other medical conditions. A subset of the subjects 
underwent multiple scans to assess the m ethod’s reliability and this is described in 
detail below. This project had approval from the ethics committee of the National
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Hospital for Neurology and Neurosurgery, Queen Square, London, UK. All subjects 
gave informed consent.
Scan acquisition
Scans were acquired as outlined in section 3.1.2. Three subjects underwent 
scanning on two identically specified scanners (see section 3.1) to assess 
quantification dependence upon individual scanner factors.
Metabolite and tissue quantification
Voxel metabolite concentrations and tissue contents were estimated as 
outlined in section 3.1.2.
Tissue specific metabolite quantification
LCModel estimates the certainty of metabolite quantifications in terms of a 
percentage SD (%SD) i.e. it provides an estimate of confidence limits for a 
metabolite concentration derived from a given voxel. In order to allow for the 
inherently different quantification errors associated with different metabolites, voxels 
were retained if LCModel estimates of the quantification error were less than 23% 
for Cho, 9% for Cr, 78% for Ins, 6% for NAA and 24% for Glx. If errors for one of 
these metabolites exceeded this limit then all metabolite data from the voxel was 
discarded. These figures were estimated as the upper 95% limit (mean + (2 x %SD)) 
of the quantification error for metabolites derived from a combined cohort of the 29 
control subjects and the 27 MS subjects included in the work presented in section 
4.3.
Voxels were retained if they contained > 80% GM plus N AW M  and, in 
subjects with MS, <1% lesion. Voxels were classified as CGM or NAW M  if they
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contained > 60% of a given tissue type. From 1712 NC voxels acquired, 918 voxels 
remained after exclusion of those that were incompletely excited, 819 remained after 
excluding those that exceeded the allowed quantification errors. O f these 469 WM 
and 84 GM voxels were extracted. In a given subject, average tissue contents and 
metabolite concentrations for a particular voxel type were estimated from the 
extracted voxels.
Voxel by voxel reliability
Voxel by voxel reliability was estimated both within and between scanners. 
For the single scanner study, one subject underwent three sessions of scanning, each 
separated by 2 days. At each session, three 'H-MRSI scans were acquired without 
subject repositioning. For the dual scanner study, single scans were acquired in three 
subjects using two machines, in sessions separated by an average of 60 days (56, 62 
and 63 days in each subject respectively).
Tissue specific reliability
Tissue specific reliability was assessed using data from eight normal control 
subjects (5 males and 3 females) who had three scans, each pair separated by an 
average of 191 days (median 193, range 141 to 215 days). On one occasion a single 
subject, while producing useable WM voxels, yielded no suitable GM voxels. 
Statistical analyses
RC and CV were estimated as outlined in section 2.5, using variance 
estimates from restricted estimate of maximum likelihood (REM L) variance 
components models (Scheffe, 1959; Tedeschi et al., 1996). The single scanner model 
included voxel and sessions as random factors with all other variability partitioned to
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the error term. The dual scanner study model included subject and voxel as random 
factors. Differences in tissue specific metabolite concentrations were assessed using 
Wilcoxon signed rank tests. The effects of age and gender on tissue specific 
metabolite concentrations were assessed using models that included age as a 
continuous covariate, gender as a fixed factor, voxel tissue contents (GM contents of 
WM voxels and vice versa), CSF contamination and BP volumes.
Results
The reliability results suggest that on a voxel by voxel basis, more than 50% 
of measurement variability for all metabolite concentrations estimated may be 
attributable to factors other than measurement error (Tables 3.4a and 3.4b). Mean 
LCModel estimates of quantification error (%SD) from the single scanner data were: 
Cho 8.9, Cr 7.4, Glx 18.3, Ins 11.0, and tNAA 4.2. GM voxels on average contain 
71% GM, 16% WM and 12% CSF, while WM voxels on average contain 19% GM, 
80% WM and 1%CSF.
Tissue specific metabolite concentrations appear different for all metabolites 
except for tNAA, with the most marked differences being for Glx and least obvious 
being for Cho (Table 3.4c). Wilcoxon signed rank tests confirm that these differences 
are significant at a P<0.05 level.
Estimates of WM metabolite concentrations were derived from an average of 
16 voxels per subject, and are generally more reliable than those of individual voxels, 
regardless of the duration o f  follow-up (Table 3.4d). GM metabolite concentrations 
are derived from an average of 3 voxels per subject, and while tending to be more 
reliable than results from individual voxels, the differential is less clear than that
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observed for WM. With longer follow-up tissue specific reliability appears to 
decrease for GM but not WM measurements.
Age and gender effects were assessed allowing for voxel tissue contents, CSF 
contamination and BP volume. The latter factor was included to account for the 
potential effects of age related atrophy leading to increasing albeit subtle partial 
volume effects not reflected in voxel tissue and CSF contents. Gender effects were 
found to be significant at a P<0.()5 level for GM Cho (-0.291 females compared with 
males, Cl -0.579 to -0.003, P=0.048), and WM Glx (-1.007, Cl -1.743 to -0.271, 
P=0.009), and of borderline significance (P<0.06) for GM and WM Cr (-0.788, Cl - 
1.601 to 0.026, P=0.057; -0.509, 95% Cl -1.022 to 0.004, P=0.052 respectively), and 
WM Ins (-0.422, 95% Cl -0.843 to 0.000, P=0.050). Age effects were not significant 
for any metabolites although age effects may also be subsumed by age-related 
reductions in BP volumes. BP volumes were found to significantly influence the 
results of GM Cho, Cr and Ins, and WM Cr. WM contamination of GM voxels did 
not significantly influence results, while GM contamination of WM voxels did for Cr 
and Glx. CSF contamination was significant factor in the models of WM Ins and Glx 
concentrations.
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Metabolite Variance components RC, CV, (%) 
and w ith in -  
voxel SD
Voxel Session Error
Cho 0.068 0.001 0.019 0.771, 11.9, 
0.142
Cr 0.680 0.000 0.204 0 .7 6 9 ,  9 .5 ,  
0.452
Glx 4.744 0.066 1.842 0.713, 15.2, 
1.381
Ins 0.392 0.000 0.398 0.496, 18.4, 
0.631
tNAA 1.075 0.000 0.255 0 .8 0 8 ,  5 .7 ,  
0.505
Table 3.4a: Variance components with reliability coefficients (RC), coefficients of 
variation (CV) and within-subject within-session SD estimated from the single 
scanner data.
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Metabolite Variance components RC, CV (%) 
and w ith in -  
subject SD
Voxel Subject Error
Cho 0.047 0.003 0.014 0.782, 10.2, 
0.118
Cr 0.475 0.016 0.325 0.602 , 12.3, 
0.570
Glx 3.978 0.571 1.477 0.755, 13.8, 
1.215
Ins 0.296 0.064 0.261 0.580, 14.7, 
0.511
tNAA 0.397 0.452 0.512 0 .6 2 4 ,  8 .9 ,  
0.716
Table 3.4b: Variance components with reliability coefficients (RC), coefficients of 
variation (CV) and within-subject SD estimated from the dual scanner data.
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Tissue Metabolite
Cho Cr Glx Ins tNAA
GM
male
1.197, 
1.169, 0.94 
to 1.56
6.235, 
6.200, 5.45 
to 7.34
12.556, 
12.808, 
9 .8 6  to 
15.46
4.461, 
4.225, 3.79 
to 5.48
8.746, 
8.801, 7.92 
to 9.79
W M
male
1.229, 
1.199, 1.05 
to 1.50
4.767, 
4 .784,4.12 
to 5.46
7.833, 
7.858, 6.93 
to 8.90
3.812, 
3.611, 2.99 
to 4.66
8.772, 
9.010, 7.65 
to 9.50
G M
female
1.128, 
1.114, 0.78 
to 1.59
6.378, 
6.371, 5.15 
to 7.80
12.043, 
11.909, 
1 0 .56  to 
13.50
4.544, 
4.467, 3.83 
to 5.42
9.082, 
8.689, 8.01 
to 11.55
W M
female
1.330, 
1.282, 1.00 
to 1.75
4.954, 
4.791,4.11 
to 6.39
7.637, 
7.833, 6.64 
to 8.54
3.523, 
3.467, 3.10 
to 4.32
8.845, 
8.725, 7.61 
to 10.28
Table 3.4c: tissue specific metabolite concentrations in mmol/1 by gender. Mean, 
median and range values are given.
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Follow-up Reliability coefficients, coefficients of variation (%) and within- 
subject SD
GM Cho GM Cr GM Ins GM tNAA GM Glx
6 months 0.810, 8.8, 
0.105
0.557, 8.2, 
0.523
0.147, 9.8, 
0.457
0.401,
10.3,0.920
0 .000,
13.5, 1.585
12 months 0.147,
18.4,0.207
0 .000,
15.0, 0.903
0 .000,
14.0,0.619
0 .000,
12.9, 1.113
0 .000,
15.6, 1.758
WM Cho WM Cr WM Ins WM tNAA WM Glx
6 months 0.680, 9.3, 
0.117
0.497, 8.0, 
0.397
0.562, 7.6, 
0.291
0.478, 5.7, 
0.509
0.362, 6.6, 
0.507
12 months 0 .666, 8.8, 
0.109
0.391, 8.0, 
0.389
0.477, 9.6, 
0.354
0.274, 6.4, 
0.564
0.203, 7.1, 
0.534
Table 3.4d: Reliability coefficients, coefficients of variation and within-subject SD 
for GM and WM metabolite quantifications using data from 8 subjects imaged on 3 
occasions a mean of 191 days apart. Values are presented for both six and 12 month 
follow-up.
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Discussion
Reliability
The reliability figures suggest that on average more than 50% of variability in 
tissue metabolite concentrations is related to factors other than measurement error. 
However the figures are not as high as that observed for tissue volume measures (see 
section 3.2) and this is mirrored by correspondingly higher CV. Reliability does not 
appear to markedly differ within or between scanners, suggesting that measurement 
error, in particular bias, is not markedly dependent upon the scanner used.
Tissue specific metabolite estimates appear more reliable than those derived 
from single voxels (as reflected in CV and intra-subject SD measures, but not RC as 
discussed below). This is more clearly seen for WM when compared with GM 
results, and may be explained by a number of factors. Firstly, the WM results are 
derived from more voxels per subject (on average 16 compared with 3 for GM). 
Secondly, WM metabolite concentrations may be more homogeneous than GM, thus 
differences in voxel location may have less of an effect upon apparent tissue 
metabolite concentrations. Thirdly, the anatomical complexity of GM means that 
GM voxels are more likely to be contaminated with CSF and WM than WM voxels 
are to be with CSF and GM. This effect may be subtle and difficult to observe 
directly, particularly in GM voxels where GM-CSF boundaries will be less distinct 
than W M -CSF boundaries, and this may explain why a direct effect of CSF 
contamination is only observed in WM (Ins and Glx) while BP volumes are more 
consistently related to GM rather than WM metabolite concentration estimates. 
Finally, WM metabolite concentrations may be more stable with time. This latter
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hypothesis is supported by the observation that WM reliability is less influenced by 
the follow-up period than is the case for GM. It seems unlikely that scanner related 
measurement error would differentially affect WM and GM, leaving differences in 
the natural temporal variability of metabolites as the more likely explanation for this 
finding.
Age and gender effects upon tissue specific metabolite concentrations
Age effects were not found to be a significant factor in determining any of the 
tissue specific metabolite concentrations studied. However, BP volume in particular, 
and voxel contents to a lesser degree, may vary with age and as such be subsuming 
age related effects. Indeed, if these factors are removed from the models, age effects 
are significant for GM Ins, WM Cr, Cho and Ins, and to a borderline degree GM Cho 
(data not shown). In MS, brain atrophy may result both from normal ageing and 
disease effects thus partially decoupling relationships between age and BP volume. 
Given this, it would seem prudent to include both age and BP volumes in models 
exploring disease effects. In contrast to the tissue volume results, age and gender 
interactions were not detected when included in the model.
Bias associated with fo ca l white matter abnormalities
Lesions may influence tissue specific metabolite concentrations in two main 
ways. Firstly, they can contaminate voxels otherwise classified as WM or GM, and 
due to genuine alterations in metabolite concentrations in lesion tissues alter the 
apparent concentration of metabolites in a given tissue. Secondly, MS lesions are 
associated with macromolecular peaks at <2ppm (Davie et al., 1994; M ad e r  et 
al.,2001; Narayana et al., 1998). These may alter peak fitting and thus influence the
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quantification of other metabolites. However, work by McLean et al. suggests that 
LCModel estimates of metabolite concentrations are little affected by additional 
unaccounted for peaks, although reliability may be improved by metabolite nulling 
(McLean et al.,2002).
Tissue specific metabolite concentration estimates compared with literature values
Comparing values obtained in this work with others is complicated by the 
relative paucity of such data from other studies. While several have explored this, 
many have quantified metabolites in arbitrary units or relative to Cr or Cho, making 
it difficult to make direct comparisons. In the context of those presenting tissue 
specific metabolite concentrations in mmol/1, the present values are not unreasonable 
(see section 2.4.4).
Validity
The validity coefficients for voxel by voxel metabolite concentrations range 
from 0.70 for Ins to 0.90 for tNAA (estimated from the single scanner data presented 
in Table 3.4d). Sub-selection of tissue specific voxels, while reducing CV, appears 
also to reduce RC. If RC alone were considered, we would conclude that the 
technique em ployed is not a valid m easure of tissue specific m etabolite  
concentrations. However, this observation is artefactual given that significant 
elements of inter-voxel variability may be explained by differences in their tissue 
contents (Tables 3.4a, 3.4b and 3.4c). Sub-selection of voxels will reduce inter-voxel 
variability while not necessarily equally reducing measurement errors. A reduced RC 
in these circumstances paradoxically would appear not to refute validity.
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Validity is also supported by the observation of significant tissue specific 
differences in metabolite concentrations consistent with previous findings. Age and 
gender effects are less well characterised and presently cannot be used to reliably 
support validity, although the present observations do not seem out of line with 
general themes observed in the literature (see section 2.4.4).
Conclusions
When compared with brain tissue volume measurements, tissue specific 
metabolite estimates derived from the technique employed in this work appear less 
reliable and valid, although they are still reliable enough to the detect biologically 
plausible differences in tissue specific metabolite concentrations in limited cohorts.
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4 ASSESSMENT OF EARLY DISEASE EFFECTS IN MULTIPLE
SC LER O SIS
4.1 IN TR O D U C TIO N
M S Cohort
This work made use of data from 27 subjects with relapsing-remitting MS, as 
defined using standard criteria (Poser  et al., 1983) (section 2.1.2). The group 
consisted of 20 females and 7 males; mean age 34.9 years when first scanned, 
median 33.7, range 24.1 to 48.4. All subjects were recruited within three years of 
first symptom onset (mean disease duration from first symptom onset 1.8 years, 
median 1.7 years, range 0.5 to 2.8 years). The mean EDSS score at their baseline 
assessments was 1.2 (median 1.0, range 0.0 to 3.0). Subjects were clinically assessed 
as outlined in section 2.1.6 and MR imaging performed at six monthly intervals. 
Each collection of MR data was divided into two sessions. Conventional T, (Gd- 
enhanced and non-enhanced) and T2/PD-weighted images were acquired (section
3.1.1) in a separate session from the volumetric (section 3.1.1) and 'H-MRSI (section
3.1.2) data. It is the latter data that form the core of this thesis.
In addition, diffusion tensor, magnetisation transfer, T,-relaxation, spinal cord 
T,-weighted (Gd-enhanced and non-enhanced), and spinal cord volumetric imaging 
were also undertaken. It is intended that subjects be followed-up over three years.
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4.2 CROSS-SECTIONAL ESTIM ATES OF BRAIN TISSUE ATROPH Y  
Introduction
There has been considerable work on quantifying the severity and extent of 
brain tissue damage in MS using MRI and relating this to clinical outcome. This has 
included the use of brain atrophy techniques that have been employed in relapsing- 
remitting and progressive clinical subtypes of MS (Miller et al.,2002). These studies 
have shown that atrophy occurs at a significantly faster rate in MS subjects compared 
with a normal healthy population.
It has not been clear how early in the course of MS atrophy appears and 
whether it affects both WM and GM. In addition, atrophy measures and estimates of 
T, or T2 lesion loads are only weakly correlated in established MS (Bermel et 
a l.,2003), if at all (De Stefano et al.,2002; Gasperini et al.,2002; Ge et al.,2000; 
Losseff et al., 1996), and a recent review of the association between Gd-enhancing 
lesion loads and atrophy revealed a similarly limited relationship (Zivadinov and 
Zorzon, 2002). Whether this atrophy is the result of earlier lesion-induced damage, 
raising the possibility that it is more directly related to lesion measures in the early 
stages of MS, remains to be determined.
M ethods
Subjects
NC data came from a cohort of 29 subjects (16 females and 13 males, mean 
age 36.6 years at first scan, median 33.5, range 23.2 to 55.2) with no history of 
neurological disease or other medical conditions (section 2.1.8).
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RRMS data came from a cohort of 27 subjects (20 females and 7 males; mean 
age 34.9 years when first scanned, median 33.7, range 24.1 to 48.4). The patients 
were required to have a disease duration of less than 3 years when recruited for the 
study. At time of scanning, mean delay from first symptom onset was 1.8 years 
(median 1.7, range 0.5 to 2.8). Their mean EDSS score was 1.2 (median 1.0, range 
0.0 to 3.0). None of the MS subjects had received beta-interferon or glatiramer 
acetate at any stage prior to scanning, nor had they been treated with corticosteroids 
within the previous month. The project had approval from the ethics committee of 
the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. 
All subjects gave informed consent.
Scan acquisition
Data from four scans were included in the study. The first was a 3D FSPGR; 
the second was a dual fast spin echo (FSE) sequence; the third and fourth were pre- 
and 20 minutes post-gadolinium enhanced (0.3 mmol per kg body weight of 
Magnevist (Schering AG, Berlin, Germany)) T,-weighted spin echo sequences. 
These sequences are described in section 3.1.1.
The second, third and fourth scans were acquired during the same scanning 
session; the first (3D FSPGR) scan was acquired during an earlier separate session. 
Sessions were separated by a mean of 9 days (median 7, range 2 to 60 days), during 
which time subjects did not report any additional clinical events.
Image analysis
Tissue and lesion segmentation was performed as described in section 3.1.1. 
Clinical assessments
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MS subjects underwent examination to estimate their EDSS (Kurtzke, 1983), 
TW T (Cutter et al., 1999), HPT (Goodkin et al., 1988), and PAS AT (3 second 
stimulus interval) (Gronwell, 1977) scores. The average of two trials for the TWT 
and average of four trials of the HPT (averaged as reciprocals of the mean times from 
two trials for each hand) (Fischer et al., 1999) were calculated and, along with the 
PASAT and MSFC scores (calculated using the preferred method (Fischer et 
a l.,\999)), were used in further analyses.
Statistical analyses
Statistical analyses were performed using SPSS 10.0 (SPSS Inc., Chicago, 
Illinois, USA). The associations between EDSS and tissue fractional volumes, lesion 
volumes, age and disease duration were investigated using Spearman correlations. 
MS disease effects were assessed using multiple linear regression models with age as 
a continuous covariate, gender and subject type (MS or normal control) as 
categorical factors, and an age-gender interaction term. For MS subjects, the relative 
effects on fractional tissue volumes of T2, T, and Gd-enhancing lesion volumes, and 
disease duration on fractional tissue volumes were assessed using Spearman 
correlations. 3D FSPGR lesion volumes were not investigated because they were 
used to correct fractional volumes and were therefore not independent of the other 
measures. Two-tailed significance values were estimated for correlations. A P-value 
<0.05 was regarded as significant. In MS subjects, associations with T2 lesion load 
and disease duration were also explored using multiple linear regression, with both 
factors included as continuous covariates. During initial analysis, age and gender
140
effects were not found to be significant in MS subjects and so were not included in 
the models.
Results
Lesion volumes
In the MS subjects the mean total lesion volumes were: 3D FSPGR hypo- 
intense lesion volume 7.7 ml (median 4.1, range 0.5 to 39.9 ml); T2 lesion volumes 
(contoured on the PD-weighted FSE sequence) 9.0 ml (median 4.8, range 1.1 to 40.8 
ml); T, hypo-intense lesion volume (on the pre-contrast T, weighted SE sequence) 
2.0 ml (median 0.2, range 0.0 to 9.9 ml) and GD enhancing lesion volume 0.6 ml 
(median 0.2, range 0.0 to 4.3 ml).
Correlations between lesion volumes, brain tissue fractions and clinical parameters 
None of the lesion volume measurements were correlated with age or disease 
duration. PASAT correlated modestly with age (rs=-0.404, Cl -0 .686  to -0 .017, 
P=0.037) but otherwise EDSS, HPT, TWT and MSFC did not; these parameters did 
not significantly correlate with disease duration. 3D FSPGR lesion volume correlated 
with TWT (rs=0.39, Cl -0.00 to 0.68, P=0.045); T 2 lesion load correlated with EDSS 
(rs=0.39, Cl -0 .00  to 0.67, P=0.047), HPT (estimated as the reciprocal average) 
(r=0.38, Cl -0.01 to 0.67, P=0.050) and MSFC (rs=-0.43, Cl 0.05 to 0.70, P=0.024); 
WMF with HPT (rs=-0.44, Cl -0.71 to -0.06, P=0.023). Other correlations were not 
significant.
Fractional tissue volumes: absolute disease and disease duration effects
MS disease effects were found to be significant for both GM and WM. 
Estimated disease effects allowing for age and gender were: -0.032 (Cl -0 .047  to
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-0.018) for BPF (-3.9% compared with controls at age 35.8 years [the mean age of 
both MS and normal control cohorts] PcO.OOl, R2=0.354); -0.016 (Cl -0 .029  to 
-0.003) for GM F (-2.9%, P=0.014, R2=0.326); and -0.016 (Cl -0 .024 to -0.008) for 
W M F (-5.7%, PcO.OOl, R2=0.335) (Table 4.2a). Disease duration did not 
significantly correlate with any fractional tissue volumes directly. However, when 
modelled with T2 lesion load, both were significant factors for GMF (-0.013 [Cl - 
0.024 to -0.001] per year, P=0.035; and T 2 -0.002 per ml [Cl -0.003 to -0.001], 
PcO.OOl, R2=0.569), while only T 2 lesion load significantly contributed towards BPF 
estimates (-0.002 per ml, [Cl -0.003 to -0.001], PcO.OOl, R2=0.595) and neither was 
significant for WMF.
Fractional tissue volumes: comparative lesion volume effects
Table 4.2b shows the correlations of tissue fraction measures with lesion 
volumes in MS subjects. BPF and GMF were both strongly correlated with T2 and 
moderately with T, hypo-intense lesion volumes, but not with T, post-gadolinium 
enhancing lesion volumes. W M F was not correlated with any lesion volume 
measure. Figure 4.2a shows tissue fractions plotted against T2 lesion loads.
Discussion
Many previous studies have detected brain tissue atrophy in MS (reviewed in 
(Miller et al.,2002)), but relatively few had looked specifically for GM changes when 
this study was performed (Cifelli et al.,2002; Ge et al.,2001; Liu et al., 1999), or for 
atrophy in people with clinically early MS. This study reveals significant brain 
atrophy, affecting both white and grey matter, in a cohort of clinically definite MS 
subjects with clinical disease duration of 1.8 years. Subsequent work has confirmed
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this observation (Quarantelli et al.,2003; Sanfilipo et c//.,2005; Sastre-Garriga et 
al.,2004; Tedeschi et al.,2005).
Brain tissue fraction findings in MS
After allowing for age and gender effects, BPF was significantly reduced in 
the MS group, with a greater proportional reduction in WMF (mean c. -5 .7% ) than 
GMF (mean c. -2.9%). In controls, age related changes were more apparent for GMF 
(mean -0.3% per year) than WMF (mean -0.1% per year). Therefore, atrophy early in 
the clinical course of MS does not appear to represent a simple acceleration of the 
usual age related changes.
The reduction in BPF in the present early relapsing-remitting MS study 
accords with previous reports of subjects with CIS (Brex et a l.,2000a) and studies 
assessing atrophy in subjects within 5 years of clinical disease onset (Zivadinov et 
al.,2001). It therefore seems reasonable to conclude that brain atrophy occurs in the 
early stages of MS.
There had been little previous work investigating white matter and grey 
matter separately for the presence of atrophy in MS. Liu et al. (Liu et al., 1999) in a 
mixed cohort of 40 RR and SP MS subjects (median disease duration 7 years) found 
significant WM atrophy (-11.9%, p<0.001) but no discernable effect upon GM. No 
significant difference was observed between RR and SP cohorts. This is concordant 
with work by Ge et al. (Ge et al.,2001) concluded that in a cohort of 30 RRMS 
subjects with a mean disease duration of 3.8 years, loss of brain tissue was mainly 
confined to WM (-6.4%). While no overall disease effect was observed on %GM (as 
a fraction of intra-cranial volume) a correlation with T 2 lesion load was seen (rs=-
143
0.52, P<0.0()5). No association between T 2 lesion load and %WM was seen. 
However, subsequently, Quarantelli et al. (2003) have also detected GM (-7.1%, 
p<0.001), although without WM atrophy, in a cohort of 50 RRMS subjects (mean 
clinical disease duration 9.9 years) and an association between GM (rs=-0.43, 
p<0.001) but not WM atrophy and T2 lesion loads; De Stefano et al. (2003) have 
observed neocortical atrophy in people with RRMS and disease durations less than 5 
years; Sastre-Garriga et al. (2004) in a cohort of 43 PPMS compared with 45 normal 
control subject found both GM (GMF -3.5% ) and WM (WMF -6.2% ) atrophy, using 
the same technique employed in the present work; while Tedeschi et al. (2005) and 
Sanfilipo et al. (2005) also both found atrophy in GM and WM (although Sanfilipo et 
al. did not find WM atrophy to be significant). Work assessing thalamic volumes, 
normalised for intracranial volumes, in 14 subjects with SPMS (median disease 
duration 18.5 years) has also found a -17%  decrease in volume when compared with 
age and gender matched normal control subjects (Cifelli et a l.,2002); and in 14 
subjects with RRMS a -25%  decrease (Wylezinska et al.,2003).
Relationship between brain tissue fractions and lesion measures
There was no correlation between the enhancing lesion loads and measures of 
atrophy. Enhancing lesions are correlated with active inflammation on pathological 
studies (Bruck et «/.,1997; Katz et al., 1993); however, only a small proportion of 
lesions will display inflammation at a single time point. A realistic evaluation of the 
relationship between this MR marker of inflammation and atrophy would require an 
assessment of serial data obtained from multiple enhancing scans obtained at 
frequent intervals (noting that new lesions enhance on average for only one month)
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(Harris et al., 1991; Thompson et al., 1991). There is little of such data available in 
patients with early disease; data from cohorts with longer disease durations has 
revealed only modest correlations (Coles et al., 1999; Saindane et al.,2000; Simon et 
a l,  1999).
Inspection of figure 4.2a reveals a readily apparent relationship between T 2 
lesion volumes and both BPF and GMF, but not WMF. Assessment of correlations 
(Table 4.2b), confirm the association for both T2 and T, lesion volumes. The stronger 
relationship was with T 2 volume, which gave an r  of 0.41 for BPF and 0.30 for GMF 
suggesting that about a third of the BPF and GMF reduction can be explained by 
variations in T 2 load. These lesion load effects were confirmed after allowing for 
disease duration by the model.
There are several potential explanations for this relationship between T2 
lesions, which are virtually all located in white matter, and atrophy located in grey 
matter. First, the decrease in GMF may reflect both retrograde degeneration to the 
cell body and Wallerian (predominantly anterograde) degeneration extending along 
fibre tracts (Simon et al.,2000) following axonal transection in white matter lesions 
(Trapp et al., 1998). Secondly, axonal damage without transection but associated with 
demyelination per se (Ferguson et a/., 1997) may lead to axonal and neuronal atrophy 
(Yin et al., 1998). Thirdly, grey matter lesions, though rarely seen on MRI, are 
commonly found at post mortem (Bo et al.,2000; Brownell and Hughes, 1962; Kidd 
et a l ,  1999); such lesions are associated with demyelination and possibly with local 
axonal and neuronal damage, and their total volumes may be correlated with white 
matter lesion loads. They might also cause subtle changes in signal intensity that
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affects segmentation between cortex and CSF such that grey matter volume appears 
reduced. Finally, both overt lesion genesis and tissue atrophy may be manifestations 
of some other common pathogenic mechanism that has yet to be elucidated.
The absence of a clear correlation between lesion volumes and WMF, despite 
the greater extent of WMF reduction when compared with GMF, could be interpreted 
as an early global WM disease process resulting in atrophy which is at least partly 
independent of overt lesion genesis. Alternatively, water content changes due to low 
grade inflammation or oedema, along with glial proliferation in the normal-appearing 
white matter (Allen and McKeown, 1979; Tourtellotte and Parker, 1968) might alter 
white matter volumes and obscure a relationship between lesion volume and WMF 
loss. It is also worth recalling that WMF reproducibility was not quite as good as that 
for GMF, and this may contribute towards the masking of relationships. Studies 
making use of a larger sample with greater lesion volume heterogeneity are needed.
The present study indicates a stronger relationship between atrophy and T 2 
than T, hypo-intense lesion load in a cohort with clinically early MS. It has been 
suggested that T, lesions are associated with greater axonal loss (van Walderveen et 
al., 1998b) when compared with T2 lesions, and they should therefore correlate more 
strongly with atrophy if the link mechanism is secondary tract degeneration. 
However, the T, lesion load was relatively small in this early disease cohort and the 
stronger correlation of grey matter atrophy with T2 lesion volumes suggests that in 
early MS, the link between white matter lesions and grey matter atrophy may have 
additional mechanisms. Relatively few studies have presented data on the association 
between atrophy and both T, and T2 weighted lesion loads. Paolillo et al. (2000)
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explored the cross-sectional relationship between atrophy and lesions in a cohort 
with RRMS and a mean disease duration of 5.6 years. They found a correlation 
between a regional cerebral hemisphere volume measure and T, (r=-0.48, P<0.001), 
but not T2 lesion loads, although both T, and T2 lesion loads correlated equally with 
corpus callosum area (r=-0.53, P<0.001 and r=-0.52, P<0.001 respectively). 
Similarly, Sailer et al. in a mixed cohort of 29 RRMS and SPMS subjects found no 
association between T2 lesion load and cerebral atrophy, although they did observe a 
relationship with T, lesion load (Sailer et al.,2001). However Zivadinov et al. (2003) 
found nearly equal correlations between both T1 and T2 lesion loads, and BPF (r=- 
0.54 and r=-0.52 respectively, P<0.005).
Relationship between brain tissue fractions and disease duration
Disease duration was found to have a modest but significant additional effect 
upon GMF but not WMF. This was detected after allowing for associations between 
T2 lesion load and tissue fractional volumes. A possible explanation for this result is 
that there is on-going grey matter atrophy which was initiated during acute lesion 
genesis but is not dependent on further lesion activity. The observation that on-going 
axonal loss occurs in chronically demyelinated plaques may be relevant here (Kornek 
et al.,2000). The disparity between GMF and WMF has been considered above, with 
all the same reasons applying to these findings as were discussed in relation to lesion 
volume and tissue fraction correlations. Saindane et al. (2000) have also noted an 
association between disease duration at baseline and fractional brain tissue volume 
(rs=-0.64, p<0.001), and Paolillo et al. (2000) observed a correlation between disease 
duration and corpus callosum area (rs=-0.31, p=0.03).
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Atrophy and cell loss
The disease associated volume reduction in our subjects of c. 2.8 % in GMF 
and c. 4.9% in WMF, compares with a reduction in NAA in the normal appearing 
GM (mean 5.6%) and WM (mean 4.5%) in subjects from the same cohort (see 
section 4.3). If we assume that neuronal numbers are directly proportional to both 
tissue volumes and tNAA concentrations, which they may not be, these results would 
represent a ~10% reduction in GM and ~ 1 1% reduction in WM total neuronal and 
axonal populations.
Other investigators have reported a proportionately greater reduction in NAA 
to Cr ratios than brain volumes in relapsing-remitting MS (Collins et al.,2000) (a 
circa -1.1% change in brain normalised to intracranial volume and a circa -8.7% 
reduction in the NAA to Cr ratio in a large central voxel). These discordant findings 
could indicate that axonal and neuronal loss is more marked than that indicated by 
fractional tissue volume loss alone (for reasons already discussed) or that the more 
marked reduction in NAA may indicate a transient effect of axonal and neuronal 
dysfunction rather than absolute axonal and neuronal loss on the concentration of this 
metabolite (Mader et al.,2000; Narayana et al., 1998).
Study limitations
While this study indicates atrophy can be detected early in the clinical course 
of MS, it is based upon relatively homogeneous cross-sectional data, and the strength 
of associations with either lesion loads or disease duration in the MS cohort should 
be considered in this light. In addition, while age, disease duration and lesion 
volumes were all found to significantly influence disease related tissue specific
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atrophy, the trends detected need to be explored again in more heterogeneous and 
larger samples. It is important not to extrapolate the results outside of the parameter 
ranges covered by the present study: while the assumptions of linear relationships 
between parameters, such as age and tissue fractions, appear satisfactory for the 
present cohort, this can not be assumed to be true for a greater range of values. In 
addition, when interpreting the magnitude of disease effects, it should also be 
remembered that various methods for assessing tissue volumes might yield different 
absolute values dependent upon both the segmentation methodology and scan 
acquisition utilised.
It should also be recalled that the data have been explored with multiple 
statistical tests, and as such there is real potential for results considered significant at 
a P<0.05 level to be spurious. In particular, nearly 40 correlations between brain 
lesion loads and other parameters have been assessed, and so it may be expected that 
about two statistically significant results would be seen even if there were no true 
associations.
Brain tissue segmentation in any disease processes may be complicated by 
both changes in tissue signal intensity characteristics and, in the case of MS, the 
presence of lesions. There are a number of further segmentation strategies which 
could be employed to potentially improve upon that used in this study, although each 
method will be associated with differing susceptibilities for disease related 
segmentation bias. In addition, there is no accepted standard technique for measuring 
brain tissue volumes, thus it is not possible to fully validate and calibrate any 
segmentation methodology. Given this, it is important that multiple segmentation
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m ethodologies are independently im plem ented and applied to d ifferent scan 
acquisitions as each will have their own advantages and disadvantages.
W hile the MS and control subjects were well matched for age, there was 
some imbalance in genders. However, this should not have markedly impacted upon 
our results as gender and age effects were allowed for in the models used. Indeed, 
neither age nor gender effects were detected in the MS cohort, probably because they 
were obliterated by overlying disease related effects (as seen on inspection of Figure 
4.2b).
Conclusions
The present study shows that, after allowing for normal age and gender 
effects, there is evidence that significant fractional brain volume loss has already 
occurred early on in the clinical course of relapsing remitting MS and that, unlike age 
related changes, this is proportionally more evident in white matter. Significant 
relationships were found between lesion volumes and the degree of tissue atrophy in 
grey but not white matter. This suggests that white matter, and to a lesser degree grey 
matter, pathology may occur by mechanisms that are at least partly independent of 
overt lesion genesis.
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Gender Subject type
Normal control MS
BPF GMF WMF BPF GMF W M F
Male 0.839, 
0.850, 
0.784 to 
0.868
0.552, 
0.550, 
0.515 to 
0.574
0.288, 
0.284, 
0.263 to 
0.320
0.793, 
0.817, 
0.717 to 
0.820
0.530, 
0.544, 
0.467 to 
0.562
0.263, 
0.257, 
0.250 to 
0.280
Female 0.840, 
0.850, 
0.782 to 
0.871
0.563, 
0.570, 
0.507 to 
0.600
0.277, 
0.275, 
0.252 to 
0.303
0.819, 
0.823, 
0.773 to 
0.852
0.553, 
0.551, 
0.510 to 
0.588
0.266, 
0.268, 
0.231 to 
0.303
Both 0.840, 
0.850, 
0.782 to 
0.871
0.558, 
0.560, 
0.507 to 
0.600
0.282, 
0.281, 
0.252 to 
0.320
0.812, 
0.818, 
0.717 to 
0.852
0.547, 
0.551, 
0.467 to 
0.588
0.265, 
0.266, 
0.231 to 
0.303
Table 4.2a: Mean, median (range) fractional tissue volumes by gender in normal 
control and MS subjects. Results are from 13 male (mean age at scanning 36.3 years, 
median 32.3, range 27.2 to 52.7) and 16 female (mean age at scanning 36.8 years, 
median 33.5, range 23.2 to 55.2) controls subjects; and 7 male (mean age at scanning 
33.4 years, median 31.8, range 24.8 to 48.1) and 20 female (mean age at scanning 
35.3 years, median 34.5, range 24.1 to 48.4) MS subjects.
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Tissue
parameter
Lesion parameter
T2 hyper-intense T, hypo-intense Gd-enhancing
BPF -0.64,
-0 .83  to -0 .34 , 
<0.001
-0.58,
-0 .79  to -0 .25 , 
0.001
-0.26,
-0 .5 9  to  0 .1 4 , 
0.189
GMF -0.55,
-0 .77  to -0 .20 , 
0.003
-0.57,
-0 .79  to -0 .23 , 
0.002
-0.18,
-0 .53  to  0 .2 3 , 
0.378
WMF -0.18,
-0 .5 3  to 0 .2 3 , 
0.382
-0.07,
-0 .45  to  0 .3 3 , 
0.735
-0.05,
-0 .43  to 0 .3 5 , 
0.798
Table 4.2b: Spearman correlations, Cl and P-values, of tissue fractions with total 
lesion volumes in MS subjects.
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Figure 4.2a: T2 lesion and fractional brain tissue volumes. Gradients associated with 
increasing lesion loads can be seen in both the BPF and GM F data, but not the W M F 
data.
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Figure 4.2b: MS disease effects upon fractional brain tissue volumes. Subjects with 
MS show consistently lower BPF and WMF volumes, and to a lesser degree GM F 
volumes, when com pared with NC subjects, and this effects appears to be greater 
than age-related trends observable in the NC subjects.
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4.3 C R O S S -S E C T IO N A L  E S T IM A T E S  O E B R A I N  M E T A B O L IT E  
CON CENTRA TIONS 
Introduction
There is growing evidence to suggest that the effects of MS on brain tissues 
are not limited to focal WM lesions or even WM per se. In the NAW M there is 
evidence from MRI and histopathology studies indicating extensive involvem ent 
despite the apparent absence of overt lesions on conventional T, or T2-weighted MRI 
images. GM is also involved, although it has not been the focus o f much 
investigation until recently. Despite the considerable volume of GM, its com plex 
anatomy has meant that it has been difficult to study using MRI. The introduction of 
additional MRI techniques and refinements to conventional imaging methodologies 
has made the study o f this potentially im portant but under-investigated tissue 
possible.
This present study investigates clinically early MS disease effects in both 
NAWM and cortical GM (CGM ), using 'H-M RSI to determ ine tissue specific 
metabolite concentrations and assessing their relationships with clinical outcome. It 
builds upon previous preliminary work (Kapeller et al.,2001), expanding the MS and 
NC cohorts; updating the 'H-M RSI processing technique and tissue segm entation 
m ethodology (with inclusion of form al lesion quantification); and em ploying 
statistical analyses to account for age, gender, tissue type and partial volume effects 
associated with differences in brain parenchymal volumes.
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Methods
Subjects
NC data came from a cohort of 29 subjects (16 females and 13 males, mean 
age 36.6 years at first scan, median 33.5, range 23.2 to 55.2) with no history of 
neurological disease or other medical conditions (section 2.1.8).
RRMS data came from a cohort of 27 subjects (20 females and 7 males; mean 
age 34.9 years when first scanned, median 33.7, range 24.1 to 48.4). The patients 
were required to have a disease duration of less than 3 years when recruited for the 
study. At time o f scanning, mean delay from first symptom onset was 1.8 years 
(median 1.7, range 0.5 to 2.8). Their mean EDSS score was 1.2 (median 1.0, range 
0.0 to 3.0). None of the MS subjects had received beta-interferon or glatiram er 
acetate at any stage prior to scanning, nor had they been treated with corticosteroids 
within the previous month.
Scan acquisition
Volumetric, T1 and T2-weighted, and Gd-enhanced images were acquired as 
outlined in section 3.1.1.
'H-MRSI data were acquired as outlined in section 3.1.2. The size of PRESS 
selected volume varied between subjects: in MS subjects the m ean anterior to 
posterior extent was 95 mm (median 97, range 69 to 111 mm) and the mean left to 
right extent was 66 mm (median 66, range 54 to 74 mm); in NC subjects the mean 
anterior to posterior extent was 98 mm (median 98, range 77 to 118 mm) and the 
mean left to right extent was 69 mm (median 69, range 59 to 80 mm). Figure 4.3a 
shows an axial section through the brain at the level of the spectroscopic slice, with
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an overlaid grid o f extracted spectra, a selection of which have been enlarged to 
provide more detailed spectra.
Image processing
'H-M RSI data were processed as outlined in section 3.1.2, yielding tissue 
specific estim ates o f metabolite concentrations for a given subject. Brain tissue 
volumes and lesion loads were determined as described in section 3.1.1.
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Clinical Assessments
MS subjects were clinically assessed as outlined in section 4.2.
Statistical analyses
Statistical analyses were performed using SPSS 10.0 (SPSS Inc., Chicago, 
Illinois, USA). MS disease effects on metabolite concentrations were estim ated 
using multiple (linear) regression models that included gender and disease status (MS 
or NC) as categorical variables; and age, WM contents o f CGM voxels (and vice 
versa  for NAW M  voxels), voxel CSF contents and BP volum e as continuous 
covariates. This was designed to allow for differences in GM and WM m etabolite 
concentrations; the potential effects of age and gender; and both overt voxel CSF 
contamination and partial volume effects associated with differences in whole brain 
volumes.
The relationships betw een m etabolite concentrations and lesion load 
measures, disease duration, fractional brain tissue measures (BPF, GM F and W M F) 
and clinical parameters (EDSS, MSFC, HPT, TW T and PASAT) were assessed using 
Spearman correlations.
Results
Subject demographics, clinical parameters and brain tissue volume measures
CGM data came from 24 of the MS (mean age 35.2 years, median 34.3, range 
24.1 to 48.4 years; 19 females and 5 males; mean disease duration (estim ated from 
first symptom onset) 1.7 years, median 1.6, range 0.5 to 2.7 years) and 26 o f the NC 
(mean age 34.8 years, median 33.3, range 23.2 to 55.2 years; 14 fem ales and 12 
males) subjects. NAWM data came from 25 of the MS (mean age 35.0 years, median 
33.7, range 24.1 to 48.4 years; 19 females and 6 males; mean disease duration 1.7
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years, median 1.6, range 0.5 to 2.7 years) and 29 of the NC (mean age 36.6 years, 
median 33.5, range 23.2 to 55.2 years; 16 females and 13 males) subjects. Clinical, 
lesion load and tissue volume data for the whole MS cohort are given in section 4.2. 
Disease effects upon tissue metabolite concentrations
A fter allow ing for age, gender, voxel tissue contents and brain tissue 
volum es, sign ificant disease effects (at a P<0.05 level) were found in the 
concentrations of CGM Cho, CGM tNAA, CGM Glx, NAW M tNAA and NAW M  
Ins (Tables 4.3a, 4.3b and 4.3c).
Relationships between tissue metabolite concentrations and both lesion load and  
clinical parameters
Spearman correlations between m etabolite concentrations and other MRI 
parameters were significant for T2 lesion load and NAW M Ins (rs=0.44, Cl 0.04 to 
0.71, P=0.030) but not for T, hypo-intense or G d-enhancing lesion loads, or 
fractional brain tissue volumes. Disease duration did not significantly correlate with 
any metabolite concentrations.
Correlations between metabolite concentrations and measures o f disability 
were significant for CGM Glx with EDSS (rs=-0.43, C l -0.72 to -0.02, P=0.035), 
M SFC (rs=0.58, Cl 0.22 to 0.80, P=0.003), HPT (r= -0 .42 , Cl -0.71 to -0.01, 
P=0.039) and PAS AT (r =0.54, Cl 0.16 to 0.78, P=0.006); NAW M  Ins with M SFC 
(r =-0.56, -0.79 to -0.20, P=0.004), HPT (r =0.61, Cl 0.27 to 0.82, P=0.001), TW T 
(r=0.45, 0.06 to 0.73, P=0.023) and PASAT (r=-0.41, C l -0.70 to -0.01, P=0.040); 
and CGM Cr (noting that a significant overall disease effect was not observed) with 
MSFC (r=0.52 , Cl 0.14 to 0.77, P=0.009) and HPT (r= -0 .54 , C l -0.78 to -0.16, 
P=0.007). Figures 4.3b and 4.3c show the relationship betw een M SFC and both
159
CGM Glx and NAWM Ins respectively. In those subjects who contributed NAWM 
voxel data, lesion load measures and disease duration did not correlate significantly 
with clinical impairment.
Discussion
These results show that in MS compared with NC subjects, tNAA is reduced 
in both CGM and NAWM; that Ins is elevated in NAWM; and that Cho and Glx are 
both reduced in CGM. They were obtained allowing for age and gender effects, 
voxel tissue contents and potential partial volume effects related to brain tissue 
volumes. Before considering these results further there are some factors that need to 
be recalled when reviewing them, and some potential pathological interpretations of 
changes in metabolite concentrations.
Methodological and analytical considerations
Given the volume of 'H-MRSI voxels utilized in this study (2.3 mL), it was 
not possible to select pure CGM or NAWM voxels. Instead selection criteria were 
used that would yield voxels with minimal lesion contamination (< 1%); limited CSF 
and non-brain tissue contents (GM plus NAWM > 80%); and approxim ately equal 
proportions of a given tissue type (excluding CSF) to a given voxel type (circa 79% 
for both CGM and NAW M voxels). Lesion contam ination was predom inantly an 
issue with NAWM voxels, whereas brain tissue content was a lim iting factor when 
setting the criteria to yield CGM voxels due to the proximity of CGM to CSF spaces.
In order to assess intrinsic disease effects upon a given tissue type, multiple 
regression m odels were used. These allowed for voxel tissue contents and CSF 
contamination, variability in whole brain volume, age and gender. Previous work has 
shown tissue specific and regional differences in m etabolite concentration, along
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with age and gender effects (see section 2.4.4). The inclusion of these factors in the 
model was designed to ensure the robustness o f our overall d isease effect 
conclusions against confounding effects, rather than offer further insight into the role 
these factors may have in determining metabolite concentrations. These should be 
explored again in future work.
There are no clearly established methods for constructing appropriate or 
optim al data m odels, and there are d isadvantages to both under or over- 
param eterisation (Freund and W ilson, 1998). Erring on the side o f caution, all 
potential confounding factors for which measures were available (age, gender, 'H- 
MRSI tissue and CSF contents, and BP volume) were included. The relationships 
between outcome variables and covariates were assumed to be linear and, while this 
appeared adequate for the present data, this may not be optimal and should be 
reconsidered in future work. Rather than try to include other disease related 
parameters such as lesion loads, disease duration and separate brain tissue volume 
measures in an all-encompassing but potentially markedly over-parameterised model, 
these were explored separately with Spearman correlations. W hen considering the 
results, it should also be recalled that multiple comparisons have been made, and as 
such some of the results reported to be significant at a P<0.05 level may be due to 
chance alone.
Given that a small amount of brain atrophy has been detected in this MS 
cohort (see section 4.2), the question arises whether the tissue m etabolite changes 
seen, particularly in CGM, reflect partial volume effects or not. This would appear 
unlikely for two reasons. Firstly, the reported magnitude of the reduction in the GM F 
(circa 2.8%) is less than those observed for the significant m etabolite decreases in
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GM (circa 6.6% to 15.1%). Secondly, the statistical models allowed for 'H-M RSI 
voxel tissue contents and whole brain volume, yet still identified significant changes 
in tissue metabolite concentrations.
Cortical grey matter observations
In CGM, Cho, tNAA and Glx were all reduced in MS compared with NC 
subjects, and this was unrelated to lesion load measures. The marked reduction in 
Cho may indicate both reduced cellular density and metabolic activity, although 
subsequent work has not replicated this in deep GM (Inglese et al.y2004). The 
absence of a significant decrease in Ins would suggest that glial loss is not a major 
contributing factor, assuming that intracellular Ins concentrations remain relatively 
unchanged in MS. Reductions in tNAA point to more specific neuronal involvement, 
which may be related to cell loss or metabolic dysfunction or both. Reductions in Glx 
could mark metabolic dysfunction and loss of neurons and glial cells; once again, the 
lack of a concurrent significant decrease in Ins favours interpretation o f the present 
results as representing neuronal metabolic dysfunction or loss or both.
O ther proton m agnetic resonance GM studies in MS had been relatively 
limited (K apeller et al.,2001; Sharma et al.,2001), and had not consistently shown 
reductions in NAA; subsequent work has detected reductions in NAA in SPMS (but 
not RRM S, although only five subjects in each MS group) (A dalsteinsson et 
a l.,2003), RRM S (Inglese et al.,2004), and PPMS (Sastre-G arriga et al.,2005b). 
H istopathology studies have found cortical lesions (Bo et al.,2000; Brownell and 
Hughes, 1962; Kidd et al., 1999), with neuronal involvem ent including axonal and 
dendritic transection, and neuronal apoptosis (Peterson  et al.,2001). The present 
observations appear consistent with these findings.
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Normal-appearing white matter observations
M etabolite changes in NAWM were more limited than for CGM. NAWM Ins 
was significantly elevated and was modestly related to T2 lesion loads. This may 
indicate glial proliferation in NAWM and, given that T2 lesions are to a significant 
degree associated with previous focal inflammation (Bruck et al., 1997; Ciccarelli et 
al., 1999; Katz et al., 1993; Lai et al., 1996; Miller et al., 1988), this would also suggest 
that focal inflamm atory activity is related to a more widespread WM process. The 
reduction in tNAA in NAW M is compatible with axonal metabolic dysfunction or 
loss or both.
Pathology studies have shown both gliosis (Allen and McKeown, 1979) and 
axonal loss (B ja rtm ar et a l.,2000; Evangelou et al.,2000) in NAW M . Proton 
spectroscopy studies o f NAW M  have found reductions in absolute NAA 
concentrations all clinical subtypes o f MS (Adalsteinsson et a l.,2003; Davie et 
al., 1997; K apeller et al.,2001; Sastre-Garriga et al.,2005b; Suhy et a l.,2000; van 
W alderveen et al., 1999a), although not entirely consistently (V renken et al.,2005), 
and also reduced relative (to Cr) (Fu et al., 1998; Leary et al., 1999a; Tourbah et 
al., 1999), although in the case of ratio analyses this may in part be due to increased 
Cr concentrations (Rooney et al., 1997; Suhy et al.,2000; Vrenken et al.,2005). Ins 
concentrations have also been found to be absolutely (K apeller et al.,2001; Sastre- 
G arrig a  et a l.,2005b; V renken et al.,2005) and relatively (to Cr) (T ourbah et 
al., 1999) elevated. The present findings appear consistent with previous studies and 
mirror known histopathology.
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Clinical outcome and M RI parameters
CGM Glx and NAW M Ins concentrations correlated most consistently with 
clinical outcome in this clinically early cohort, while tNAA did not correlate with 
any outcome measure. An overall disease effect on CGM Cr was not found to be 
significant and caution is needed when interpreting its relationship to clinical 
parameters. Taken together, the present findings could be interpreted as showing a 
relationship betw een neuronal m etabolic dysfunction and clinical im pairm ent, 
hinting that the former may be an important factor in determining clinical status at an 
early stage in the clinical evolution of relapsing-remitting MS. This may not be the 
case in the long-term: absolute axonal and neuronal loss may be more important as 
the disease progresses. This may in part explain the discrepancy between the present 
results and those from some previous studies that have investigated cohorts with 
longer disease durations and shown a correlation between disability and reductions in 
NAA:Cr ratios (De Stefano et al., 1998; De Stefano et al.,2001; Fu et al., 1998; Fu et 
al., 1996; Ruiz-Pena et a l.,2004). In PPMS subjects, correlations between CGM  
tNAA, NAWM Glx and Ins have been observed using the same techniques employed 
in the present work (Sastre-Garriga et al.,2005b), although an overall reduction in 
NAWM Glx was again not observed.
The relationship between clinical im pairm ent and NAW M  Ins im plies that 
glial proliferation is associated with a negative effect upon clinical function. W hile 
NAWM Ins concentrations appear to be modestly related to T2 lesion loads (rs = 0.44, 
P=0.030), only circa 19% (rs2= 0.19) of variability can be accounted for by this link, 
suggesting that glial proliferation is to a large extent independent of focal lesion 
genesis. Further, clinical status was not related to T 2 lesion load, w hich would
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support the concept that glial proliferation intrinsically, or another pathological 
process leading to it, has a significant role to play in determining impairment.
Study limitations
In addition to those considerations mentioned at the start o f this discussion, 
there are a number of other limitations that should be noted when comparing results 
from this present work with others. W hile the metabolite quantification technique 
employed yields mmol/L values, it is not possible to calibrate these against actual in 
vivo  values. Thus, different m etabolite quantification techniques may produce 
different values and so a direct comparison cannot be made. Further, imperfect 'H- 
MRSI slice excitation profiles will also influence estim ates o f m etabolite  
concentrations, although we would anticipate that this would affect MS and NC 
subjects similarly. Brain tissue volume quantifications also cannot be considered 
entirely accurate, with scan acquisition and processing m ethodologies all affecting 
the apparent tissue volum es, and no definitive gold standard in vivo results to 
calibrate these against. Further, the estimated magnitude of disease effects will, to a 
degree, be dependent upon the statistical model em ployed and this m ust be 
remembered when looking at the values given in Table 4.3c.
As noted above, cortical lesions are found in MS. Such lesions are visible on 
MRI scans (Bakshi et al.,2001; Boggild et al., 1996; Rovaris et al.,2000), although 
this is hampered by the structural complexity of GM and the relatively sim ilar MRI 
signal intensity characteristics of GM and lesions on some sequences. Further, MRI 
probably underestimates their extent (Geurts et al.,2005). Given this, tissue classified 
as CGM in the present study is likely to contain some focal lesions and it is not 
possible to determine w hether the observed CGM m etabolite changes reflect the
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effects of lesions or more diffuse abnormality. The apparent absence of an increase 
in CGM Ins contrasts with observations made on focal WM lesions (B rex et 
al.,2000b; Davie et al., 1994; De Stefano et al., 1995; Kapeller et al.,2001; Koopmans 
et al., 1993) and may reflect relatively less glial proliferation in GM lesions when 
compared with those found in WM.
Conclusions
This study provides evidence for neuronal and axonal metabolic dysfunction 
or loss, or both, in CGM and NAW M, and for glial proliferation in NAW M, early in 
the clinical course of MS. The results suggest that metabolic dysfunction, particularly 
evident in CGM, may be more closely related to disability in the early stages of MS 
than absolute neuronal and axonal loss. Further work is required to clarify the 
metabolic and structural contributions towards disability throughout the clinical 
course of MS.
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Voxel Parameter Subject type
type
NC MS
CGM Cho 1.16, 1.15(0.78 to 1.59) 1.00, 0.97 (0.74 to 1.36)
Cr 6 .31,6 .26 (5.15 to 7.80) 5.73,5.81 (3.93 to 6.93)
Ins 4.51,4.41 (3.79 to 5.48) 4.29, 4.38 (3.23 to 4.99)
tNAA 8.93,8 .76 (7.92 to 11.55) 8.21, 8.33 (6.30 to 9.27)
Glx 12.28, 12.01 (9 .86  to 
15.46)
10.61, 10.81 (6 .88 to 
13.46)
GM% 71.29, 71.02 (65.49 to 
77.65)
67.99, 67.87 (61.18 to 
76.86)
WM % 16.19, 16.76 (7.45 to 
28.63)
18.07, 18.59 (8 .89  to 
24.71)
CSF % 1 1.93, 12.22 (5 .29  to 
16.86)
13.25, 13.27 (8 .63  to 
18.04)
Lesion % - 0.04, 0.00 (0.00 to 0.39)
Table 4.3a: Proton m agnetic resonance spectroscopic im aging voxel m etabolite 
concentrations (mmol/L) and tissue (percentage of total) contents presented as mean, 
median (range) values in NC and MS subjects’ CGM. Data came from 24 MS and 
26 NC subjects.
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Voxel Parameter Subject type
type
NC MS
NAWM Cho 1.28, 1.23 (1.00 to 1.75) 1.20, 1.17 (0.96 to 1.60)
Cr 4.87 ,4 .79  (4.11 to 6.39) 4.86, 4.85 (4.17 to 5.83)
Ins 3.65,3 .56 (2.99 to 4.66) 3.98, 3.76 (2.93 to 5.45)
tNAA 8.81,8 .79 (7.61 to 10.28) 8.30, 8.22 (6.84 to 9.92)
Glx 7.72, 7.86 (6.64 to 8.90) 7.51,7.73 (5.07 to 9.43)
GM % 19.07, 19.06 (13.64 to 
27.42)
20 .53 , 21.18 (5 .10  to 
28.24)
WM % 79.57, 79.13 (71.09 to 
85.58)
77.12, 77.06 (62.75 to 
92.94)
CSF % 0.81 ,0 .76  (0.08 to 2.09) 1.55, 1.06 (0.36 to 9.02)
Lesion % - 0 .13 ,0 .08  (0.00 to 0.78)
Table 4.3b: Proton magnetic resonance spectroscopic im aging voxel m etabolite 
concentrations (mmol/L) and tissue (percentage of total) contents presented as mean, 
median (range) values in NC and MS subjects’ NAWM. Data came from 25 MS and 
29 NC subjects.
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Metabolite A d ju s ted  m eans (SE ) 
(mmol/L)a
MS disease effectsb
NC MS M ean (SE) 
(mmol/L)
Percentage 
e ffec tc
P value
CGM Cho 1.18 (0.04) 1.02 (0.05) -0.17 (0.06) -14.0% 0.011
CGM Cr 6.26 (0.12) 5.93 (0.15) -0.33 (0.20) -5.2% 0.108
CGM Ins 4.50 (0.10) 4.35(0.11) -0.15 (0.15) -3.2% 0.347
CGM tNAA 8.85 (0.14) 8.37 (0.17) -0.48 (0.23) -5.6% 0.041
CGM Glx 12.13 (0.29) 11.12(0.34) -1.01 (0.47) -8.3% 0.035
NAWM Cho 1.28 (0.04) 1.22 (0.04) -0.06 (0.05) -4.9% 0.243
NAWM Cr 4.92 (0.08) 4.88 (0.09) -0.04 (0.12) -0.8% 0.745
NAWM Ins 3.69 (0.10) 4.09 (0.11) +0.40 (0.15) +11.0% 0.008
NAWM tNAA 8.77 (0.13) 8.38 (0.14) -0.39 (0.19) -4.5% 0.048
NAWM Glx 7.75 (0.14) 7.84 (0.16) +0.09 (0.22) + 1.2% 0.677
Table 4.3c: MS disease effects estimated from multiple regression models. Model R2: 
CGM Cho 0.306; CGM Cr 0.426; CGM Ins 0.251; CGM tNAA 0.366; CGM  Glx 
0.410; NAWM Cho 0.203; NAWM Cr 0.311; NAW M Ins 0.344; NAW M  tNAA 
0.259; NAW M Glx 0.412. a Tissue metabolite concentrations in MS and norm al 
control subjects estimated from multiple regression models, evaluated at the mean
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BPV, age, voxel tissue and CSF contents of both MS and NC subjects. b MS disease 
effects estimated from multiple regression models allowing for age, gender, voxel 
tissue and CSF contents, and BPV. c Percentage difference in MS CGM or NAWM 
voxels compared with adjusted mean values in NC subjects.
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Figure 4.3a: 3D FSPGR (T,-weighted) structural image overlaid by the proton 
magnetic resonance spectroscopic imaging grid in a normal control subject. Only 
those voxels fully within the spectroscopic excitation volum e are shown. The 
inverted-contrast section of the image corresponds to the magnified spectra shown 
below it. The two central voxels in the magnified grid come from voxel fulfilling the 
GM classification criteria, while the others fulfil the WM criteria. The main peaks 
from left to right are: Ins, Cho, Cr and NAA, with sm aller Glx peaks to be found 
between those of Cr and NAA.
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Figure 4.3b: CGM Glx concentrations (mmol/L) against M SFC scores in MS 
subjects.
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Figure 4.3c: NAW M Ins concentrations (mmol/L) against M SFC scores in MS 
subjects.
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4.4 LONGITUDINAL ESTIMATES OF BRAIN ATROPHY  
Introduction
Having previously noted that atrophy may be detected both in GM and WM 
early in the clinical course of MS, the dynamics of early tissue specific atrophy was, 
and to a degree remains, unclear. At the time the work presented in this section was 
undertaken only a lim ited num ber of longitudinal studies had been perform ed 
(Dalton et al.,2002; Luks et al.,2000). Noting that previous cross-sectional work in 
this cohort has observed both WM and GM atrophy, with the former predominating 
when considered as fractions of intra-cranial volumes (see section 4.2), it would 
appear that there is potential for rates of atrophy to differ in WM and GM, and for 
such atrophy to differentially relate to clinically apparent disease progression.
This study addresses such issues in clinically early relapsing-rem itting MS 
subjects followed-up with brain WM and GM volume m easurem ent, and clinical 
assessments, every 6 months for 18 months.
Methods
Subjects
Data came from 13 patients with clinically definite RRM S (mean age at 
baseline 36.4 years, median 36.5, range 26.9 to 48.1; 9 females and 4 males; mean 
disease duration at baseline 1.9 years [estimated from first symptom onset], median 
2.1, range 0.5 to 2.7; mean EDSS 1.0, median 1.0, range 0.0 to 2.0); and 9 NC 
subjects (mean age at baseline 36.7 years, median 33.5, range 31.2 to 52.7; 4 females 
and 5 males) followed up over 18 months (mean 1.5 and 1.6 years in MS and NC 
subjects respectively. None of the MS subjects had received beta-interferon or 
glatiram er acetate at any stage prior to scanning, nor had they been treated with
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corticosteroids within the previous month. These subjects represent a subset of those 
included in the cross-sectional study (section 4.2).
Scan acquisition
Subjects were scanned at six-month intervals as outlined in section 4.1.
Image processing
Image data were processed as outlined in section 3.1.2.
Clinical assessments
Clinical assessm ents as outlined in section 4.2 were undertaken at six 
monthly intervals coincident with scanning. The number o f relapses during the 18 
months prior to baseline assessments and during the 18 months of follow-up was also 
estimated.
Statistical analyses
In order to minimise the number of statistical tests, gradients over time were 
examined, after allowing for global inter-subject differences. For MS versus NC 
comparisons of fractional tissue volumes, the model included subject and subject 
type (MS or NC) as categorical covariates, time in follow -up as a continuous 
covariate and subject type x time in follow-up interaction term. Change in lesion 
load and clinical parameters (except for EDSS) in the MS subjects were assessed 
using models that included subject as a categorical covariate and time in follow-up as 
a continuous covariate. Change in EDSS was assessed using the W ilcoxon signed 
rank test. Associations between changing fractional tissue volumes and lesion loads 
were assessed using a model that included subject as a categorical variable, and time 
in follow-up and lesion load as continuous covariates.
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Results
W hile all subjects were scanned at baseline, six and 18 months, one MS and 
one NC subject was not scanned at 12 months. MS subjects were followed up on 
average after 191, 373 and 559 days after baseline assessments (medians 193, 377 
and 563 respectively); NC subjects were followed up on average after 201, 380 and 
581 days after baseline scanning (medians 203, 383 and 565 respectively).
Tissue volume changes over time
The rate of change of BPF was significantly higher in the MS com pared with 
the control subjects (difference P=0.010; -0.002 per year in NC, Cl -0.006 to 0.003; 
-0.010 in MS subjects, Cl -0.014 to -0.006; model R2=0.954). Sim ilarly GM F 
decreased significantly faster in the MS compared with the NC subjects (difference 
P=0.013; -0.0022 per year in NC, Cl -0.006 to 0.002; -0.009 per year in the MS 
subjects, Cl -0.012 to -0.005; model R2=0.950). No such significant difference was 
observed in the WMF. These patterns can be seen in Table 4.4a.
Lesion volume changes over time
There was no evidence of significant change in lesion loads over the 18 
months of follow-up for the whole MS sample (Table 4.4b). Estimated mean changes 
(Cl) in lesion loads (ml per year) were for T ,: -0.164 (-0.482 to 0.153), P=0.302; T2: 
0.071 (-0.592 to 0.733), P=0.830; Gd-enhancing: -0.080 (-0.389 to 0.229), P=0.601; 
3D FSPGR: 0.200 (-0.188 to 0.587), P=0.303.
Associations between fractional tissue volumes and lesions volumes
3D FSPGR, T2 and T1 lesion loads significantly influenced W M F (0.002 per 
lesion ml, Cl 0.001 to 0.004, P=0.007; 0.001 per lesion ml, C l 0.000 to 0.002,
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P=0.010; 0.002 per lesion ml, Cl 0.000 to 0.005, P=0.027 respectively), otherwise no 
associations were observed.
Clinical measures
In the 18 months prior to baseline there was a mean of 1.6 relapses per 
subject, median 1, range 0 to 3; in the 18 months of follow-up there was a mean of
1.5 relapses per subject, median 1, range 0 to 6.
There was a suggestion that EDSS score at the end of follow-up was higher 
than at baseline (P=0.053, W ilcoxon Sign Rank test). W hile there was no clear 
evidence of change in the overall MSFC scores over follow-up (Table 4.4c) (0.062 
per year; Cl -0.125 to 0.248; P=0.507), patients appeared to improve on the HPT 
(average reciprocal value as used to estimate MSFC; 0.003 per year; Cl 0.001 to 
0.005; P=0.010) and PASAT (4.095 per year; C l 0.783 to 7.406; P=0.017) 
components, while deteriorating on the TW T component (0.303 per year; Cl 0.001 to 
0.605; P=0.049).
Discussion
Disease related tissue atrophy
The results o f this study suggest that while WM atrophy may be more 
apparent at baseline, GM changes are more dynamic over the period of observation. 
These results appear consistent with the previous cross-sectional work on this cohort 
(section 3.2.1), confirming an association between GM - but not WM - atrophy and 
disease duration. Further, in subjects with clinically isolated syndromes suggestive of 
dem yelination, WM atrophy has been observed w hile GM atrophy has not 
(T raboulsee et al.,2002), indicating that WM atrophy may be an early event. 
Subsequent longitudinal work appears to support these findings, noting progressive
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GM volume loss in subjects with CIS (D alton et al.,2004), RRMS (V alsasina et 
al.,2005) and PPMS (Sastre-Garriga et al.,2005a). Similarly progressive GM changes 
have also been observed with DTI (Oreja-Guevara et al.,2005).
Considering the WM observations first, these suggest that atrophy in WM is 
either of earlier onset and a less rapid process than that seen in GM, or that they are 
non-linear processes that need not occur concurrently. The two may be related, with 
a variable time delay, or they may be sem i-independent. The results raise the 
question of when, if ever, the WM volume in MS subjects was normal? The rates of 
change observed in this study, if linear from onset, would suggest that WM 
abnormalities might have occurred several years in advance of clinical onset of MS. 
However, atrophy may not be a linear process, and as such we may simply be 
observing a period of relative WM volume stability, with previously more rapid WM 
atrophy. This apparent stability may not be matched by pathological quiescence: 
oedema and cellular infiltration associated with inflammation may mask concurrent 
axonal degeneration and myelin loss. The present data cannot directly answ er these 
questions but further work focusing on subjects with clinically isolated syndromes 
and continued follow-up of the present cohort may offer useful insight.
GM atrophy in the MS subjects, while modest at baseline, progressed at a rate 
in excess of that observed with normal ageing. Backward linear projections would 
suggest that, in contrast to WM effects, this process began at around the same time as 
clinical onset of the disease.
Tissue specific atrophy and foca l lesions
The MS subjects had a relatively limited range of lesion loads with no readily 
apparent sustained change in brain lesion loads over the 18 months o f follow-up, and
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this counsels caution when interpreting results. W M F appeared to be m odestly 
related to lesion 3D FSPGR and T, lesion loads, although BPF and GM F were not. 
Considered overall, these results suggest that GM and WM volum es may be 
differentially influenced by focal lesion genesis.
The modest correlations also suggest that in general the relationship between 
focal lesion genesis and atrophy is not strong and that additional factors may have a 
significant role to play in determining tissue loss.
Pathological basis o f  atrophy
The apparent dissociation of GM and WM atrophy raises questions as to the 
pathological interpretation of these changes. W ith certain  caveats, it appears 
reasonable to assume that neuronal and axonal loss is a significant com ponent of 
observed atrophy (Miller et al.,2002). However, if this equally affected neuronal cell 
bodies and axonal projections we may expect to observe both GM and WM atrophy 
in equal proportion. Given this, either the magnitude of axonal loss is greater than 
neuronal cell body loss in early relapsing-rem itting MS or other factors, such as 
demyelination, contribute directly towards apparent WM atrophy.
Demyelination may lead to axonal atrophy (Yin et al., 1998), and increased 
vulnerability to additional stressors such as nitric oxide (Sm ith et a l.,2 0 0 1 ) . 
However, this need not immediately lead to axonal (Kornek et al.,2000) or neuronal 
cell body loss. The findings of this study could be interpreted as show ing pre­
existing WM focal demyelination and axonal damage (decrease in W M F on entry to 
the study) priming subsequent neuronal cell body atrophy and loss (progressive 
decrease in GMF during the study). If this were the case then we would anticipate 
that GM changes would eventually be in proportion to those in W M , although there
179
may be a substantial delay before parity is reached. An alternative interpretation is 
that GM and WM atrophy are at least semi-independent, and that m echanism s for 
neuronal cell body damage may differ from those leading to axonal and myelin loss 
in white matter.
Clinical features and tissue specific atrophy
The cohort of MS subjects included in this study showed only limited clinical 
im pairm ent (Table 4.4c), with a m odest increase in EDSS concurrent with 
im provem ents in scores on HPT and PASAT. These latter observations may 
represent a learning effect, and as such be biasing the M SFC against detecting 
progressive neurological impairment. Given this, it was felt inappropriate to explore 
longitudinal associations, and accordingly the results are not presented. Further work 
is required to optim ise the use of longitudinal clinical data, paying particular 
attention to the interplay between neurological function and potential learning 
effects. The inclusion of a greater range of cognitive assessm ents should also be 
considered.
Study limitations
There are a num ber of study lim itations that should be recalled when 
considering the results, as previously outlined in section 4.2. It is reassuring to note 
that lesion misclassification or associated segmentation bias is unlikely to markedly 
influence any conclusions drawn from the results presented here: MS associated 
reductions in W MF volumes are around four times greater than the total observable 
brain lesion loads (relative to TI volumes), while the rate of change in GM F volumes 
was about 50 times greater than that of concurrent changes in lesion loads (relative to 
TI volumes).
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Conclusions
In this early relapsing-remitting MS cohort, while WM atrophy was more 
apparent at baseline, progressive GM atrophy was more noticeable over the 18 
months of follow-up. This suggests that factors leading to WM and GM atrophy may 
be semi-independent of each other or temporally dissociated, or both. The results 
also indicate that the relationship between focal lesion genesis and both GM and WM 
atrophy is lim ited and that other factors may have a significant role to play 
determining atrophy. Further work is required to confirm the present observations 
independently (although longer follow up of the same cohort yields concordant 
results (Tiberio et al.,2005)), to explore the dynamics of tissue specific atrophy over 
greater periods of follow-up, and to address more effectively any potential links 
between tissue specific atrophy, focal lesion genesis and clinical outcome.
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Time-
point
Tissue volume
BPF GMF W MF
MS NC MS NC MS NC
Baseline 0.82, 
0.82, 
0 .74  to 
0.85
0.84, 
0.84, 
0 .78  to 
0.87
0.55, 
0.55, 
0 .49  to 
0.59
0.55, 
0.55, 
0 .52  to 
0.58
0.27, 
0.27, 
0 .25  to 
0.30
0.29, 
0.29, 
0 .27  to 
0.30
6 months 0.81, 
0.81, 
0 .72  to 
0.85
0.83, 
0.84, 
0 .78  to 
0.86
0.54, 
0.54, 
0 .47  to 
0.58
0.55,
0.55,
0.51 to 
0.58
0.27, 
0.27, 
0 .25  to 
0.30
0.28, 
0.28, 
0 .2 7  to 
0.30
12
months
0.80, 
0.81, 
0 .72  to 
0.84
0.84, 
0.84, 
0 .7 9  to 
0.87
0.54, 
0.54, 
0 .47  to 
0.58
0.55, 
0.55, 
0 .52  to 
0.58
0.27, 
0.27, 
0 .25  to 
0.30
0.29, 
0.29, 
0 .2 7  to 
0.30
18
months
0.80,
0.81,
0.71 to 
0.84
0.83, 
0.83, 
0 .77  to 
0.87
0.53, 
0.54, 
0 .47  to 
0.57
0.55,
0.55,
0.51 to 
0.58
0.27, 
0.27, 
0 .2 4  to  
0.31
0.29, 
0.29, 
0 .2 7  to 
0.30
Table 4.4a: Fractional brain tissue volumes (mean, median and range) in MS and NC 
subjects throughout the 18 months of follow-up MS n=13 except at 12 months when 
n=12; NC n=9 except at 12 months when n=8.
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Time-point Lesion volume measure
3D FSPGR t 2 T, Gd-enhancing
Baseline 6.3, 3.3, 
0.5 to 21.0
7.2, 4.5, 
1.4 to 26.6
1.5, 0.5, 
0.0 to 9.9
0.6, 0.2, 
0.0 to 4.3
6 months 6.2, 3.3, 
0.6 to 21.0
7.1, 3.8, 
1.0 to 29.2
1.1,0.5, 
0.0 to 7.9
0.2, 0.1, 
0.0 to 0.9
12 months 6.8, 3.6, 
1.0 to 21.5
7.8, 5.0, 
2.0 to 28.1
1.4, 0.8, 
0.0 to 7.3
0.4, 0.2, 
0.0 to 1.3
18 months 6.6, 3.5, 
0.4 to 22.4
7.3, 5.0, 
0.8 to 26.7
1.2, 0.7, 
0.1 to 6.3
0.4, 0.1, 
0.0 to 2.5
Table 4.4b: Lesion volumes (mean, median and range) in the MS subjects throughout 
the 18 months of follow-up; n=13 except at 12 months when n=12.
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Time-point Clinical measure
EDSS MSFC TW T HPT PASAT
Baseline 1.0, 1.0, 
0.0 to 2.0
0.0, 0.1, 
-0 .9 9  to  
0.86
4.3, 4.3, 
3.8 to 5.5
21.3, 19.7,
16 .8  to
29.8
46.5, 52.0,
1 1 .0  to
60.0
6 months 1.6, 2.0, 
0.0 to 3.0
0.0, 0.4, 
-2.0 to 0.9
4.5, 4.1, 
3.5 to 7.3
21.0, 19.3, 
16 .4  to  
30.1
r50.8, 56.0,
2 3 .0  to
60.0
12 months 1.4, 1.5, 
0.0 to 2.5
0.3, 0.4, 
-1.1 to 1.1
4.5, 4.4, 
4.0 to 5.5
19.5, 18.5, 
15 .0  to  
32.5
56.3, 57.0,
5 1.0 to  
60.0
18 months 1.6, 1.5, 
0.0 to 3.5
0.1, 0.3, 
-1.9 to 1.0
4.7, 4.7, 
3.7 to 7.3
19.8, 18.7, 
15 .8  to  
31.0
50.0, 55.0,
1 3 .0  to
60.0
Table 4.4c: Clinical measures (mean, median, and range) in MS subjects throughout 
the 18-month of follow-up; n=13 except at 12 months when n=12.
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Figure 4.4a: serial WMF results in individual subjects. Red lines indicate data from 
MS subjects; black lines represent data from NC.
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Figure 4.4b: serial GMF results in individual subjects. Red lines indicate data from 
MS subjects; black lines represent data from NC.
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5 SUMMARY AND CONCLUSIONS
The main focus of the work contained in this thesis has been the study of MS 
disease effects upon tissue volumes and tissue metabolite concentration with a view 
to gaining greater insight in to early pathology, the inter-relationship between focal 
lesion genesis and more global tissue involvement, and any associations with clinical 
outcome. This has required the developm ent o f integrated approaches to data 
collection, data and statistical analyses, with the results being set in the context of 
methodological limitations such as sensitivity to cross-sectional and longitudinal 
gradients, and differential measurement errors. The main observations were that:
i. WM atrophy is more prominent than GM atrophy early in the course o f the 
disease;
ii. Despite this, GM atrophy over an 18 month period of observation (covering 
disease durations from 1.9 to 3.4 years) is more rapid than that of W M;
iii. WM atrophy may precede both clinical onset and GM atrophy;
iv. In contrast, early m etabolite alterations appear m ore prom inent in GM 
compared with WM, with decreases in GM and WM tNAA, GM Glx and GM 
Cho, and increases in WM Ins;
v. Lesion loads appear to be associated with only a fraction o f disease 
associated atrophy and metabolite concentration changes;
vi. Cross-sectional data suggest that there is a stronger association between GM 
compared with WM atrophy and lesion loads;
vii. N oting that the cohort studied had only lim ited  clin ical im pairm ent; 
m etabolite alterations appear more tightly related  to clinical status than 
atrophy in the early stages of the disease.
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Before considering these observations further, it should be noted that, given 
the number of statistical tests presented in this thesis, there is real potential for some 
of the results found to be significant at a P<0.05 level to be spurious, although it is 
not possible to definitively determine which without further independent studies 
being undertaken. In this regard: GM atrophy has been relatively consistently seen in 
subsequent cross-sectional and longitudinal studies, as has the limited relationship 
between brain lesion loads and atrophy (reviewed by Bermel & Bakshi, 2006); 
reduced brain GM and WM NAA levels have also been near constant findings, as 
noted in a recent meta-analysis by Caramanos et al. (2005) of 30 peer-review ed 
published studies, along with increased WM Ins concentrations (Sastre-Garriga et al., 
2005b; Vrenken et al., 2005; Fernando et al., 2005); while GM Cho and Glx 
concentration reductions have not been reproduced, and as such should be regarded 
with due caution.
The results presented in this thesis would appear to suggest that neuronal 
metabolic dysfunction and loss are early events in the clinical course o f MS, as is 
WM glial proliferation and or activation. It is also interesting to note that while 
reductions in tNAA are more marked in GM than WM, WM atrophy appears more 
marked than GM. Assuming that total neuronal and axonal populations may be 
estim ated from tissue volume and tNAA concentrations, this suggests that total 
disease associated reductions in neuronal cell body (GM ) and axonal (W M ) 
populations are similar (-10%  in GM and -11%  in W M ), a perhaps surprisingly 
large disease effect to remain apparently clin ically  silent. Instead, m etabolic 
dysfunction may be more tightly related to clinical status in the early stages o f the 
disease, as indicated by associations between clinical measures, GM Glx and GM Cr.
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This should not be taken as suggesting that metabolic dysfunction is more important 
in determining clinical outcome than neuronal and axonal loss. In the early stages, 
while not apparently overtly linked to clinical status, such cell loss may serve to 
magnify the effects of metabolic dysfunction, while later on it may assume a more 
overt role, as suggested by studies exploring cohorts with longer disease durations 
(De Stefano et al., 1998; De Stefano et al.,2001; Fu et al., 1998; Fu et a l .,1 996). 
Further, noting that elevations in WM Ins appear to be related to clinical status early 
in the clinical course of the disease, the potential importance of glial activiation and 
or proliferation in determ inig longer term clinical outcom es should also not be 
overlooked. These are matters that the present work is unable to effectively resolve 
and it will require further longitudinal follow-up to attempt to do so.
It is also somewhat surprising that GM disease effects appear to be quite so 
extensive and at least as relevant to early clinical outcome as WM effects. Indeed, 
the limited relationship between WM changes and outcomes, when compared with 
GM findings, is curious and may in part be explained by the presence of a clinically 
less relevant process that differentially affects WM and GM. It has previously been 
noted that inflamm ation is more marked in WM than in GM lesions (Peterson et 
al.,2001) indicating the potential for such differential tissue effects.
The findings also serve to reiterate that the most obvious disease effect on 
MRI, the accumulation of focal lesions, need not determ ine absolutely the course of 
other more global processes. Global disease effects may be at least as im portant as 
focal lesion genesis when determining clinical outcome. This is not surprising when 
we recall that focal lesions constitute the minority o f  brain tissue, even in subjects 
with long-standing and clinically advanced MS. In the present cohort, on average
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less than 1% of brain tissue was overtly abnormal on structural images; even if tissue 
destruction was absolute within such lesion, this would only account for a 1% 
reduction in axons. In contrast more subtle but global effects may constitute a -10%  
reduction in brain neuronal and axonal populations. From the present work it is only 
possible to comment on the early stages of the disease, but studies looking at longer- 
term follow-up have similarly suggested a limited role for lesions in the long term 
(Brex et al.,2002; Beck et al.,2004; Chard et al.,2003; Jasperse et a /.,2007).
It would be interesting to explore longitudinal changes in m etabolite 
concentrations, but in the cohort available sensitivity to disease effects would be 
limited (see section 3.1.2). For the most reliable measure, WM tNAA as defined by 
CV, in 15 subjects changes of -8%  would be detectable, although this figure assumes 
only two m easurem ents are made, one baseline and one follow -up. Indeed, 
preliminary analysis of data from 20 of the MS subjects included in the present work 
appears consisten t w ith this, observing a partial recovery  in WM tN A A  
concentrations, but otherwise no significant change in m etabolite profiles (Tiberio et 
al., 2006).
It rem ains for the prognostic significant o f early global changes to be 
determined and longitudinal studies should be undertaken to explore this along with 
characterising the dynamics of tissue damage on MS extending through from the 
earliest stages through to progressive phases of the disease. It may transpire that 
while lesions offer only limited prognostic inform ation, this may be augm ented by 
assessm ent of global tissue damage. In subjects w ith CIS, it would appear that 
changes in lesion loads in the first five years only partially relates to outcomes 14
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years after disease onset, suggesting that early disease effects may have prognostic 
value (Brex et al.,2002).
In conclusion, the work contained in this thesis indicates that MS disease 
effects occur early; are more extensive than would be suggested if we were to 
consider focal lesions alone; and include neuronal and axonal dam age, and glial 
activation and or proliferation. GM and WM effects may be either semi-independent 
of each other or focal lesion genesis, or be temporally separated, or both. Clinical 
outcome at an early stage of the disease does not appear to be strongly related to 
irreversible tissue degeneration but may be related to neuronal and axonal metabolic 
dysfunction, and glial activation or proliferation. Further m ultiparam etric MR and 
clinical studies are required to confirm  and expand upon these observations, 
hopefully including additional MR measures such as estimates o f tissue relaxation, 
diffusion and magnetisation transfer characteristics; and additional clinical measures 
including a more complete assessment of cognitive function.
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7 APPENDIX
FUNCTIONAL SYSTEM AND EXPANDED DISABILITY STATUS SCALE  
SCORES
Table A l: functional systems
Pyramidal functions
0 Normal.
1 Abnormal signs without disability.
2 Minimal disability.
3 Mild or moderate paraparesis or hemiparesis; severe monoparesis.
4 Marked paraparesis or hemiparesis; moderate quadriplegia; or monoplegia.
5 Paraplegia, hemiplegia, or marked quadriparesis.
6 Quadriplegia.
Cerebellar functions
0 Normal.
1 Abnormal signs without disability.
2 Mild ataxia.
3 Moderate truncal or limb ataxia.
4 Severe ataxia, all limbs.
5 Unable to perform coordinated movements due to ataxia.
X Is used throughout after each number when weakness (grade 3 or more on 
pyramidal) interferes with testing.
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Brain stem functions
0 Normal.
1 Signs only.
2 Moderate nystagmus or other mild disability.
3 Severe nystagmus, marked extra-ocular weakness, or moderate disability of 
other cranial nerves.
4 Marked dysarthria, or other marked disability.
5 Inability to swallow or speak.
Sensory functions
0 Normal.
1 Vibration or figure-writing decrease only, in one or two limbs.
2 Mild decrease in touch or pain or position sense, and/or moderate decrease 
in vibration in one or two limbs; or vibratory (c/s figure writing) decrease 
alone in three or four limbs.
3 Moderate decreases in touch or pain or position sense, and/or essentially lost 
vibration in one or two limbs; or mild decrease in touch or pain and/or 
moderate decreases in all proprioceptive tests in three or four limbs.
4 M arked decrease in touch or pain or loss o f proprioception, alone or 
combined, in one or two limbs; or moderate decrease in touch or pain and/or 
severe proprioceptive decrease in more than two limbs.
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5 Loss (essentially) of sensation in one or two limbs; or moderate decrease in 
touch or pain and/or loss of proprioception for most of the body below the 
head.
6 Sensation essentially lost below the head.
Bowel and bladder functions
0 Normal.
1 Mild urinary hesitancy, urgency, or retention.
2 Moderate hesitancy, urgency, retention of bowel or bladder, or rare urinary 
incontinence.
3 Frequent urinary incontinence.
4 In need of almost constant catheterization.
5 Loss of bladder function.
6 Loss of bowel and bladder function.
Visual (or optic) functions
0 Normal.
1 Scotoma with visual acuity (corrected) better than 20/30.
2 Worse eye with scotoma with maximal visual acuity (corrected) of 20/30 to 
20/59.
3 Worse eye with large scotoma, or m oderate decreases in fields, but with 
maximal visual acuity (corrected) of 20/60 to 20/99.
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4 W orse eye with marked decrease of fields and m aximal visual acuity 
(corrected) of 20/100 to 20/200; grade 3 plus maximal acuity o f better eye 
of 20/60 or less.
5 Worse eye with maximal visual acuity (corrected) less than 20/200; grade 4 
plus maximal acuity of better eye of 20/60 or less.
6 Grade 5 plus maximal visual acuity of better eye of 20/60 or less.
X Is added to grades 0 to 6 for presence of temporal pallor.
Cerebral (or mental) functions
0 Normal.
1 Mood alteration only (does not affect EDSS score).
2 Mild decrease in mentation.
3 Moderate decrease in mentation.
4 Marked decrease in mentation (chronic brain syndrome-moderate).
5 Dementia or chronic brain syndrome-severe or incompetent.
Other functions
0 None.
1 Any other neurologic findings attributed to MS (specify).
237
Table A2: The expanded disability status scale
Score Description
0 Normal neurologic exam (all grade 0 on FS; cerebral grade 1 acceptable).
1.0 No disability, minimal signs in one FS (i.e., grade 1 excluding cerebral 
grade 1).
1.5 No disability, minimal signs in more than one FS (more than one grade 1 
excluding cerebral grade 1).
2.0 Minimal disability in one FS (one FS grade 2, others 0 or 1).
2.5 Minimal disability in two FS (two FS grade 2, others 0 or 1).
3.0 M oderate disability in one FS (one FS grade 3, others 0 or 1), or mild 
disability in three or four FS (three/four FS grade 2, others 0 or I) though 
fully ambulatory.
3.5 Fully ambulatory but with moderate disability in one FS (one grade 3) and 
one or two FS grade 2; or two FS grade 3; or five FS grade 2 (others 0 or 1).
4.0 Fully ambulatory without aid, self-sufficient, up and about some 12 hours a 
day despite relatively sever disability consisting of one FS grade 4 (others 0 
or 1), or combinations of lesser grades exceeding limits of previous steps. 
Able to walk without aid or rest some 500 metres.
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4.5 Fully ambulatory without ad, up and about much of the day, able to work a 
full day, may otherwise have some limitation of full activity or require 
minimal assistance; characterized by relatively severe disability; usually 
consisting of one FS grade 4 (others 0 or 1) or combinations of lesser grades 
exceeding limits of previous steps. Able to walk without aid or rest for some 
300 metres.
5.0 Ambulatory without aid or rest for about 200 metres; disability severe 
enough to impair full daily activities (e.g., to work a full day without special 
provisions). (Usual FS equivalents are one grade 5 alone, others 0 or 1; or 
combinations of lesser grades usually exceeding specifications for step 4.0).
5.5 Ambulatory without aid or rest for about 100 metres; disability severe 
enough to preclude full daily activities. (Usual FS equivalents are one grade 
5 alone, others 0 or 1; or combinations of lesser grades usually exceeding 
those for step 4.0).
6.0 Interm ittent or unilateral constant assistance (cane, crutch, or brace) 
required to walk about 100 metres with or w ithout resting. (Usual FS 
equivalents are combinations with more than two FS grade 3+).
6.5 Constant bilateral assistance (canes, crutches, or braces) required to walk 
about 20 metres without resting. (Usual Fs equivalents are com binations 
with more than two FS grade 3+).
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7.0 Unable to walk beyond about 5 metres even with aid, essentially restricted 
to wheelchair; wheels self in standard wheelchair and transfers alone; up 
and about in w/c some 12 hours a day. (Usual FS equivalen ts are 
combinations with more than one FS grade 4+; very rarely, pyramidal grade 
5 alone).
7.5 Unable to take more than a few steps; restricted to wheelchair; may need aid 
in transfer; wheels self but cannot carry on in standard wheelchair a full day; 
may require motorized wheelchair. (Usual FS equivalents are combinations 
with more than one FS grade 4+).
8.0 Essentially restricted to bed or chair or perambulated in wheelchair, but may 
be out of bed itself for much of the day; retains many self-care functions; 
generally has effective use of arms. (Usual FS equivalents are combinations, 
generally grade 4+ in several systems).
8.5 Essentially restricted to bed much of the day; has some effective use of 
arm (s); retains some self-care functions. (Usual FS equivalen ts are 
combinations, generally 4+ in several systems).
9.0 Helpless bed patient; can communicate and eat. (Usual FS equivalents are 
combinations, mostly grade 4+).
9.5 Totally helpless bed patient; unable to com m unicate effectively  or 
eat/swallow. (Usual FS equivalents are combinations, almost all grade 4+).
10 Death due to MS.
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